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Abstract 
Parkinson’s disease (PD) is a movement disorder with progressive neurodegeneration. As populations 
continue to age, the burden of this disease will increase. Although both environmental and genetic factors 
seem to play a major role in the etiology of PD, the causes of the neuronal death underlying the disease 
remains largely unknown. As curative treatment for PD remains a challenge, knowledge to aid in the 
development of prevention tools is crucial. Thus, identifying risk factors, especially modifiable ones, is 
essential.  
The aim of the present study was to examine the prediction of dietary, lifestyle and metabolic factors on 
PD risk in a cohort study design. 
This study included men and women free from PD at baseline of the Finnish Mobile Clinic Health 
Examination Survey (FMC, 1966–1972, n=4,524), the Follow-up study of the FMC (FMCF, 1973–1975, 
n=6,715), and the Mini-Finland Health Survey (1978–1980, n=4,828). Over a follow-up of 22–41 years, the 
PD cases (International Classification of Diseases 10, code G20, from the World Health Organization) in the 
FMC (n=85), the FMCF (n=101), and the Mini-Finland Health Survey (n=89) were identified through linkage 
with the nationwide Drug Reimbursement Register of Social Insurance Institution. 
Information on lifestyle factors, socioeconomic background, and physiological and biochemical 
determinants were collected by questionnaires, interview, and health examinations at the baselines of 
these three surveys. Dietary intake was assessed with a 1-year dietary history interview in the FMC.  
The exposure factors studied here were diet (individual food groups and items, as well as a diet quality 
index), leisure-time physical activity, smoking, alcohol consumption, coffee consumption, body mass 
index, blood pressure, as well as concentration of serum HDL cholesterol, serum triglyceride, fasting 
plasma glucose, and serum total cholesterol.  
Cox’s proportional hazards model was used to estimate the strength of association between the exposure 
factors and PD risk. Potential confounding factors were adjusted by inclusion in multivariate models. 
Most of the individual food groups and items, as well as the diet quality, did not predict the risk of PD. 
There were few exceptions however, e.g. high consumption of milk was associated with increased PD risk 
in women. Smoking, heavy consumption of coffee, as well as heavy leisure-time physical activities were 
associated with decreased PD risk. Alcohol consumption had no clear association with PD risk. Those who 
had metabolic syndrome had a reduced risk of PD, mainly due to high serum triglyceride and fasting 
plasma glucose concentration. Serum HDL cholesterol, serum total cholesterol concentration, and blood 
pressure, however, had no association with PD risk. After taking into account the potential preclinical 
disease phase, we observed that obesity might increase the risk of PD. 
In conclusion, diet and other lifestyle factors, as well as metabolic health, may predict the risk of PD. The 
prospective design of this study is a strength when providing etiologic clues for unraveling the mystery of 
PD. The overall evidence from the literature is, however, currently too sparse for making 
recommendations for public health purposes to prevent PD. In the future, perhaps, the results of the 
present study, as well as previous studies, may be used in clinical practice when planning tools for the 
early identification of PD patients. 
Keywords: Parkinson’s disease, cohort study, diet, lifestyle factors, metabolic health  
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Tiivistelmä 
Parkinsonin tauti on hermosolujen etenevästä tuhoutumisesta johtuva liikehäiriösairaus. Väestön 
ikääntyessä taudin ennustetaan kuormittavan yhä useampia. Parkinsonin taudin syntyyn vaikuttavat sekä 
geneettiset että ympäristötekijät, mutta varsinaista syytä taudin aiheuttavalle hermosolujen 
tuhoutumiselle ei vielä tunneta. Toistaiseksi Parkinsonin tautia ei pystytä parantamaan, joten tietoa 
Parkinsonin taudin ehkäisemiskeinojen löytämiseksi tarvitaan. Siksi on oleellista tunnistaa etenkin sellaiset 
taudin riskitekijät, joihin on mahdollista vaikuttaa. 
Tämän tutkimuksen tavoitteena oli selvittää kohorttiasetelmassa, ennustavatko ravitsemus-, elintapa- tai 
metaboliset tekijät Parkinsonin taudin riskiä. 
Tutkimusaineisto koostui Autoklinikka-tutkimuksiin osallistuneista miehistä ja naisista, jotka eivät 
tutkimuksen alkutilanteessa sairastaneet Parkinsonin tautia (Autoklinikan moniseulontatutkimus, AK, 
vuosina 1966–1972, n=4 524; Autoklinikan uusintatutkimus, AU, 1973–1975, n=6 715; sekä Mini-Suomi -
tutkimus, MS, 1978–1980, n=4 828). Parkinsonin tautiin sairastuneet henkilöt (Maailman terveysjärjestön 
ICD-10 -tautiluokitus, koodi G20) tunnistettiin 22–41 vuoden seurannassa Kansaneläkelaitoksen 
ylläpitämästä, lääkkeiden erityiskorvausoikeuden saaneita koskevasta rekisteristä (AK, n=85; AU, n=101; ja 
MS, n=89). Tutkimuksessa kerättiin kyselylomakkeiden, haastatteluiden ja terveystarkastusten avulla 
tietoa elintapatekijöistä, sosioekonomisesta taustasta, sekä fysiologisista ja biokemiallisista tekijöistä 
kaikkien kolmen tutkimuksen alkutilanteessa. Autoklinikan moniseulontatutkimuksessa tutkittavien 
edeltäneen vuoden ruoankäyttöä selvitettiin ruokavaliohaastattelulla.  
Tämä tutkimus tarkasteli seuraavien tekijöiden yhteyttä riskiin sairastua Parkinsonin tautiin: ruokavalio 
(yksittäiset ruoka-aineryhmät ja ruoka-aineet, sekä ruokavalion laatua kuvaava indeksi), vapaa-ajan 
liikunta, tupakointi, alkoholin ja kahvin kulutus, painoindeksi, verenpaine, sekä seerumin HDL-kolesterolin, 
seerumin triglyseridien, plasman paastoglukoosin ja seerumin kokonaiskolesterolin konsentraatio. 
Altistemuuttujien ja Parkinsonin taudin välisen yhteyden voimakkuutta arvioitiin Coxin mallin avulla. 
Mahdolliset sekoittavat tekijät vakioitiin sisällyttämällä ne monimuuttujamalleihin. 
Suurin osa yksittäisistä ruoka-aineryhmistä tai ruoka-aineista, samoin kuin ruokavalion laatu, eivät olleet 
yhteydessä Parkinsonin taudin riskiin. Tästä havaittiin kuitenkin muutamia poikkeuksia, esimerkiksi naisilla 
suurempi maidon kulutus oli yhteydessä kohonneeseen riskiin sairastua Parkinsonin tautiin. Runsas vapaa-
ajan liikunta ja kahvin juonti sekä tupakointi puolestaan pienensivät riskiä sairastua Parkinsonin tautiin. 
Alkoholin kulutus ei ollut selkeästi yhteydessä Parkinsonin tautiin. Henkilöillä, joilla oli metabolinen 
syndrooma, oli pienentynyt riski sairastua Parkinsonin tautiin, mikä johtui pääasiassa kohonneista 
seerumin triglyseridiarvoista ja plasman paastoglukoosiarvoista. Seerumin HDL-kolesteroli tai 
kokonaiskolesteroli eivät olleet yhteydessä Parkinsonin tautiin, kuten ei ollut myöskään verenpaine. Kun 
analyyseissä huomioitiin mahdollinen prekliinisen taudin vaikutus, havaittiin että lihavuus saattaa lisätä 
riskiä sairastua Parkinsonin tautiin. 
Yhteenvetona voidaan todeta, että ruokavaliolla tai muilla elintapatekijöillä saattaa olla yhteyttä riskiin 
sairastua Parkinsonin tautiin. Tämän tutkimuksen prospektiivinen asetelma on vahvuus etsittäessä 
etiologisia vihjeitä Parkinsonin taudin arvoituksen ratkaisemiseksi. Tällä hetkellä tutkimusnäyttö on vielä 
riittämätöntä, jotta voitaisiin laatia suosituksia toimista Parkinsonin taudin ehkäisemiseksi. Tämän 
tutkimuksen sekä aikaisempien tutkimusten tuloksia voidaan hyödyntää kliinisessä potilastyössä, kun 
suunnitellaan menetelmiä Parkinson taudin varhaiseksi tunnistamiseksi.  
Avainsanat: Parkinsonin tauti, kohorttitutkimus, ruokavalio, elintapatekijät, metabolinen terveys  
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1 Introduction  
Parkinson’s disease (PD) is a complex neurodegenerative disease wherein progressive death of 
dopaminergic neurons leads to a movement disorder with numerous non-motor symptoms (see Kalia and 
Lang 2015a). Although PD was first described almost two centuries ago, the conceptualization of the 
disease continues to evolve. The understanding of pathogenesis of the disease is expanding, but there is 
no treatment that could prevent or delay the progression of the disease.  
Non-motor symptoms often manifest in early PD before the motor symptoms, and are present during the 
entire disease course. They include olfactory dysfunction, cognitive impairment, psychiatric symptoms, 
sleep disorders, autonomic dysfunction, pain, and fatigue (see Kalia and Lang 2015a). There are estimates 
that motor symptoms first appear when about 30% of substantia nigra dopamine neurons are lost (see 
Cheng et al. 2010). The principal motor symptoms include bradykinesia, muscular rigidity, rest tremor, and 
postural and gait impairment (see Jankovic 2008). 
The motor symptoms related to dopamine deficiency in PD can be relieved with several drugs, of which 
the oral replacement of dopamine by its precursor levodopa is the most effective.  Other dopaminergic 
drugs include direct-acting dopamine agonists and agents, such as monoamine oxidase B and catechol-O-
methyltransferase inhibitors, that enhance dopamine’s effect through the inhibition of distinct metabolic 
pathways. However, the broad range of symptoms and treatment-related complications, especially in late-
stage PD, contribute to substantial disability (see Kalia and Lang 2015a). Both the motor and non-motor 
symptoms vary between PD patients, and different subtypes of PD have been suggested (see Kalia and 
Lang 2015a). Altogether, due to the progressive nature of the disease, PD is characterized by a worsening 
of the symptoms, eventually leading to a reduced quality of life, increased need for institutional care, and 
increased mortality (see Kalia and Lang 2015a). 
Neurodegenerative diseases are the seventh leading cause of death and a major cause of disability in high-
income-countries (see Lopez et al. 2006). There are estimates that in 2005 the number of individuals (aged 
50 and above) with PD was between 4.1 and 4.6 million in 15 countries around the world (Western 
Europe's 5 most and the world's 10 most populous nations), and will grow to between 8.7 and 9.3 million 
by 2030 (see Dorsey et al. 2007). In Finland, the estimated number of PD patients is currently about 
17,000, based on the number of individuals receiving the Social Insurance Institution’s reimbursement 
right code 110 for PD ("Tilastotietokanta Kelasto", Kansaneläkelaitos. <http://www.kela.fi/kelasto>. 
January 21st 2016). With the world’s populations aging, the importance of PD as a public health issue is 
expected to increase.  
Both the human and economic burden of PD are substantial. Despite the several causative monogenetic 
mutations that have recently been discovered, the etiology of PD is multifactorial in about 90% of cases, 
with both non-genetic (environmental) and genetic factors seeming to play a major role (see de Lau and 
Breteler 2006a). Thus, it is essential to identify modifiable risk factors and to clarify under what 
circumstances changes in them would optimally reduce the risk of PD. Epidemiological studies on PD could 
help in identifying targets for research into the etiology of PD, and in developing prevention strategies. 
Furthermore, epidemiological studies may help in developing tools for early detection of the disease. The 
premotor phase of the disease provides a potential window of opportunity, during which a disease-
modifying therapy – if available – could be administered (see Siderowf and Lang 2012).  
Several hypotheses have been presented suggesting that dietary, lifestyle, and biological factors may 
provide protection against PD (see Wirdefeldt et al. 2011; see de Lau and Breteler 2006a). The overall 
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epidemiological evidence, however, is still scarce. Large prospective cohort studies with proper exposure 
assessments and PD ascertainment are needed. The three cohorts used in this study, the Finnish Mobile 
Clinic Health Examination Survey, the Finnish Mobile Clinic Follow-up Survey, and the Mini-Finland Health 
Survey, were well-suited for this purpose due to their long follow-up periods and relatively large sample 
sizes. Therefore, the aim of this study was to predict the risk of PD by dietary, lifestyle, and metabolic 
factors in a prospective cohort study design. Regarding diet, the aim was to assess the diet as a whole. 
Thus, this study included dietary assessments at both the summary level (utilizing a diet quality index) as 
well as at the level of individual food groups and items (components of the index). Furthermore, lifestyle 
factors selected for this study included leisure-time physical activity, smoking, alcohol consumption, and 
coffee consumption. Metabolic health was approached by examining both obesity as well as metabolic 
syndrome and its components.  
2 Review of the literature 
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2 Review of the literature 
2.1 Parkinson’s disease 
Parkinson’s disease (PD), originally described by James Parkinson in 1817, is the most common 
neurodegenerative disease after Alzheimer's disease (see Dorsey et al. 2007). PD is characterized by the 
progressive death of selected but heterogeneous populations of neurons, including the dopaminergic 
neurons of the pars compacta of the substantia nigra, leading to a loss of dopamine in the striatum which 
accounts for most of the classic clinical motor features of PD (see Lang and Lozano 1998). 
It appears that multiple different pathogenic pathways and mechanisms can ultimately lead to PD, and 
both genetic and environmental factors are believed to play a central role (Bronstein et al. 2009). The 
exact pathogenic mechanisms underlying the neurodegeneration remain largely unknown, but some of 
the pathways that have been implicated so far include mitochondrial dysfunction, oxidative stress, kinase 
pathways, calcium dysregulation, inflammation, protein handling, and prion-like processes (see Schapira 
et al. 2014). 
2.1.1 Prevalence and incidence 
PD is an age-related disease, being rare before the age of 50. The prevalence increases with age, with up 
to 4% in the highest age groups (80-90 year olds) (see de Lau and Breteler 2006a). The literature, 
however, presents varying prevalence and incidence rates for PD, partly due to geographical and 
demographic factors. In addition, methodological differences produce varying rates, for example, utilizing 
varying diagnostic criteria or case-finding strategies (registry diagnosis vs. door-to-door survey) (see 
Wirdefeldt et al. 2011). A review based on 12 US and European studies estimated that the prevalence of 
PD among people 65 years or older was 950 per 100,000 (see Hirtz et al. 2007). The median incidence rate 
based on 8 studies in developed countries was 14 per 100,000 person-years for all age groups, and 160 
per 100,000 person-years when restricted to individuals aged 65 years and above (see Hirtz et al. 2007). 
Due to the increased global life expectancy, the burden of the disease has grown and will likely continue 
to do so (see Dorsey et al. 2007). 
2.1.2 Diagnosis of PD 
The diagnosis of PD is based on clinical criteria, with rest tremor, bradykinesia, rigidity, and postural 
instability generally considered to be the cardinal signs (see Jankovic 2008). Furthermore, other clinical 
features, including secondary motor symptoms and non-motor symptoms, may cause severe disability in 
patients with advanced disease. The Hoehn and Yahr scale, or the Unified Parkinson’s Disease Rating 
scale, are commonly used to provide assessment of disease progression, disability, and impairment (see 
Jankovic 2008).  
The established diagnostic criteria have been developed by the UK Parkinson’s Disease Society Brain Bank 
(Table 1) and the National Institute of Neurological Disorders and Stroke (see Gelb et al. 1999). However, 
the clinical diagnosis of PD can be challenging, and requires expertise in differentiating it from related 
disorders. Currently, imaging techniques can aid in this task, but a reliable diagnostic test for PD remains 
to be found. While potential neuroimaging and pathological markers are being explored and tested, it may 
be that some combination of imaging, and biochemical and genetic biomarkers are required (see Kalia and 
Lang 2015a). 
2 Review of the literature 
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Table 1. UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria. Adapted from following reviews: Kalia 
and Lang 2015a; Jankovic 2008; and Gelb et al. 1999. 
Step 1: Diagnosis of parkinsonian syndrome 
Bradykinesia (i.e., slowness of initiation of voluntary movement with progressive reduction in speed and 
amplitude of repetitive actions), plus one or more of the following features: 
• Muscular rigidity 
• 4–6 Hz rest tremor 
• Postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction 
Step 2: Exclusion criteria for Parkinson’s disease 
At least one of the following features suggests an alternate diagnosis: 
• History of repeated strokes with stepwise progression of parkinsonian features 
• History of repeated head injury 
• History of definite encephalitis 
• Neuroleptic treatment at onset of symptoms 
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure 
• Negative response to large doses of levodopa (if malabsorption excluded) 
• More than one affected relative* 
• Sustained remission 
• Strictly unilateral features after 3 years 
• Early severe autonomic involvement 
• Early severe dementia with disturbances of memory, language, and praxis 
• Oculogyric crises 
• Supranuclear gaze palsy 
• Babinski sign 
• Cerebellar signs 
• Presence of a cerebral tumour or communicating hydrocephalus on CT scan or MRI 
Step 3: Supportive prospective positive criteria for Parkinson’s disease 
At least three of the following features: 
• Unilateral onset 
• Rest tremor present 
• Progressive disorder 
• Persistent asymmetry affecting the side of onset most 
• Excellent response (70–100%) to levodopa 
• Severe levodopa-induced chorea 
• Levodopa response for 5 years or more 
• Clinical course of 10 years or more 
Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging. 
*This criterion is generally no longer applied. 
 
Typically, however, as a gold standard, post-mortem confirmation is required for a definite diagnosis of 
PD. Thus, clinical criteria can lead to a diagnosis of probable PD at best. The pathological features of PD 
include loss of dopaminergic neurons within the substantia nigra pars compacta and the presence of the 
Lewy pathology, an intracellular aggregation of abnormally folded α-synuclein proteins (see Kalia and Lang 
2015a). 
In epidemiological studies, the diagnosis of PD is generally based on clinical criteria. A diagnosis of 
probable PD was confirmed in 83% of patients when re-evaluated according to strict clinical diagnostic 
criteria (the UK Parkinson’s Disease Society Brain Bank criteria) (Schrag et al. 2002). Another study 
suggested that the accuracy of the established clinical criteria was up to 90%, when confirmed with 
neuropathological examination (see Hughes et al. 2001). 
The slow progression of PD creates further challenges to epidemiologic investigation. The exact time of 
onset of the pathophysiologic process of PD in any individual cannot be determined. The mean age of 
symptom onset was from 60 to 65 years in eight individual studies and over 65 years in a review of five 
studies (see Twelves et al. 2003). There are suggestions that the non-motor symptoms in PD could begin, 
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in many instances, decades before the onset of motor symptoms (see Gaig and Tolosa 2009). The early 
premotor symptoms, such as olfactory deficit, constipation, sleep disorders, depression, and anxiety (see 
Siderowf and Lang 2012), are likely to influence individual’s behavior. Thus, the possibility that underlying 
preclinical PD may alter or mask the associations observed in epidemiological studies should be 
acknowledged. 
2.2 Epidemiological studies on the risk of PD 
2.2.1 An overview of PD epidemiology 
There are few reviews providing an insight into the broad spectrum of research on the epidemiology of PD 
(see Wirdefeldt et al. 2011; see de Lau and Breteler 2006a). Several risk and protective factors for PD have 
been proposed on the basis of presumed pathogenic mechanisms of the disease (Figure 1). The dietary, 
lifestyle, and metabolic factors will be reviewed in more detail in following chapters; other factors are 
briefly mentioned below. 
Despite the large number of studies examining PD and occupational exposures, causal relationships have 
not been established (see Wirdefeldt et al. 2011). The factors grouped under ‘pre-existing medical 
conditions’, for example metabolic factors and dementia, are interesting as some of them could also be 
interpreted as early manifestations of PD. Ultimately, the epidemiologic evidence for most of the 
proposed risk or protective factors is inconclusive. 
A large number of genetic association studies of PD have been published. The known PD genes, however, 
are estimated to account for only a small proportion of the PD cases occurring at the population level (see 
Wirdefeldt et al. 2011). Furthermore, genetic heterogeneity complicates the research on new PD genes 
and loci. In addition, there is little information on gene-environment interactions in PD (see Wirdefeldt et 
al. 2011).  
The majority of studies regarding PD epidemiology have been case-control studies. The meta-analysis by 
Hernan et al. (2002) included 44 case-control and four cohort studies on smoking and PD. The systematic 
review by Ishihara and Brayne (2005) included 33 case-control studies and seven cohort studies, with each 
study only looking at a small selection of the following exposures: food items, energy-yielding nutrients, 
vitamins, and other factors. Furthermore, the review by Wirdefeldt et al. (2011) found 14 case-control and 
five prospective studies on alcohol and PD, and three case-control and four prospective studies on 
physical activity and PD. Regarding coffee consumption and PD, one meta-analysis included 17 cross-
sectional or case-control studies and nine prospective studies (see Costa et al. 2010). 
  
2 Review of the literature 
?
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?
?
?
?
?
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????? ??????????????? ????? ?????????? ????????????????????????????????? ????????????????????????
???????
 
Regarding metabolic factors and PD, the review by Wirdefeldt et al. (2011) found 10 case-control and four 
prospective studies on diabetes and PD, and 11 case-control and three prospective studies on 
hypertension or blood pressure and PD. Furthermore, the review identified six case-control and one 
prospective studies on heart disease or stroke and PD, as well as three case-control and four prospective 
studies on serum cholesterol levels and PD. 
Cross-sectional or case-control studies are not an optimal design for etiologic studies, as retrospective 
exposure measurements are extremely prone to bias, for example when addressing nutritional exposure 
occurring many years in the past (Willett 1998). A focus on prospective studies in the future is clearly 
needed. Furthermore, the studies vary greatly in methodological aspects, such as case ascertainment and 
inclusion of confounding factors. Thus, the following review attempts to acknowledge these aspects too. 
Occupational and environmental exposures 
Occupational history 
Urban and rural areas (farming, rural living, 
well water use) 
Metals 
Pesticides 
Organic solvents 
Other chemicals 
Magnetic fields 
 
Genetic epidemiology 
Family studies  Twin studies  Susceptibility genes 
PD genes: autosomal recessive/dominant  
Pre-existing medical conditions 
REM sleep behavior disorder 
Olfactory dysfunction Cancer 
Dementia  Diabetes 
Mental illness  Vascular diseases 
Essential tremor Metabolic factors 
Head trauma  Obesity (BMI) 
Inflammation  Estrogen 
Infections  Uric acid and gout 
Lifestyle factors 
Physical activity  Smoking 
Alcohol consumption 
Coffee or tea consumption 
  
Diet 
Diet quality 
Specific food items (e.g. dairy products) 
Macronutrients Micronutrients 
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2.2.2 Inclusion criteria for the literature review 
The literature review of this thesis covers only those prospective studies examining the associations 
between PD risk and those exposures stated in the aims of this study (diet quality; food groups; physical 
activity; alcohol consumption; smoking; obesity; blood pressure; blood concentration of triglycerides, HDL 
cholesterol, total cholesterol, and glucose; metabolic syndrome). However, if the literature on a specific 
topic was limited or lacking prospective studies, studies employing other designs are briefly mentioned. 
Furthermore, the results of a few systematic reviews and meta-analyses are mentioned to complement 
the overview. 
All relevant prospective studies have been included, without any limitations on the size of the study, type 
of the publication, or publication or baseline year. An example of search protocol for the literature review 
is presented in Appendix Table 1. In addition to the literature search, the references of included studies 
and a few recent review articles were also searched. In this review, the term ‘prospective study’ refers to 
cohort designs, nested case-control designs, or other longitudinal designs.  
One reason for restricting the review to prospective studies is that the focus of the current study is not on 
PD patients, but in predicting future PD. Furthermore, a case-control design is not optimal for studying 
etiologic clues. Retrospective studies were excluded because they are prone to bias, especially when 
addressing exposure occurring many years in the past. 
The results of the studies mentioned in the following chapters and tables are from multivariate models 
that adjusted for at least smoking, unless otherwise stated. Smoking is a strong confounding factor both 
predicting PD and associating with most of the exposures examined.  
2.2.3 Diet and the risk of PD  
As the aim of this study was to assess the diet as a whole, this review focuses on studies of diet quality, as 
well as food groups and items that are components of the diet quality indices. However, a brief chapter on 
nutrients is also included to support the interpretation of the results by giving background on potential 
biological mechanisms underlying the associations. Furthermore, coffee and alcohol consumption have 
been reviewed separately in chapter 2.2.4. 
A wide variety of nutritional exposures have been studied for their association with PD, e.g. food items, 
macronutrients (such as protein, fat, and carbohydrates), and micronutrients (e.g. vitamins, minerals, and 
phytochemicals) (see Ishihara and Brayne 2005). However, the number of prospective studies on 
individual dietary factors is limited.  
There were seven publications on prospective studies of specific food groups or items and the risk of PD. 
These studies and their results are described in Tables 2 and 3. Five of these studies were from the United 
States, as well as one from Greece and one from China. Studies with more than 100 PD cases were all 
from the United States. Most of the studies measured dietary intake with food frequency questionnaires, 
while two reported using 24-hour recall (Table 2).  
Diet quality 
Diet quality can be studied with dietary indices reflecting adherence to a predefined dietary habit, with 
data-driven approaches (principal components analysis and cluster analysis) describing actual intake 
patterns in the population, or with reduced rank regression looking for associations between food intake 
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and the outcomes (see Tucker 2010). In this study, we used the dietary index method to describe the diet 
quality. 
There is only one previous prospective study on diet quality and PD risk. This large cohort study (n=508 PD 
cases) pooling together the Nurses’ Health Study and the Health Professionals Follow-Up Study assessed 
participant’s dietary intake with a food frequency questionnaire (131 items for men and 116 for women) 
(Gao et al. 2007). Diet quality was measured with the Alternate Healthy Eating Index (AHEI) and with the 
alternate Mediterranean Diet Score (aMED). Both indices had an inverse association with PD risk (P for 
trend for AHEI 0.01, and for aMED 0.07). The risk of PD was 30% lower for those in the highest quintile of 
the AHEI score compared with the lowest quintile. The corresponding reduction in risk for aMED was 25%. 
These results indicate that a diet characterized by a high intake of fruits, vegetables, legumes, whole 
grains, nuts, fish, and poultry and a low intake of saturated fat and a moderate intake of alcohol may 
protect against PD. This finding was supported by a case-control study from the United States where PD 
patients (n=257) were found to be less likely to adhere to the Mediterranean-type diet than controls 
(Alcalay et al. 2012). The study assessed the current diet (i.e. from the preceding year) with a 61-item food 
frequency questionnaire. 
In addition, Gao et al. (2007) conducted a principal components analysis identifying two dietary patterns, 
prudent and Western. The prudent score, characterized by high intakes of fruit, vegetables, and fish, was 
inversely associated with PD risk (P for trend 0.04), but the Western pattern was not. Furthermore, a case-
control study from Japan with 249 PD patients identified three dietary patterns (Healthy, Western, and 
Light) by factor analysis (Okubo et al. 2012). The Healthy pattern, consisting of high intakes of vegetables, 
fruits, and fish, was inversely associated with PD risk. The study assessed the current diet (i.e. from the 
preceding month) of the PD patients with a dietary history questionnaire of 150 items.  
However, it is possible that the dietary habits of the PD patients are a result of the PD status rather than 
its cause. The non-motor symptoms of PD, such as loss of sense of smell, constipation, and mood and 
cognitive disorders (see Gaig and Tolosa 2009) are likely to affect individuals’ dietary habits. More 
prospective studies on diet quality and PD risk are urgently needed. 
Food groups or items 
In general, no association between any individual food groups or items and the risk of PD were found in 
most of the prospective studies (Table 3). The few exceptions were consumption of milk products, nuts, 
and legumes.  
Four studies found a positive association between consumption of milk and the risk of PD (Kyrozis et al. 
2013; Chen et al. 2007; Park et al. 2005; Chen et al. 2002). Three of the studies were from the United 
States (Chen et al. 2007; Park et al. 2005; Chen et al. 2002), and one from Greece (Kyrozis et al. 2013). 
However, two of these studies, large cohorts from the United States (Chen et al. 2007; Chen et al. 2002), 
analyzed the results separately for men and women and found the positive association between milk 
product consumption and PD risk in men only. The study by Park et al. (2005) included only men, whereas 
Kyrozis et al. (2012) did not report men and women separately. Thus the potential gender difference in 
this association should be examined in future studies.  
Furthermore, an inverse association between PD risk and the consumption of nuts (Zhang et al. 2002) and 
legumes (Morens et al. 1996) has been observed in large cohort studies from the United States. However, 
there are no other prospective studies to replicate these findings.  
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Table 3. Summary of prospective study findings on food groups or items and the risk of Parkinson’s diseasea. 
Food groups or item No association Increased risk (positive 
association) 
Decreased risk (inverse 
association) 
Grains (or cereals) NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 
EPIC-G, Kyrozis et al. 2012 
NR NR 
- Rye NR NR NR 
- Wheat NR NR NR 
- Whole grains NR NR NR 
Vegetables NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 
EPIC-G, Kyrozis et al. 2012 
NIT, Ma et al. 2006 
NR NR 
- Legumes and nuts NR NR Nuts:  
NHS, Zhang et al. 2002 
HPFS, Zhang et al. 2002 
Legumes:  
HAAS, Morens et al. 1996 
- Potato NR NR NR 
- Roots NR NR NR 
Fruits and berries NR NR NR 
- Fruits, fresh NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 (NR 
whether fresh or canned) 
NIT, Ma et al. 2006 
NR NR 
- Berries NR NR NR 
Margarines NR NR NR 
Oils, mayonnaise NHS, Zhang et al. 2002 
HPFS, Zhang et al. 2002 
HAAS, Morens et al. 1996 
NR NR 
Butter HPFS, Chen et al. 2002 NR NR 
Milk and milk products NHS, Chen et al. 2002 HPFS, Chen et al. 2002 
CPS-II, Chen et al. 2007 
EPIC-G, Kyrozis et al. 2012 
NR 
- Milk NR HPFS, Chen et al. 2002 
HAAS, Park et al. 2005 
CPS-II, Chen et al. 2007 
EPIC-G, Kyrozis et al. 2012 
NR 
- Cheese CPS-II, Chen et al. 2007 
EPIC-G, Kyrozis et al. 2012 
HPFS, Chen et al. 2002 NR 
- Fermented milk 
products 
CPS-II, Chen et al. 2007 
EPIC-G, Kyrozis et al. 2012 
HPFS, Chen et al. 2002 NR 
Meat and meat 
products (i.e. Total 
meat) 
NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 
EPIC-G, Kyrozis et al. 2012 
NR NIT, Ma et al. 2006 
- Red meat NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 
NR NR 
- Processed meat and 
sausages 
NR NR NR 
- Poultry NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 
NR NR 
- Ratio of white meat to 
red meat 
NR NR NR 
Fish  NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 
EPIC-G, Kyrozis et al. 2012 
NR NR 
Eggs NIT, Ma et al. 2006 NR NR 
Sugar and sugar rich 
condiments (or sweets 
and desserts) 
NHS, Chen et al. 2002 
HPFS, Chen et al. 2002 
NR NR 
Abbreviations: NR, not reported or no previous studies exist; NHS, Nurses' Health Study; HPFS, Health Professionals 
Follow-up Study; EPIC-G, EPIC-Greece; HAAS, Honolulu-Asia Aging Study; CPS-II, Cancer prevention Study II; NIT, 
Nutritional Intervention Trial. 
a the categories in the table are chosen to represent the whole diet 
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Energy-yielding nutrients  
Most of the prospective studies on diet and PD risk have examined the association between individual 
nutrients and PD risk.  
Total protein intake was not associated with PD risk in three of the large cohort studies: the Singapore 
Chinese Health Study (Tan et al. 2008), the Nurses’ Health Study (Chen et al. 2003a), and the Health 
Professionals Follow-up Study (Chen et al. 2003a). The Cancer Prevention Study II Nutrition Cohort study, 
however, reported a higher risk of PD for increased total protein intake, and this association was stronger 
for protein from dairy sources than from non-dairy sources (Chen et al. 2007). For carbohydrates, two 
cohort studies found no association (Tan et al. 2008; Chen et al. 2003a), but in the Honolulu-Asia Aging 
Study PD incidence rose significantly with increasing intake both in non-coffee drinkers and never smokers 
(Abbott et al. 2003). 
The Nurses’ Health Study and the Health Professionals Follow-up Study reported that the intakes of total 
fat or major types of fat were not significantly associated with PD risk (Chen et al. 2003a). However, they 
found that, in men, replacement of polyunsaturated fat with saturated fat was associated with a 
significantly increased risk. Additionally, the National Institutes of Health-American Association of Retired 
Persons Diet and Health Study found no association between overall fat intake or other macronutrients 
and PD risk, but a weak positive association between intake of n-6 polyunsaturated fatty acids and PD risk 
was observed (Dong et al. 2014). An inverse association between PD incidence and intake of total fat, as 
well as monounsaturated and polyunsaturated fat, was found in the prospective Rotterdam Study (de Lau 
et al. 2005a). In accordance, the Greek  cohort of the European Prospective Investigation into Cancer and 
Nutrition (EPIC), EPIC-Greece study, found an inverse association between polyunsaturated fat intake and 
incident PD (Kyrozis et al. 2013), as did the Honolulu-Asia Aging Study, reporting that the intake of 
polyunsaturated fats appeared protective against PD in men who never smoked cigarettes (Abbott et al. 
2003). While the Singapore Chinese Health Study did not find an inverse association for polyunsaturated 
fat, an inverse association was found for monounsaturated fat (Tan et al. 2008). 
Total energy intake had no association with PD in the four prospective cohort studies (Kyrozis et al. 2013; 
Chen et al. 2003a; Abbott et al. 2003). 
A recent meta-analysis examined macronutrient intakes and the risk of PD (see Wang et al. 2015). The 
meta-analysis included studies reporting on protein intake (4 prospective studies and 3 case-control 
studies), carbohydrate intake (4 and 4, respectively), fat intake (7 and 5, respectively), and energy intake 
(4 and 4, respectively). The meta-analyses concluded that after adjusting for smoking and coffee/caffeine 
intake, no associations were found between these macronutrients and PD risk, but that higher 
polyunsaturated fat intake might be inversely associated with PD risk.  
Vitamins and other factors 
As oxidative stress is one of the hypothesized pathogenic mechanisms in PD, the role of antioxidants has 
been studied; however, the number of prospective studies is low. The review by Wirdefeldt et al. (2011) 
reports that three out of four prospective studies found an inverse association between vitamin E intake 
and PD incidence. Four prospective studies in the review examined vitamin C intake, two vitamin A intake, 
and one beta-carotenoid intake, but none of them found an association with PD risk. Only one prospective 
study has examined the association between dietary flavonoids and risk of PD, and the results suggested 
that total flavonoid intake was inversely associated with PD risk in men but not women (Gao et al. 2012). 
Furthermore, four prospective studies have assessed the relationship between serum uric acid levels and 
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PD, all reporting an inverse association between baseline serum uric acid and PD (see Wirdefeldt et al. 
2011). 
Since homocysteine has been hypothesized to have neurotoxic effects, vitamins B6, B12, and folate have 
been examined in relation to PD. According to the review by Wirdefeldt et al. (2011), the three 
prospective studies conducted on those vitamins did not find any particular associations with PD risk, 
except one which showed an inverse association between the intake of vitamin B6 and risk of PD. 
There is only one known prospective study reporting on blood levels of vitamin D; the Mini-Finland Health 
Survey found an inverse association between serum 25-hydroxy vitamin D level and PD incidence (Knekt 
et al. 2010). On the other hand, a large cohort study from the United States found that total dietary intake 
of vitamin D was unrelated to PD risk, but that vitamin D intake from dairy products was associated with a 
higher risk of PD (Chen et al. 2007). Another cohort study from Greece found no association between 
dietary vitamin D intake and PD risk (Kyrozis et al. 2013).  
The prospective studies examining the associations between minerals and PD risk are even more scarce 
than for other nutrients. The Nurses’ Health Study and the Health Professionals Follow-up Study reported 
that calcium supplements were not related to PD risk (Chen et al. 2002). However, after stratification of 
participants by levels of vitamin intake, non-heme iron was associated with an increased risk in those who 
had low vitamin C intake (Logroscino et al. 2008). 
Summary on dietary factors 
There are only ten prospective datasets that include dietary measurements at baseline as well as follow-
up information on PD. The studies reported a selected set of varying nutritional factors, most focusing on 
reporting specific nutrients, while some reported on specific food items. Prospective studies are 
particularly lacking for diet quality, as well as for different types of items within major food groups (Table 
3).  
The majority of the previous studies, based on this review and the one by Ishihara and Brayne (2005), did 
not find significant associations between nutritional factors and PD. Some associations were found in 
case-control studies (see Ishihara and Brayne 2005), but could not be replicated in cohort studies. 
Furthermore, it should be noted that the categorization of food items into larger food groups may differ 
between studies. These differences may have an impact on the results, thus being one contributor to the 
discrepancies in the literature, especially between prospective and case-control studies. Furthermore, 
prospective studies more often used food frequency questionnaires with a one year reference period, 
whereas most of the case-control studies used undefined questionnaires or interviews with different 
reference periods. Accordingly, these different methods produce varying results. 
Overall, dietary factors do not seem to play a major role in PD, although a few promising results have been 
obtained (e.g. associations with vitamin E and polyunsaturated fat intake, as well as urate concentration). 
However, more prospective studies are needed.  
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2.2.4 Lifestyle and the risk of PD 
Leisure-time physical activity  
Physical activity has been suggested to be one of the most important protective factors against chronic 
diseases like cardiovascular disease, diabetes, and some cancers (see Reiner et al. 2013). There is also 
evidence that exercise may protect against some neurodegenerative diseases like Alzheimer’s disease (see 
Han and Han 2014). Furthermore, the association between physical activity and PD risk has increasingly 
gained attention over the past few years.  
The prospective studies regarding physical activity and PD conducted thus far are described in Tables 4 
and 5. Additionally, a few case-control studies have been carried out (see Wirdefeldt et al. 2011), though 
most of those reported either a non-significantly reduced risk of PD or no association, with rather similar 
results in both genders. However, the largest cohort study, with 413 PD cases and 141,339 subjects in 
total, from the United States (Thacker et al. 2008), reported a significant inverse association between 
leisure-time physical activity and PD risk, suggesting that the association was due to moderate to vigorous 
rather than light activity. Furthermore, the most recent cohort study, from Sweden (including 43,368 
subjects, 286 with incident PD), reported an inverse association between PD risk and overall physical 
activity (household, commuting activity, and leisure-time exercise together), but not leisure-time exercise 
alone (Yang et al. 2015).  
A meta-analysis of four prospective studies showed a pooled hazard ratio of 0.66 (95% confidence interval 
(CI) 0.57–0.78) for highest versus lowest physical activity level (Yang et al. 2015). However, the study did 
not report the classification of the physical activity levels, or type of physical activity, for the pooled result. 
Moreover, the analysis did not include the findings from four studies reporting no association or a non-
significant decreased risk of PD (Kyrozis et al. 2013; Tan et al. 2008; Paganini-Hill 2001; Sasco et al. 1992). 
The authors stated that the reason for this exclusion was to analyze only studies reporting gender-specific 
information. 
In summary, several observational studies on PD risk and physical activity point toward a weak inverse 
association, but the type of protective physical activity remains unknown. 
Smoking  
Smoking is one of the most studied risk factors for PD. An inverse association between smoking and PD 
was first reported in a study from 1959 examining death rates and tobacco consumption (Dorn 1959). 
However, accuracy and underreporting of PD diagnoses remain a concern if PD ascertainment is made 
based solely on death certificates.  
The results from previous cohort studies, described in Tables 6 and 7, are consistent in reporting a strong 
inverse association between smoking and PD. Meta-analyses have also found similar results (see Ritz et al. 
2007; see Allam et al. 2004; see Hernan et al. 2002; see Sugita et al. 2001). The meta-analysis by Hernan et 
al. (2002) included four cohort studies and 44 case-control studies from 20 countries, and reported a 
pooled relative risk (RR) of 0.39 (95% CI 0.32–0.47) for current vs. never smokers, 0.59 (95% CI 0.54–0.63) 
for ever vs. never smokers, and 0.80 (95% CI 0.69–0.83) for past vs. never smokers.  
Furthermore, the meta-analysis by Ritz et al. (2007) (3 cohort and 8 case-control studies, all from the 
United States) focused on the intensity, duration, and types of tobacco use, suggesting a dose-dependent 
reduction in PD risk with cigarette smoking and potentially other types of tobacco use. They also found 
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that the shorter the time since smoking cessation, the lower the risk of PD. This meta-analysis did not find 
any effect modification by sex or education.  
The inverse association between smoking and PD risk could be explained by different biases, such as 
information bias, difficulties in diagnosing PD, competing causes of death, reverse causation (if PD 
patients were less prone to smoke), or confounding not accounted for in the studies (e.g. genetic factors). 
However, twin studies controlling for both genetic and shared early environmental factors have reported 
an inverse association between smoking and PD, thus implying that confounding by genetic factors is 
unlikely (Wirdefeldt et al. 2005; Tanner et al. 2002).  
One suggestion for why PD patients would be less prone to smoke is the premorbid personality of PD 
patients, including reduced sensation-seeking traits, which in turn relates to abstaining from addiction-
related habits (Evans et al. 2006). Patients with PD show reduced scores on impulsive sensation-seeking 
inventories and are less likely to engage in sensation-seeking behavior (see Menza 2000). Whether this 
type of personality shares a genetic background with PD pathogenesis, or is an early preclinical symptom 
of the disease, is unknown. However, a meta-analysis of 3 cohort and 8 case-control studies reporting that 
even subjects who stopped smoking 15-25 years before the study baseline had a decreased risk of PD 
compared to never smokers (see Ritz et al. 2007), argues against the above mentioned hypothesis of 
premorbid personality as an early symptom of the disease. Therefore, an alternative hypothesis to explain 
the inverse association between smoking and PD is that patients in the prodromal phase of PD might have 
a decreased “responsiveness” to nicotine resulting in less long-term use and addiction (Ritz et al. 2014). 
One cohort study examining the association between parental smoking and PD risk (to account for a non-
genetic unknown confounding factor) found an inverse association (O'Reilly et al. 2009). The authors 
concluded that if the inverse association between smoking and PD were due to confounding by an 
environmental factor or were the result of reverse causation, it is unlikely that parental smoking would 
predict PD. Finally, although causality has been debated, the inverse association between smoking and PD 
risk has been found across different study designs and populations around the world, while taking into 
account different effect-modifying factors or potential confounding, and indicates a clear dose-response 
relationship (see Wirdefeldt et al. 2011). 
In summary, there seems to be strong epidemiological evidence that smokers have a lower risk of PD. 
However, the biological mechanism underlying this potentially protective effect has not been identified, 
and there is still doubt that the association is due to reverse causation or some unknown confounding 
factor.   
Alcohol consumption 
There are suggestions of an inverse association between addiction-related habits (e.g. smoking and coffee 
consumption) and PD risk, due to the reduced sensation-seeking traits of PD patients (Evans et al. 2006). 
Thus, association between alcohol consumption and PD risk has also been examined. 
The prospective studies conducted previously, described in Tables 8 and 9, report mostly no association 
between alcohol intake and PD risk. In addition, the results from case-control studies were rather similar 
(see Wirdefeldt et al. 2011). However, summarizing the results of these studies is difficult, as exposure 
variables were estimated differently, from calculation of the total amount of alcohol consumed (as 
ethanol, or as number of drinks per month or week) to simple dichotomous ‘ever vs. never’ variables. 
Furthermore, studies utilizing only dichotomous variables on alcohol consumption ignore the dose effect.  
Additionally, few studies examined consumption levels across specific types of alcohol. Indeed, a large 
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cohort study from the United States found a statistically significant inverse association between beer 
consumption (estimated as number of drinks) and risk of PD (Hernan et al. 2003).  
Results from these previous studies show that controlling for confounding factors is important, as many 
studies found an inverse association in univariate analyses, but after controlling for confounding factors 
like smoking and coffee consumption the results were no longer statistically significant (see Wirdefeldt et 
al. 2011). This might imply that the inverse association between alcohol consumption and PD risk found in 
some case-control studies could be due to residual confounding. On the other hand, smoking could also 
be an effect-modifying factor, masking the association between alcohol and PD: a Swedish nested case-
control study found an inverse association between alcohol consumption and PD risk only among never 
smokers (odds ratio 0.56, 95% CI 0.39–0.80 for ever vs. never drinkers) (Wirdefeldt et al. 2005).  
In summary, the number of prospective studies is limited, though the results point toward no association 
between alcohol consumption and PD risk. However, the lack of uniformity in reporting alcohol intake as 
well as inadequate sample sizes and variable PD ascertainment method should be considered when 
interpreting the results. Converting drink units and portions into grams of ethanol for analysis, as well as 
measuring different beverage types, would enhance comparability between the studies. 
Coffee consumption 
Coffee consumption is a dietary habit that has been inversely associated with alcohol consumption and 
smoking (Sääksjärvi et al. 2008; Hu et al. 2007a; Ascherio et al. 2004). Therefore, it has also been of 
interest in epidemiological studies on PD. 
This review revealed 14 previously conducted prospective studies, described in Tables 10 and 11, although 
two of them were re-analyses of data that had previously been reported (highlighted with grey in the 
Table 10: Ross et al. (2000), Ascherio et al. (2003)). Most of the studies found a statistically significant 
inverse association between coffee consumption or caffeine intake and PD risk. There are observations of 
an effect modification by gender that could be explained by hormone replacement therapy; a few studies 
from the United States suggest that coffee or caffeine intake reduces PD risk among those women not 
using postmenopausal hormones (Palacios et al. 2012b), however, among hormone users, the risk might 
increase (Ascherio et al. 2004; Ascherio et al. 2003). Additionally, smoking has been found to modify the 
association between coffee consumption or caffeine intake and risk of PD, but with contrasting results (for 
women, the association was present in ever smokers, but for men, in never smokers) (Palacios et al. 
2012b). 
Caffeine from non-coffee sources (e.g. tea, cola beverages, chocolate) has also been inversely associated 
with PD risk (Ascherio et al. 2001; Ross et al. 2000). In contrast, three prospective studies reported no 
association between tea intake and PD risk (Kyrozis et al. 2013; Hu et al. 2007a; Paganini-Hill 2001). 
However, only one study has examined black and green tea separately, finding an inverse association 
between black tea intake and PD risk (Tan et al. 2008). 
There are three meta-analyses of observational studies on self-reported coffee or caffeine exposure and 
PD risk (see Qi and Li 2014; see Costa et al. 2010; see Hernan et al. 2002). The largest one included 26 
studies (7 cohort, 2 nested case-control, 16 case-control, and 1 cross-sectional study) and reported a 
summary relative risk of 0.76 (95% CI 0.72–0.80) per 300 mg increase in caffeine intake (see Costa et al. 
2010). Two of the meta-analyses (see Costa et al. 2010; see Hernan et al. 2002) concluded that caffeine 
exposure or coffee drinking is associated with a lower risk of PD, while the third one stated that further 
research is required to confirm the findings (see Qi and Li 2014).  
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The previously mentioned biases (regarding the association between smoking and PD risk) are also a 
concern in studies on coffee and PD (see page 24). Indeed, a twin study controlling for both genetic and 
shared early environmental factors did not find an association between coffee consumption and PD risk 
(Wirdefeldt et al. 2005). Furthermore, reverse causation is generally thought to be an unlikely bias in a 
prospective design. However, since PD is a disease with a several decades-long preclinical disease phase 
(see Gaig and Tolosa 2009), reverse causation remains a concern, as there are suggestions that reduced 
sensation-seeking traits in preclinical PD patients lead to abstaining from addiction-related habits (Evans 
et al. 2006). This concern has not adequately been addressed in studies regarding coffee or caffeine 
exposure and PD risk. Thus, further prospective studies with several decades of follow-up (enabling the 
exclusion of the first 10–20 years of follow-up), or retrospective information on coffee consumption 10–
20 years prior to the study baseline, is needed. 
2.2.5 Obesity, metabolic health, and the risk of PD 
Metabolic health and obesity are complex conditions which may have adverse health effects. However, 
little is known about their association with PD risk.  
Obesity 
Conflicting results on the association between obesity and PD risk have been reported (Tables 12 and 13).  
In prospective studies, subjects with high BMI (Hu et al. 2006) or increased tricep skinfold thickness 
(Abbott et al. 2002) have been associated with higher risk of PD. However, one nested case-control study 
found an inverse association between BMI and PD incidence (Ma et al. 2006). On the other hand, all the 
other reviewed prospective studies (Vikdahl et al. 2015; Kyrozis et al. 2013; Palacios et al. 2011; Tan et al. 
2008; Logroscino et al. 2007; Chen et al. 2004; Paganini-Hill 2001) reported null associations. 
This inconsistency could be explained by the preclinical disease stage of PD masking the associations, since 
PD patients tend to lose weight as the disease progresses, with the process beginning several years before 
clinical diagnosis (Chen et al. 2003b). The large cohort studies from the United States that did not find an 
association between BMI and PD risk excluded only the first 3–5 years of follow-up (Palacios et al. 2011; 
Logroscino et al. 2007; Chen et al. 2004). Moreover, most of the studies evaluated here did not report 
performing any kind of lag analyses, or excluded less than a year from the beginning of follow-up (Vikdahl 
et al. 2015; Kyrozis et al. 2013; Tan et al. 2008; Hu et al. 2006; Ma et al. 2006; Abbott et al. 2002; Paganini-
Hill 2001). 
Further studies should consider the effect of the potential preclinical disease phase that could mask the 
association between BMI and PD risk with sensitivity analyses regarding the beginning of the follow-up 
period. 
Furthermore, smoking could be an effect-modifying factor, as a large cohort study from the United States 
(including 164,762 total subjects, 451 with PD) found that higher waist circumference and waist-to-hip 
ratios were associated with increased PD risk when analyses were restricted to never smokers (Chen et al. 
2004). 
Blood Pressure or hypertension 
There were seven prospective studies on the association between blood pressure or hypertension 
diagnosis and PD, as described in Tables 14 and 15. Results are conflicting; most of the studies found no 
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association between blood pressure/hypertension and PD risk, while a few found either a decreased risk 
(Vikdahl et al. 2015; Paganini-Hill 2001) or increased risk (Qiu et al. 2011). However, it should be noted 
that three of the studies finding no association were vague in their reporting of methods or analysis 
results (Tan et al. 2008; Ma et al. 2006; Grandinetti et al. 1994). The studies did not report, for example, 
the exposure categories compared, or what factors were adjusted for. 
Gender might be an effect-modifying factor here, as a Finnish cohort study (including 59,540 total 
subjects, 794 with PD) reported no association for men but a positive association for women (Qiu et al. 
2011).  
Blood pressure or hypertension diagnosis have been examined in more than ten case-control studies, as 
reviewed by Wirdefeldt et al (2011). However, the results from them have also been conflicting (see 
Wirdefeldt et al. 2011). One reason for the varying results in observational studies could be different 
methodology, as some studies included measurements on blood pressure while others relied on self-
reported information on blood pressure or diagnosed hypertension. 
Serum HDL cholesterol and total cholesterol 
There are two prospective studies on the association between HDL cholesterol and PD risk as described in 
Table 14. Neither of the studies found any association with PD risk. It should be, however, noted that the 
article by Huang et al. (2008) stated only that there was no association between HDL cholesterol and PD 
risk. For example, they did not report what exposure categories were compared or whether the models 
were adjusted or not. 
Similarly, the case-control studies from Italy and the United States did not found association between HDL 
cholesterol levels and PD (Cereda et al. 2012; Huang et al. 2007). Further prospective studies are, 
however, needed.  
Serum HDL cholesterol was included in the present study since it is one of the criteria of metabolic 
syndrome. However, serum total cholesterol has also gained interest in previous studies. Thus, serum 
total cholesterol was also included in this study. Briefly, two cohort studies reported reduced (Simon et al. 
2007; de Lau et al. 2006b) and one increased (Hu et al. 2008) PD risk for increasing total cholesterol levels. 
Serum triglycerides and glucose 
There are no previous cohort studies examining the association between serum triglycerides and PD risk, 
or between blood glucose levels and PD risk. One nested case-control study from Sweden, however, 
included these factors (see Table 15). The study comprised 84 PD cases and 336 controls, and had a rather 
short follow-up time (2–8 years) (Vikdahl et al. 2015). There appeared to be an inverse association 
between serum triglycerides and PD risk, but after adjustments in the multivariate model, including 
smoking, the result was borderline significant. However, the results from the study by Vikdahl et al. (2014) 
are hard to interpret, and more studies are needed. 
There are three previous case-control studies on PD and serum triglyceride concentration, all reporting 
that cases had a significantly lower serum triglyceride level than controls (Wei et al. 2013; Cereda et al. 
2012; Scigliano et al. 2006). Two of the studies also reported lower levels of fasting blood glucose in PD 
cases compared to controls (Cereda et al. 2012; Scigliano et al. 2006). 
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Metabolic syndrome 
There are no previous prospective studies examining the association between metabolic syndrome and PD 
risk. One case-control study from Italy (80 PD cases and 80 controls) found a similar prevalence of 
metabolic syndrome among cases and controls (Cereda et al. 2012). That study used The National 
Cholesterol Education Program’s Adult Treatment Panel III criteria (Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2001) which are otherwise 
the same as those used in the present study, but did not include information on antihypertensive drug 
treatment and used a higher cut-off point for glucose (6.1 mmol/l, whereas 5.6 mmol/l was used in the 
present study). Furthermore, the study had information on waist circumference, whereas the present 
study used information on BMI. 
  
 
27 
2 Review of the literature 
Ta
bl
e 
4.
 P
hy
si
ca
l a
ct
iv
ity
 a
nd
 P
ar
ki
ns
on
’s
 d
is
ea
se
: C
oh
or
t s
tu
di
es
. 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 
(9
5%
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ (
C
he
n 
et
 a
l. 
20
05
) 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
98
6 
 
77
,2
54
 
/1
35
, F
 
12
 
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
Q
 
le
is
ur
e-
tim
e 
ph
ys
ic
al
 a
ct
iv
ity
, 
w
al
ki
ng
, a
nd
 s
ta
ir 
cl
im
bi
ng
 to
ge
th
er
 
(M
E
T-
h/
w
ee
k)
 
 vi
go
ro
us
 a
ct
iv
ity
 
(M
E
T-
h/
w
ee
k)
 
hi
gh
es
t v
s.
 
lo
w
es
t 
qu
in
til
e 
   hi
gh
es
t v
s.
 
lo
w
es
t 
qu
in
til
e 
1.
3 
(0
.7
–
2.
3)
 
 
   1.
0 
(0
.6
–
1.
7)
 
0.
97
 
     0.
7 
ag
e,
 s
m
ok
in
g,
  a
lc
oh
ol
, 
ca
ffe
in
e,
  e
ne
rg
y 
in
ta
ke
, 
la
ct
os
e 
in
ta
ke
, B
M
I 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
C
he
n 
et
 a
l. 
20
05
) 
H
ea
lth
 
P
ro
fe
ss
io
na
ls
 
Fo
llo
w
-U
p 
S
tu
dy
, 1
98
6 
48
,5
74
 
/2
52
, M
  
 
14
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
Q
 
to
ta
l l
ei
su
re
-ti
m
e 
ph
ys
ic
al
 a
ct
iv
ity
 
+ 
w
al
ki
ng
, s
ta
ir 
cl
im
bi
ng
 (M
E
T-
h/
w
ee
k)
 
 vi
go
ro
us
  a
ct
iv
ity
 
(M
E
T-
h/
w
ee
k)
 
hi
gh
es
t v
s.
 
lo
w
es
t 
qu
in
til
e 
   hi
gh
es
t v
s.
 
lo
w
es
t 
qu
in
til
e 
0.
7 
(0
.5
–
1.
1)
  
    0.
5 
(0
.3
–
0.
9)
 
0.
00
7 
     0.
00
4 
ag
e,
 s
m
ok
in
g,
  a
lc
oh
ol
, 
ca
ffe
in
e,
  e
ne
rg
y 
in
ta
ke
, 
la
ct
os
e 
in
ta
ke
, B
M
I 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(L
og
ro
sc
in
o 
et
 a
l. 
20
06
) 
H
ar
va
rd
 A
lu
m
ni
 
H
ea
lth
 S
tu
dy
, 
19
88
 
10
,7
14
 
/1
01
, M
  
 
5 
or
 9
b  
se
lf-
re
po
rt 
or
 d
ea
th
 
ce
rti
fic
at
es
 
Q
 
le
is
ur
e-
tim
e 
ph
ys
ic
al
 a
ct
iv
ity
 
+ 
w
al
ki
ng
, s
ta
ir 
cl
im
bi
ng
 (k
ca
l 
ex
pe
nd
ed
 o
n 
ph
ys
ic
al
 
ac
tiv
ity
/w
ee
k)
 
≥3
00
0 
vs
. 
<1
00
0 
 
0.
63
 
(0
.3
6–
1.
12
) 
  
0.
12
 
ag
e,
 s
m
ok
in
g,
  a
lc
oh
ol
, 
co
ffe
e,
 te
a,
 h
is
to
ry
 o
f 
C
V
D
 o
r c
an
ce
r 
 
 
 
 
 
 
 
 
 
 
 
S
in
ga
po
re
/ 
(T
an
 e
t a
l. 
20
08
 ) 
S
in
ga
po
re
 
C
hi
ne
se
 H
ea
lth
 
S
tu
dy
, 1
99
3–
19
98
 
63
,2
57
 
/1
57
, F
 a
nd
 
M
 
12
 
se
lf-
re
po
rt 
or
 h
os
pi
ta
l 
di
sc
ha
rg
e 
da
ta
ba
se
 
or
 P
D
 re
gi
st
ry
,  
as
ce
rta
in
ed
 b
y 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
in
te
rv
ie
w
 
w
ith
 a
 
st
ru
ct
ur
ed
  
Q
 
ph
ys
ic
al
 a
ct
iv
ity
 
(N
R
) 
N
R
 
N
R
 (j
us
t 
st
at
ed
:  
N
S
) 
N
R
 
N
R
 
   
 
 
 
 
 
 
 
 
 
 
  
 
28 
2 Review of the literature 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; R
R
, r
el
at
iv
e 
ris
k;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; M
E
T-
h,
 m
et
ab
ol
ic
 e
qu
iv
al
en
t t
as
k 
ho
ur
, N
R
, n
ot
 re
po
rte
d;
 
N
S
, n
on
-s
ig
ni
fic
an
t; 
B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 C
V
D
, c
ar
di
ov
as
cu
la
r d
is
ea
se
; O
R
, o
dd
s 
ra
tio
.  
a  
To
ta
l p
op
ul
at
io
n/
P
D
 c
as
es
  
b  
Fo
llo
w
-u
p 
w
as
 5
 y
ea
rs
 if
 P
D
 a
sc
er
ta
in
m
en
t w
as
 b
as
ed
 o
n 
se
lf-
re
po
rt 
fro
m
 q
ue
st
io
nn
ai
re
, a
nd
 9
 y
ea
rs
 if
 b
as
ed
 o
n 
in
fo
rm
at
io
n 
fro
m
 d
ea
th
 c
er
tif
ic
at
es
 
c 
G
en
de
r-
sp
ec
ifi
c 
R
R
s 
w
er
e 
po
ol
ed
 to
ge
th
er
  
Ta
bl
e 
4.
 (c
on
tin
ue
d)
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 
(9
5%
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(T
ha
ck
er
 e
t 
al
. 2
00
8)
 
C
an
ce
r 
P
re
ve
nt
io
n 
S
tu
dy
 II
, 1
99
2 
14
1,
33
9 
/4
13
, F
 a
nd
 
M
c  
 
9 
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
 
to
ta
l l
ei
su
re
-ti
m
e 
ph
ys
ic
al
 a
ct
iv
ity
 
(M
E
T-
h/
w
ee
k)
 
 m
od
er
at
e 
to
 
vi
go
ro
us
 le
is
ur
e-
tim
e 
ac
tiv
ity
 
(M
E
T-
h/
w
ee
k)
 
≥2
3 
vs
. n
o 
ac
tiv
ity
 
  ≥1
6 
vs
. n
o 
or
 li
gh
t 
ac
tiv
ity
 
 
0.
8 
(0
.6
–
1.
2)
 
  0.
6 
(0
.4
–
1.
0)
 
0.
07
 
   0.
02
 
ag
e,
 e
du
ca
tio
n,
 
sm
ok
in
g,
 y
ea
rs
 s
in
ce
 
qu
itt
in
g 
sm
ok
in
g,
 
al
co
ho
l, 
ca
ffe
in
at
ed
 
co
ffe
e,
 c
al
or
ic
 in
ta
ke
, 
da
iry
 in
ta
ke
, B
M
I, 
pe
st
ic
id
e 
ex
po
su
re
, 
ib
up
ro
fe
n 
us
e 
 
 
 
 
 
 
 
 
 
 
 
G
re
ec
e/
 
(K
yr
oz
is
 e
t 
al
. 2
01
3)
 
E
P
IC
-G
re
ec
e,
 
19
93
–1
99
9 
25
,4
07
/8
8,
 
F 
an
d 
M
  
 
m
ea
n 
8.
45
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 w
ith
 s
el
f-
re
po
rte
d 
te
le
ph
on
e 
in
te
rv
ie
w
 
Q
 
ov
er
al
l a
ct
iv
ity
, 
oc
cu
pa
tio
na
l a
nd
 
le
is
ur
e-
tim
e 
1 
M
E
T-
h 
 
in
cr
em
en
t 
0.
95
 
(0
.9
0–
1.
00
) 
0.
06
 
ag
e,
 s
ex
, m
ar
ita
l s
ta
tu
s,
 
ed
uc
at
io
n,
 fa
rm
in
g,
 
sm
ok
in
g,
 c
of
fe
e 
w
ith
 
ca
ffe
in
e,
 e
ne
rg
y 
in
ta
ke
, 
B
M
I 
 
 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(Y
an
g 
et
 a
l. 
20
15
) 
S
w
ed
is
h 
N
at
io
na
l M
ar
ch
 
C
oh
or
t, 
N
R
  
43
,3
68
 
/2
86
, F
 a
nd
 
M
  
 
m
ea
n 
12
.6
 
an
y 
di
ag
no
si
s 
of
 P
D
 
in
 n
at
io
na
l 
pa
tie
nt
 re
gi
st
er
 
Q
 
ho
us
eh
ol
d 
+ 
co
m
m
ut
in
g 
ac
tiv
ity
 +
 le
is
ur
e-
tim
e 
ex
er
ci
se
 
(M
E
T-
h/
da
y)
 
 le
is
ur
e-
tim
e 
ex
er
ci
se
 (
M
E
T-
h/
da
y)
 
hi
gh
es
t v
s.
 
lo
w
es
t 
te
rti
le
 
   hi
gh
es
t v
s.
 
lo
w
es
t 
te
rti
le
 
0.
72
 
(0
.5
3–
0.
99
) 
   0.
86
 
(0
.6
2–
1.
19
) 
0.
04
 
     0.
36
 
at
ta
in
ed
 a
ge
 a
s 
tim
es
ca
le
, a
dj
us
tin
g 
fo
r 
se
x,
 e
du
ca
tio
n,
 
sm
ok
in
g,
 a
lc
oh
ol
, 
co
ffe
e,
 B
M
I  
 
 
 
 
 
 
 
 
 
 
 
Lo
ng
itu
di
na
l 
 
 
 
 
 
 
O
R
 
(9
5%
C
I)
 
 
 
U
S
A
/ (
X
u 
et
 
al
. 2
01
0)
 
N
IH
-A
A
R
P
 D
ie
t 
an
d 
H
ea
lth
 
S
tu
dy
, 1
99
6–
19
97
 
21
2,
93
4 
/7
67
, F
 a
nd
 
M
 
Fo
llo
w
-u
p 
su
rv
ey
 2
00
4–
20
06
, P
D
 
di
ag
no
se
d 
af
te
r y
ea
r 
20
00
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ne
ur
ol
og
is
t 
or
 re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
 
m
od
er
at
e 
to
 
vi
go
ro
us
 
ac
tiv
iti
es
, w
or
k 
+ 
ho
m
e 
+ 
le
is
ur
e-
tim
e 
(h
/w
ee
k 
of
 
to
ta
l a
ct
iv
ity
) 
>7
 v
s.
 
ne
ve
r 
0.
65
 
(0
.5
1–
0.
83
) 
0.
00
01
 
ag
e,
 s
ex
, r
ac
e,
 
ed
uc
at
io
n,
 s
m
ok
in
g,
 
co
ffe
e 
  
 
29 
2 Review of the literature 
Ta
bl
e 
5.
 P
hy
si
ca
l a
ct
iv
ity
 a
nd
 P
ar
ki
ns
on
’s
 d
is
ea
se
: N
es
te
d 
ca
se
-c
on
tro
l s
tu
di
es
. 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; O
R
, o
dd
s 
ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; N
R
, n
ot
 re
po
rte
d;
 N
S
, n
on
-s
ig
ni
fic
an
t; 
B
M
I, 
bo
dy
 m
as
s 
in
de
x.
  
a  
C
on
tro
ls
/P
D
 c
as
es
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 
as
ce
rta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
A
dj
us
te
d 
re
su
lt 
O
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
M
at
ch
in
g 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(S
as
co
 e
t 
al
. 1
99
2)
 
H
ar
va
rd
 C
ol
le
ge
 
an
d 
U
ni
ve
rs
ity
 o
f 
P
en
ns
yl
va
ni
a 
at
te
nd
ee
s,
 
19
16
–1
95
0 
54
8/
13
7,
 M
 
62
 o
r l
es
s,
 
de
pe
nd
in
g 
on
 b
as
el
in
e 
ye
ar
 
se
lf-
re
po
rt 
or
 
de
at
h 
ce
rti
fic
at
es
,  
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
Q
 
al
l p
hy
si
ca
l 
ac
tiv
ity
 in
 
ad
ul
th
oo
d 
(e
ne
rg
y 
ex
pe
nd
itu
re
 
kJ
/w
ee
k)
 
 cl
im
bi
ng
 s
ta
irs
 
an
d 
w
al
ki
ng
 in
 
ad
ul
th
oo
d 
(e
ne
rg
y 
ex
pe
nd
itu
re
 
kJ
/w
ee
k)
 
 an
y 
ph
ys
ic
al
 
ac
tiv
ity
 w
he
n 
yo
un
g 
≥1
3,
37
7 
vs
. 
≤2
,1
00
  
     ≥4
,8
26
 v
s.
 
≤2
,1
00
  
     an
y 
vs
. n
on
e 
1.
2 
(0
.5
6–
2.
6)
 
     0.
88
 (0
.4
8–
1.
6)
 
     0.
74
 (0
.3
1–
1.
7)
 
0.
92
 
      0.
72
 
un
iv
er
si
ty
, 
gr
ad
ua
tio
n 
ye
ar
, a
ge
 
sm
ok
in
g,
 
w
ei
gh
t, 
di
as
to
lic
 b
lo
od
 
pr
es
su
re
, 
m
ea
sl
es
 
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(P
ag
an
in
i-
H
ill
 2
00
1)
 
Le
is
ur
e 
W
or
ld
 
C
oh
or
t S
tu
dy
, 
19
81
–1
98
5 
2,
32
0/
39
5,
 F
 
an
d 
M
 
18
 
ho
sp
ita
l 
di
sc
ha
rg
e 
da
ta
ba
se
 o
r 
de
at
h 
ce
rti
fic
at
es
, o
r 
se
lf-
re
po
rt 
Q
 
ex
er
ci
se
 
N
R
 
N
R
 (j
us
t 
st
at
ed
: N
S
) 
N
R
 
se
x,
 b
irt
h 
da
te
, v
ita
l 
st
at
us
; i
f 
de
ad
, d
ea
th
 
da
te
 
 
N
R
 
 
 
 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(V
ik
da
hl
 e
t 
al
. 2
01
4)
 
N
or
th
er
n 
S
w
ed
en
 H
ea
lth
 
an
d 
D
is
ea
se
 
S
tu
dy
, 1
98
6–
20
09
 
33
6/
84
, 
F 
an
d 
M
 
2–
8 
cl
in
ic
al
 
ex
am
in
at
io
n 
by
 a
 
ne
ur
ol
og
is
t, 
co
nf
irm
ed
 b
y 
an
ot
he
r 
sp
ec
ia
lis
t 
Q
 
le
is
ur
e-
tim
e 
ph
ys
ic
al
 
ac
tiv
ity
 
re
cr
ea
tio
na
l 
ac
tiv
ity
 v
s.
 
in
ac
tiv
e 
 
    hi
gh
 a
ct
iv
ity
 
vs
. i
na
ct
iv
e 
 
F:
 4
.3
0 
(1
.0
9–
17
.0
2)
  
M
: 1
.3
4 
(0
.4
7–
3.
85
) 
  F:
 1
.5
6 
(0
.2
8–
8.
71
) 
M
: 1
.4
5 
(0
.4
3–
4.
83
) 
0.
04
 
  0.
58
 
   0.
62
 
 0.
55
 
se
x,
 a
ge
, 
ye
ar
 o
f 
he
al
th
 
su
rv
ey
, 
su
bc
oh
or
t, 
ge
og
ra
ph
ic
 
ar
ea
 
ag
e,
 s
m
ok
in
g,
 
B
M
I 
 
  
 
30 
2 Review of the literature 
Ta
bl
e 
6.
 S
m
ok
in
g 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: C
oh
or
t s
tu
di
es
. 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a 
, g
en
de
r 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(G
ra
nd
in
et
ti 
et
 
al
. 1
99
4)
 
H
on
ol
ul
u-
A
si
a 
A
gi
ng
 S
tu
dy
 
(o
rig
in
al
ly
  
H
on
ol
ul
u 
H
ea
rt 
S
tu
dy
), 
19
65
 
8,
00
6/
58
, M
 
26
 
ho
sp
ita
l r
ec
or
ds
, 
de
at
h 
ce
rti
fic
at
es
, o
r 
re
co
rd
s 
of
 lo
ca
l 
ne
ur
ol
og
is
ts
 
Q
 
sm
ok
in
g 
ev
er
 v
s.
 n
ev
er
 
0.
44
 (0
.2
6–
0.
75
) 
 
N
R
 
ag
e,
 c
of
fe
e,
 
al
co
ho
l 
 
 
 
 
 
 
 
 
 
 
 
N
et
he
rla
nd
s/
 
(W
ill
em
s-
G
ie
sb
er
ge
n 
et
 
al
. 2
00
0)
 
R
ot
te
rd
am
 S
tu
dy
, 
19
90
–1
99
3 
5,
28
9/
53
, F
 
an
d 
M
 
av
er
ag
e 
6.
07
 
P
D
 d
ia
gn
os
ed
 b
y 
ne
ur
ol
og
is
t a
t t
he
 
fo
llo
w
-u
p 
ex
am
in
at
io
n 
in
te
rv
ie
w
 
sm
ok
in
g 
ev
er
 v
s.
 n
ev
er
 
0.
54
 (0
.2
9–
1.
00
) 
N
R
 
ag
e,
 s
ex
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
H
er
na
n 
et
 a
l. 
20
01
) 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
97
6 
12
1,
70
0 
/1
53
, 
F 
20
 
  
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
  
0.
4 
(0
.2
–
0.
7)
  
  
N
R
 
ag
e 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
H
er
na
n 
et
 a
l. 
20
01
) 
H
ea
lth
 
P
ro
fe
ss
io
na
ls
 
Fo
llo
w
-u
p 
S
tu
dy
, 
19
86
 
51
,5
29
 
/1
46
, M
  
 
10
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
 
0.
3 
(0
.1
–
0.
8)
   
N
R
 
ag
e 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
Th
ac
ke
r 
et
 a
l. 
20
07
) 
C
an
ce
r P
re
ve
nt
io
n 
S
tu
dy
 II
 N
ut
rit
io
n 
C
oh
or
t, 
19
92
 
79
,9
77
 /1
42
, 
F;
  6
3,
34
8 
/2
63
, M
 
10
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
 ci
ga
re
tte
s 
pe
r 
da
y 
0.
27
 (0
.1
3–
0.
56
) 
   0.
00
9 
 
ag
eb
 
 
 
 
 
 
 
 
 
 
 
 
S
in
ga
po
re
/ (
Ta
n 
et
 a
l. 
20
08
) 
S
in
ga
po
re
 C
hi
ne
se
 
H
ea
lth
 S
tu
dy
, 
19
93
–1
99
8 
63
,2
57
 /1
57
, 
F 
an
d 
M
 
12
 
se
lf-
re
po
rt 
or
 
ho
sp
ita
l d
is
ch
ar
ge
 
da
ta
ba
se
 o
r P
D
 
re
gi
st
ry
, a
sc
er
ta
in
ed
 
by
 re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
in
te
rv
ie
w
 
w
ith
 a
 
st
ru
ct
ur
ed
  
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
  ag
e 
at
 s
ta
rti
ng
 
to
 s
m
ok
e 
0.
29
 (0
.1
6–
0.
52
) 
    <0
.0
01
 
ag
e,
 s
ex
,  
ed
uc
at
io
n,
 y
ea
r 
of
 in
te
rv
ie
w
, 
di
al
ec
t 
   
 
 
 
 
 
 
 
 
 
  
 
31 
2 Review of the literature 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; R
R
, r
el
at
iv
e 
ris
k;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; N
R
, n
ot
 re
po
rte
d;
 N
S
A
I, 
no
n-
st
er
oi
da
l a
nt
i-i
nf
la
m
m
at
or
y;
 
O
R
, o
dd
s 
ra
tio
; B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 N
IH
-A
A
R
P
, N
at
io
na
l I
ns
tit
ut
es
 o
f H
ea
lth
-A
m
er
ic
an
 A
ss
oc
ia
tio
n 
of
 R
et
ire
d 
P
er
so
ns
.  
a  
To
ta
l p
op
ul
at
io
n/
P
D
 c
as
es
  
b  
A
dj
us
tm
en
t f
or
 ra
ce
, e
du
ca
tio
n,
 p
hy
si
ca
l a
ct
iv
ity
, a
lc
oh
ol
, c
of
fe
e,
 s
up
pl
em
en
ta
ry
 v
ita
m
in
 in
ta
ke
, B
M
I, 
N
S
A
I d
ru
g 
us
e,
 p
es
tic
id
e 
ex
po
su
re
 d
id
 n
ot
 a
lte
r t
he
 re
su
lt 
Ta
bl
e 
6.
 (c
on
tin
ue
d)
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a 
, g
en
de
r 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ (
O
’R
ei
lly
 
et
 a
l. 
20
09
) 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
97
6;
 
H
ea
lth
 
P
ro
fe
ss
io
na
ls
 
Fo
llo
w
-u
p 
S
tu
dy
, 
19
86
 
92
,9
21
/2
87
, 
F;
 
30
,6
68
/1
68
, 
M
 
26
 
 18
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
 
pa
re
nt
al
 
sm
ok
in
g 
bo
th
 p
ar
en
ts
 
sm
ok
ed
 v
s.
 
ne
ith
er
 p
ar
en
t 
sm
ok
ed
 
 N
R
, 
pr
es
um
ab
ly
 
pa
ck
 y
ea
rs
 
0.
73
 (0
.5
3–
1.
00
) 
     0.
04
 
ag
e 
 
 
 
 
 
 
 
 
 
 
 
G
re
ec
e/
 
(K
yr
oz
is
 e
t a
l. 
20
13
) 
E
P
IC
-G
re
ec
e,
 
19
93
–1
99
9 
25
,4
07
 /8
8,
 F
 
an
d 
M
  
 
m
ea
n 
8.
45
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 w
ith
 
se
lf-
re
po
rte
d 
te
le
ph
on
e 
in
te
rv
ie
w
 
in
te
rv
ie
w
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
  
0.
42
 (0
.1
8–
0.
99
) 
   
ag
e,
 s
ex
, 
m
ar
ita
l s
ta
tu
s,
 
ed
uc
at
io
n,
  
fa
rm
in
g,
  
ph
ys
ic
al
 
ac
tiv
ity
,  
co
ffe
e,
 e
ne
rg
y 
in
ta
ke
, B
M
I 
 
 
 
 
 
 
 
 
 
 
 
Lo
ng
itu
di
na
l 
 
 
 
 
 
 
O
R
 (9
5%
 
C
I) 
 
 
U
S
A
/ (
C
he
n 
et
 
al
. 2
01
0)
 
N
IH
-A
A
R
P
 D
ie
t 
an
d 
H
ea
lth
 S
tu
dy
, 
19
95
–1
99
6 
30
5,
46
8 
 
/1
,6
62
, F
 a
nd
 
M
 
a 
fo
llo
w
-u
p 
su
rv
ey
 2
00
4–
20
06
, P
D
 
di
ag
no
se
d 
af
te
r 
ye
ar
 1
99
5 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ne
ur
ol
og
is
t 
or
 re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
 
sm
ok
in
g 
pa
st
 s
m
ok
in
g 
vs
. n
ev
er
 
 cu
rr
en
t v
s.
 
ne
ve
r 
  pa
ck
-y
ea
rs
 o
f 
sm
ok
in
g 
0.
78
 (0
.7
0–
0.
86
) 
 0.
56
 (0
.4
5–
0.
70
) 
       <0
.0
01
 
ag
e,
 s
ex
, r
ac
e,
 
ca
ffe
in
e 
in
ta
ke
 
  
 
32 
2 Review of the literature 
Ta
bl
e 
7.
 S
m
ok
in
g 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: N
es
te
d 
ca
se
-c
on
tro
l s
tu
di
es
. 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 
as
ce
rta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
A
dj
us
te
d 
re
su
lt 
O
R
 
(9
5%
 C
I) 
P
 fo
r 
tre
nd
 
M
at
ch
in
g 
A
dj
us
tm
en
ts
 
U
S
A
/ (
S
as
co
 
an
d 
P
af
fe
nb
ar
ge
r 
19
90
) 
H
ar
va
rd
 
C
ol
le
ge
 a
nd
  
U
ni
ve
rs
ity
 o
f 
P
en
ns
yl
va
ni
a 
at
te
nd
ee
s,
 
19
16
–1
95
0 
31
7/
76
, M
 
62
 o
r l
es
s,
 
de
pe
nd
in
g 
on
 
ba
se
lin
e 
ye
ar
 
se
lf-
re
po
rt 
or
 
de
at
h 
ce
rti
fic
at
es
,  
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
0.
51
 
(0
.2
6–
1.
0)
b  
N
R
 
un
iv
er
si
ty
, 
gr
ad
ua
tio
n 
ye
ar
, a
ge
 
  
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(P
ag
an
in
i-H
ill
 
20
01
) 
Le
is
ur
e 
W
or
ld
 
C
oh
or
t S
tu
dy
, 
19
81
–1
98
5 
2,
32
0 
/3
95
, F
 
an
d 
M
 
18
 
ho
sp
ita
l 
di
sc
ha
rg
e 
da
ta
ba
se
 o
r 
de
at
h 
ce
rti
fic
at
es
, o
r 
se
lf-
re
po
rt 
Q
 
sm
ok
in
g 
cu
rr
en
t (
≥ 
1 
pa
ck
/d
) v
s.
 
ne
ve
r 
  N
R
 
0.
42
 
(0
.2
2–
0.
80
)  
 
     0.
00
4b
 
 
se
x,
 b
irt
h 
da
te
, v
ita
l 
st
at
us
; i
f 
de
ad
, d
ea
th
 
da
te
 
 
al
co
ho
l, 
co
ffe
e,
 v
ita
m
in
 
C
 a
nd
 A
 
in
ta
ke
, b
lo
od
 
pr
es
su
re
 
m
ed
ic
at
io
n,
 
pa
rit
y 
 
 
 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(W
ird
ef
el
dt
 e
t 
al
. 2
00
5)
  
S
w
ed
is
h 
Tw
in
 
R
eg
is
try
, 1
96
7 
or
 1
97
3 
2,
38
0 
/4
76
, 
un
re
la
te
d 
F 
an
d 
M
 
   41
5 
 s
am
e-
se
x 
tw
in
s 
N
R
 
in
pa
tie
nt
 
di
sc
ha
rg
e 
re
gi
st
er
 o
r 
de
at
h 
ce
rti
fic
at
es
 
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
 ci
ga
re
tte
 
eq
ui
va
le
nt
s 
 cu
rr
en
t v
s.
 
ne
ve
r 
  ci
ga
re
tte
 
eq
ui
va
le
nt
s 
0.
56
 
(0
.4
0–
0.
79
) 
   tw
in
s:
 
0.
64
 
(0
.3
7–
1.
10
) 
   0.
01
0 
      0.
13
 
bi
rth
 y
ea
r, 
se
x,
 y
ea
r 
an
sw
er
ed
 th
e 
Q
. C
as
es
 
ha
d 
tw
o 
se
ts
 
of
 c
on
tro
ls
: 
un
re
la
te
d,
 
tw
in
  
ed
uc
at
io
n,
 
al
co
ho
l, 
co
ffe
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(K
am
el
 e
t a
l. 
20
07
) 
A
gr
ic
ul
tu
ra
l 
H
ea
lth
 S
tu
dy
, 
19
93
–1
99
7 
53
,8
88
 /7
4,
 F
 
an
d 
M
 
5 
se
lf-
re
po
rt 
of
 
ph
ys
ic
ia
n-
di
ag
no
se
d 
P
D
 
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
ne
ve
r 
0.
6 
(0
.2
–
1.
7)
 
N
R
 
no
 m
at
ch
in
g 
ag
e,
 p
la
ce
 o
f 
re
si
de
nc
e,
 
ty
pe
 o
f 
pa
rti
ci
pa
nt
 
(p
es
tic
id
e 
ap
pl
ic
at
or
 o
r 
sp
ou
se
)c
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
  
 
33 
2 Review of the literature 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; O
R
, o
dd
s 
ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; N
R
, n
ot
 re
po
rte
d;
 B
M
I, 
bo
dy
 m
as
s 
in
de
x.
  
a  
C
on
tro
ls
/P
D
 c
as
es
  
b  
U
na
dj
us
te
d 
c  9
9%
 o
f a
pp
lic
at
or
s 
w
er
e 
m
en
, s
o 
no
 fu
rth
er
 a
dj
us
tm
en
ts
 fo
r s
ex
 w
er
e 
m
ad
e 
 
 
Ta
bl
e 
7.
 (c
on
tin
ue
d)
 
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 
as
ce
rta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
A
dj
us
te
d 
re
su
lt 
O
R
 
(9
5%
 C
I) 
P
 fo
r 
tre
nd
 
M
at
ch
in
g 
A
dj
us
tm
en
ts
 
S
w
ed
en
/ 
(V
ik
da
hl
 e
t a
l. 
20
14
) 
N
or
th
er
n 
S
w
ed
en
 H
ea
lth
 
an
d 
D
is
ea
se
 
S
tu
dy
, 1
98
6–
20
09
 
33
6/
84
, 
F 
an
d 
M
 
2–
8 
cl
in
ic
al
 
ex
am
in
at
io
n 
by
 
ne
ur
ol
og
is
t, 
co
nf
irm
ed
 b
y 
an
ot
he
r 
sp
ec
ia
lis
t 
Q
 
sm
ok
in
g 
cu
rr
en
t v
s.
 
no
n-
sm
ok
er
 
F:
 0
.6
6 
(0
.2
4–
1.
78
)  
 M
: 0
.3
1 
(0
.0
8–
1.
16
)  
0.
41
 
   0.
08
 
se
x,
 a
ge
, 
ye
ar
 o
f 
he
al
th
 
su
rv
ey
, 
su
bc
oh
or
t, 
ge
og
ra
ph
ic
 
ar
ea
 
ag
e,
 p
hy
si
ca
l 
ac
tiv
ity
, B
M
I 
  
 
34 
2 Review of the literature 
Ta
bl
e 
8.
 A
lc
oh
ol
 c
on
su
m
pt
io
n 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: C
oh
or
t s
tu
di
es
. 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
eb
 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(G
ra
nd
in
et
ti 
et
 
al
. 1
99
4)
 
H
on
ol
ul
u-
A
si
a 
A
gi
ng
 S
tu
dy
 
(o
rig
in
al
ly
  
H
on
ol
ul
u 
H
ea
rt 
S
tu
dy
), 
19
65
 
8,
00
6 
/5
8,
 M
 
26
 
ho
sp
ita
l r
ec
or
ds
, 
de
at
h 
ce
rti
fic
at
es
 
or
 re
co
rd
s 
of
 lo
ca
l 
ne
ur
ol
og
is
ts
 
Q
 
al
co
ho
l  
N
R
 (i
nt
er
pr
et
ed
 
as
 e
ve
r v
s.
 
ne
ve
r)
 
0.
76
 (0
.4
5–
1.
28
) 
 N
R
 (j
us
t 
st
at
ed
: N
S
) 
N
R
 
ag
e 
   ag
e,
 s
m
ok
in
g,
 c
of
fe
e 
 
 
 
 
 
 
 
 
 
 
 
 
N
et
he
rla
nd
s/
 
(W
ill
em
s-
G
ie
sb
er
ge
n 
et
 
al
. 2
00
0)
 
R
ot
te
rd
am
 S
tu
dy
, 
19
90
–1
99
3 
5,
28
9 
/5
3,
 F
 
an
d 
M
 
m
ea
n 
6.
07
 
P
D
 d
ia
gn
os
ed
 b
y 
ne
ur
ol
og
is
t a
t t
he
 
fo
llo
w
-u
p 
ex
am
in
at
io
n 
FF
Q
 
al
co
ho
l  
dr
in
ke
rs
 v
s.
 
no
n-
dr
in
ke
rs
 
0.
61
 (0
.3
2–
1.
17
) 
N
R
 
ag
e,
 s
ex
, s
m
ok
in
g 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
H
er
na
n 
et
 a
l. 
20
03
) 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
98
0;
 
H
ea
lth
 
P
ro
fe
ss
io
na
ls
 
Fo
llo
w
-u
p 
S
tu
dy
, 
19
86
 
88
,7
22
 /1
67
, 
F;
 
47
,3
67
 
/2
48
, M
 
19
 
  15
  
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 re
vi
ew
in
g 
m
ed
ic
al
 re
co
rd
s 
Q
 
et
ha
no
l 
(g
/d
) 
 be
er
 (n
o.
 o
f 
dr
in
ks
) 
 w
in
e 
(n
o.
 o
f 
dr
in
ks
) 
 liq
uo
r (
no
. o
f 
dr
in
ks
) 
30
+ 
vs
. 0
 
  ≥1
/w
ee
k 
vs
. 
<1
/m
on
th
 
 ≥5
/w
ee
k 
vs
. 
<1
/m
on
th
 
 ≥5
/w
ee
k 
vs
. 
<1
/m
on
th
 
0.
7 
(0
.5
–1
.2
)c
 
  0.
7 
(0
.5
–0
.9
)c
 
  1.
1 
(0
.8
–1
.7
)c
 
  1.
1 
(0
.8
–1
.6
)c
 
0.
45
 
  0.
03
 
  0.
46
 
  0.
42
 
 
ag
e,
 s
m
ok
in
g,
 c
af
fe
in
e 
 
  
 
 
 
 
 
 
 
 
 
 
 
S
in
ga
po
re
/ (
Ta
n 
et
 a
l. 
20
08
) 
S
in
ga
po
re
 C
hi
ne
se
 
H
ea
lth
 S
tu
dy
, 
19
93
–1
99
8 
63
,2
57
 /1
57
, 
F 
an
d 
M
 
m
ea
n 
7 
se
lf-
re
po
rt 
or
 
ho
sp
ita
l d
is
ch
ar
ge
 
da
ta
ba
se
 o
r P
D
 
re
gi
st
ry
, 
as
ce
rta
in
ed
 b
y 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
in
te
rv
ie
w
 
w
ith
 
st
ru
ct
ur
ed
 Q
 
et
ha
no
l (
g/
d)
 
at
 le
as
t w
ee
kl
y 
dr
in
ke
rs
 v
s.
 
no
ne
 o
r l
es
s 
th
an
 w
ee
kl
y 
0.
60
 (0
.3
1–
1.
16
) 
N
R
 
ag
e,
 y
ea
r o
f i
nt
er
vi
ew
, 
se
x,
 d
ia
le
ct
, 
ed
uc
at
io
n,
 s
m
ok
in
g,
 
ca
ffe
in
e 
an
d 
bl
ac
k 
te
a 
co
ns
um
pt
io
n 
          
 
 
 
 
 
 
 
 
 
 
  
 
35 
2 Review of the literature 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; R
R
, r
el
at
iv
e 
ris
k;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; 
N
R
, n
ot
 re
po
rte
d;
 N
S
, n
on
-s
ig
ni
fic
an
t; 
FF
Q
, f
oo
d 
fr
eq
ue
nc
y 
qu
es
tio
nn
ai
re
; O
R
, o
dd
s 
ra
tio
; N
IH
-A
A
R
P
, N
at
io
na
l I
ns
tit
ut
es
 o
f H
ea
lth
-A
m
er
ic
an
 A
ss
oc
ia
tio
n 
of
 R
et
ire
d 
P
er
so
ns
.  
Ta
bl
e 
8.
 (c
on
tin
ue
d)
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
eb
 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ (
P
al
ac
io
s 
et
 a
l. 
20
12
a)
 
C
an
ce
r P
re
ve
nt
io
n 
S
tu
dy
 II
 N
ut
rit
io
n 
C
oh
or
t, 
19
92
–1
99
3 
74
,1
21
 /2
16
, 
F;
 5
8,
38
8 
/3
89
, M
 
10
, 1
2 
or
 1
4 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 re
vi
ew
in
g 
m
ed
ic
al
 re
co
rd
s 
FF
Q
 
et
ha
no
l (
g/
d)
 
     et
ha
no
l f
ro
m
 
be
er
 (g
/d
) 
 et
ha
no
l f
ro
m
 
w
in
e 
(g
/d
) 
 et
ha
no
l f
ro
m
 
liq
uo
r (
g/
d)
 
F:
 1
5+
 v
s.
 0
 
  M
: 3
0+
 v
s.
 0
 
  10
g/
d 
in
cr
ea
se
 
0.
77
 (0
.4
1–
1.
45
) 
 1.
29
 (0
.9
0–
1.
86
) 
 1.
01
 (0
.9
9–
1.
03
)d
 
 1.
02
 (0
.9
8–
1.
05
)d
 
 0.
99
 (0
.9
6–
1.
02
)d
 
0.
87
 
  0.
40
 
  N
R
 
  N
R
 
  N
R
 
ag
e,
 s
m
ok
in
g,
 c
of
fe
e 
 
 
 
 
 
 
 
 
 
 
 
G
re
ec
e/
 
(K
yr
oz
is
  e
t a
l. 
20
13
) 
E
P
IC
-G
re
ec
e,
 
19
93
–1
99
9 
25
,4
07
/8
8,
 F
 
an
d 
M
  
m
ea
n 
8.
45
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 w
ith
 
se
lf-
re
po
rte
d 
te
le
ph
on
e 
in
te
rv
ie
w
 
in
te
rv
ie
w
 
al
co
ho
l (
g/
d)
 
10
0g
 in
cr
em
en
t 
0.
88
 (0
.7
4–
1.
05
) 
0.
16
 
ag
e,
 s
ex
 
 
Lo
ng
itu
di
na
l 
 
 
 
 
 
 
O
R
 (9
5%
C
I) 
 
 
U
S
A
/  
(L
iu
 e
t a
l. 
20
13
) 
N
IH
-A
A
R
P
 D
ie
t a
nd
 
H
ea
lth
 S
tu
dy
, 
19
95
–1
99
6 
30
6,
89
5 
/1
,1
13
, F
 
an
d 
M
 
N
R
e 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ne
ur
ol
og
is
t o
r 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
FF
Q
 
al
co
ho
l  
(d
rin
ks
/d
) 
  be
er
 (
dr
in
ks
/d
) 
  w
in
e 
(d
rin
ks
/d
) 
  liq
uo
r 
(d
rin
ks
/d
) 
≥5
 v
s.
 n
on
e 
   ≥2
 v
s.
 n
on
e 
  ≥2
 v
s.
 n
on
e 
  ≥2
 v
s.
 n
on
e 
0.
92
 (0
.6
6–
1.
28
) 
  0.
86
 (0
.6
0–
1.
21
)f  
 1.
31
 (0
.8
9–
1.
94
)f  
 1.
35
 (1
.0
2–
1.
80
)f  
0.
63
 
   0.
86
 
  0.
66
 
  0.
08
 
ag
e,
 s
ex
, r
ac
e,
  
m
ar
ita
l s
ta
tu
s,
 
ed
uc
at
io
n,
  p
hy
si
ca
l 
ac
tiv
ity
, s
m
ok
in
g,
 
ca
ffe
in
e,
 s
el
f-
ev
al
ua
te
d 
he
al
th
 
st
at
us
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(K
am
el
 e
t a
l. 
20
07
) 
A
gr
ic
ul
tu
ra
l H
ea
lth
 
S
tu
dy
, 1
99
3–
19
97
 
52
,9
45
 /7
1,
 
F 
an
d 
M
 
5 
se
lf-
re
po
rt 
of
 
ph
ys
ic
ia
n-
di
ag
no
se
d 
P
D
 
Q
 
al
co
ho
l  
(d
rin
ks
/m
on
th
) 
≥3
1 
vs
. n
on
-
dr
in
ke
r 
1.
3 
(0
.5
–3
.3
) 
N
R
 
ag
e,
 p
la
ce
 o
f 
re
si
de
nc
e,
 ty
pe
 o
f 
pa
rti
ci
pa
nt
 (p
es
tic
id
e 
ap
pl
ic
at
or
 o
r s
po
us
e)
g  
  
 
36 
2 Review of the literature 
a  
To
ta
l p
op
ul
at
io
n/
P
D
 c
as
es
  
b  
If 
re
po
rte
d 
as
 e
th
an
ol
, i
t i
s 
in
di
ca
te
d 
he
re
 a
s 
et
ha
no
l. 
O
th
er
w
is
e,
 s
tu
di
es
 h
av
e 
pr
es
um
ab
ly
 c
al
cu
la
te
d 
ex
po
su
re
 a
s 
al
co
ho
lic
 d
rin
ks
 to
ge
th
er
 a
s 
g/
d,
 o
r r
ep
or
tin
g 
is
 u
nc
le
ar
 w
he
th
er
 
ca
lc
ul
at
ed
 a
s 
et
ha
no
l o
r a
lc
oh
ol
ic
 d
rin
ks
. 
c  R
es
ul
ts
 a
re
 p
oo
le
d 
R
R
s 
fro
m
 th
e 
tw
o 
co
ho
rts
 
d 
M
en
 a
nd
 w
om
en
 p
oo
le
d 
to
ge
th
er
  
e 
A
 fo
llo
w
-u
p 
su
rv
ey
 in
 2
00
4–
20
06
 in
qu
iri
ng
 a
bo
ut
 P
D
 d
ia
gn
os
ed
 a
fte
r y
ea
r 2
00
0 
f I
n 
ad
di
tio
n 
to
 th
e 
fa
ct
or
s 
st
at
ed
 in
 th
e 
“A
dj
us
tm
en
ts
” c
ol
um
n,
 th
e 
in
di
vi
du
al
 ty
pe
s 
of
 a
lc
oh
ol
ic
 b
ev
er
ag
es
 w
er
e 
ad
ju
st
ed
 fo
r s
im
ul
ta
ne
ou
sl
y 
g  
99
%
 o
f a
pp
lic
at
or
s 
w
er
e 
m
en
, s
o 
no
 fu
rth
er
 a
dj
us
tm
en
ts
 fo
r s
ex
 w
as
 m
ad
e 
  
 
37 
2 Review of the literature 
Ta
bl
e 
9.
 A
lc
oh
ol
 c
on
su
m
pt
io
n 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: N
es
te
d 
ca
se
-c
on
tro
l s
tu
di
es
. 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; O
R
, o
dd
s 
ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; N
R
, n
ot
 re
po
rte
d;
 G
P
R
D
, G
en
er
al
 P
ra
ct
ic
e 
R
es
ea
rc
h 
D
at
ab
as
e.
  
a  
C
on
tro
ls
/P
D
 c
as
es
  
b  
U
na
dj
us
te
d 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
 P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
A
dj
us
te
d 
re
su
lt 
O
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
M
at
ch
in
g 
A
dj
us
tm
en
ts
 
S
w
ed
en
/ 
(W
ird
ef
el
dt
 
et
 a
l. 
20
05
) 
S
w
ed
is
h 
Tw
in
 
R
eg
is
try
, 
19
61
/6
7 
or
 
19
73
 
2,
38
0 
/4
76
, 
un
re
la
te
d 
F 
an
d 
M
  
   41
5 
/4
15
 
sa
m
e-
se
x 
tw
in
s 
N
R
 
in
pa
tie
nt
 d
is
ch
ar
ge
 
re
gi
st
er
 o
r d
ea
th
 
ce
rti
fic
at
es
 
Q
 
al
co
ho
l 
(g
/d
ay
) 
>3
0g
 v
s.
 0
 
  ev
er
 v
s.
 
ne
ve
r 
  >3
0g
 v
s.
 0
 
 
0.
66
 (0
.3
4–
1.
29
) 
 0.
74
 (0
.5
9–
0.
93
)b
 
 tw
in
s:
 
0.
72
 (0
.1
9–
2.
65
) 
0.
75
 
      0.
25
 
bi
rth
 y
ea
r, 
se
x,
 y
ea
r o
f 
an
sw
er
in
g 
th
e 
Q
 
ed
uc
at
io
n,
 
sm
ok
in
g,
 c
of
fe
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(P
ag
an
in
i-
H
ill
 2
00
1)
  
Le
is
ur
e 
W
or
ld
 C
oh
or
t 
S
tu
dy
, 1
98
1–
19
85
 
2,
32
0 
/3
95
, F
 
an
d 
M
 
18
 
ho
sp
ita
l d
is
ch
ar
ge
 
da
ta
ba
se
 o
r d
ea
th
 
ce
rti
fic
at
es
, o
r s
el
f-
re
po
rt 
Q
 
al
co
ho
l 
(d
rin
ks
/d
ay
) 
 w
in
e 
(d
rin
ks
/d
ay
) 
 be
er
 
(d
rin
ks
/d
ay
) 
 liq
uo
r 
(d
rin
ks
/d
ay
) 
≥2
 v
s.
 0
 
  ≥2
 v
s.
 0
 
  ≥2
 v
s.
 0
 
  ≥2
 v
s.
 0
 
0.
77
 (0
.5
8–
1.
03
)  
 0.
80
 (0
.5
1–
1.
24
)b
 
 0.
32
 (0
.1
0–
1.
06
)b
 
 0.
75
 (0
.5
5–
1.
01
)b
 
0.
01
b  
se
x,
 b
irt
h 
da
te
, v
ita
l 
st
at
us
; i
f 
de
ad
, d
ea
th
 
da
te
 
 
sm
ok
in
g,
  c
of
fe
e,
 
vi
ta
m
in
 C
 a
nd
 A
 
in
ta
ke
, b
lo
od
 
pr
es
su
re
 
m
ed
ic
at
io
n,
 p
ar
ity
 
 
 
 
 
 
 
 
 
 
 
 
 
U
K
/ (
H
er
na
n 
et
 a
l. 
20
04
) 
G
en
er
al
 
P
ra
ct
ic
e 
R
es
ea
rc
h 
D
at
ab
as
e,
 
19
95
–2
00
0 
10
,1
23
  
/1
,0
19
, F
 a
nd
 
M
 
1–
6 
G
P
R
D
 d
at
ab
as
e:
 
P
D
 d
ia
gn
os
is
 a
nd
 
re
ce
iv
ed
 ≥
2 
pr
es
cr
ip
tio
ns
 to
 
tre
at
 P
D
 d
ur
in
g 
th
e 
fo
llo
w
-u
p 
G
P
R
D
 
da
ta
ba
se
: 
di
ag
no
si
s 
of
 
al
co
ho
lis
m
 o
r 
al
co
ho
l-r
el
at
ed
 
ch
ro
ni
c 
di
se
as
e 
 se
lf-
re
po
rte
d 
dr
in
ki
ng
 
al
co
ho
lis
m
 
       et
ha
no
l u
ni
ts
 
(1
 u
ni
t=
10
 
m
l/w
ee
k)
 
al
co
ho
lic
s 
vs
.  
no
n-
al
co
ho
lic
s 
     >5
0 
vs
. 0
 
1.
09
 (0
.6
7–
1.
78
) 
      1.
46
 (0
.6
9–
3.
01
) 
        0.
71
 
ag
e 
(w
ith
in
 1
 
ye
ar
), 
se
x,
 
st
ar
t d
at
e 
of
 
th
e 
st
ud
y 
th
e 
m
at
ch
in
g 
fa
ct
or
s,
 s
m
ok
in
g 
  
 
38 
2 Review of the literature 
Ta
bl
e 
10
. C
of
fe
e 
co
ns
um
pt
io
n 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: C
oh
or
t s
tu
di
es
a .
 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
b  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(G
ra
nd
in
et
ti 
et
 
al
. 1
99
4)
 
H
on
ol
ul
u-
A
si
a 
A
gi
ng
 S
tu
dy
 
(o
rig
in
al
ly
  
H
on
ol
ul
u 
H
ea
rt 
S
tu
dy
), 
19
65
 
8,
00
6/
58
, 
M
 
26
 
ho
sp
ita
l r
ec
or
ds
, 
de
at
h 
ce
rti
fic
at
es
 
or
 re
co
rd
s 
of
 lo
ca
l 
ne
ur
ol
og
is
ts
 
Q
 
co
ffe
e 
(N
R
) 
N
R
 (p
re
su
m
ab
ly
 
re
gu
la
r d
rin
ke
rs
 
vs
. n
on
-d
rin
ke
rs
) 
0.
57
 (0
.3
2–
1.
02
) 
N
R
 
ag
e,
 s
m
ok
in
g,
 
al
co
ho
l 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
R
os
s 
et
 
al
. 2
00
0)
 
H
on
ol
ul
u-
A
si
a 
A
gi
ng
 S
tu
dy
 
(o
rig
in
al
ly
  
H
on
ol
ul
u 
H
ea
rt 
S
tu
dy
), 
19
65
 
8,
00
4/
10
2,
 
M
 
30
 
ho
sp
ita
l r
ec
or
ds
, 
de
at
h 
ce
rti
fic
at
es
 
or
 re
co
rd
s 
of
 lo
ca
l 
ne
ur
ol
og
is
ts
 
Q
 
co
ffe
e 
(g
/d
) 
dr
in
ke
rs
 v
s.
 n
on
-
dr
in
ke
rs
 
 
0.
45
 (0
.3
0–
0.
71
) 
   
<0
.0
01
 
ag
e,
 s
m
ok
in
g 
 
 
 
 
 
 
 
 
 
 
 
N
et
he
rla
nd
s/
 
(W
ill
em
s-
G
ie
sb
er
ge
n 
et
 
al
. 2
00
0)
 
R
ot
te
rd
am
 
S
tu
dy
, 1
99
0–
19
93
 
5,
28
9 
/5
3,
 
F 
an
d 
M
 
m
ea
n 
6.
07
 
P
D
 d
ia
gn
os
ed
 b
y 
ne
ur
ol
og
is
t a
t t
he
 
fo
llo
w
-u
p 
ex
am
in
at
io
n 
FF
Q
 
co
ffe
e 
(c
up
s/
d)
 
pe
r c
up
 o
f c
of
fe
e 
pe
r d
ay
 
0.
91
 (0
.7
7–
1.
08
) 
N
R
 
ag
e,
 s
ex
, 
sm
ok
in
g 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
Fi
nk
 e
t 
al
. 2
00
1)
 
Fr
am
in
gh
am
 
S
tu
dy
, N
R
 
6,
04
8 
/5
8,
 
F 
an
d 
M
 
10
 
pr
es
en
ce
 o
f t
he
 
ca
rd
in
al
 fe
at
ur
es
 
of
 P
D
 a
t t
he
 
bi
en
ni
al
 
ex
am
in
at
io
n 
 
Q
 
ca
ffe
in
e 
(c
of
fe
e 
+ 
te
a,
 
es
tim
at
ed
 a
s 
cu
ps
 o
f 
ca
ffe
in
at
ed
 
co
ffe
e/
d)
 
>3
 c
up
s/
d 
vs
. n
o 
ca
ffe
in
e 
in
ta
ke
 
0.
77
 (0
.2
9–
2.
04
) 
N
R
 
ag
e,
 s
ex
, 
sm
ok
in
g 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(A
sc
he
rio
 e
t 
al
. 2
00
1)
 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
98
0;
 
H
ea
lth
 
P
ro
fe
ss
io
na
ls
 
Fo
llo
w
-u
p 
S
tu
dy
, 1
98
6 
88
,5
65
 
/1
31
, F
; 
47
,3
51
 
/1
57
, M
 
16
 
  10
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 re
vi
ew
in
g 
m
ed
ic
al
 re
co
rd
s 
FF
Q
 
co
ffe
e 
(c
up
s/
d)
 
6+
 v
s.
 0
 
F:
 1
.0
 (0
.5
–
2.
1)
 
 M
: 0
.5
 (0
.1
–
2.
1)
 
0.
96
 
  0.
02
 
ag
e,
 s
m
ok
in
g,
 
ca
ffe
in
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(A
sc
he
rio
 e
t 
al
. 2
00
3)
 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
98
0 
77
,7
13
 
/1
54
, F
 
18
 
sa
m
e 
FF
Q
 
co
ffe
e 
(c
up
s/
d)
 
4+
 v
s.
 0
, s
tra
tif
ie
d 
by
 
po
st
m
en
op
au
sa
l  
ho
rm
on
e 
us
e 
ne
ve
r v
s.
 e
ve
r 
ne
ve
r: 
0.
75
 (0
.3
1–
1.
86
) 
 ev
er
: 
1.
70
 (0
.8
1–
3.
60
) 
0.
06
 
   0.
26
 
ag
e,
 s
m
ok
in
g,
 
al
co
ho
l 
 
 
 
 
 
 
 
 
 
 
 
  
 
39 
2 Review of the literature 
Ta
bl
e 
10
. (
co
nt
in
ue
d)
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
b  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(A
sc
he
rio
 e
t 
al
. 2
00
4)
 
C
an
ce
r 
P
re
ve
nt
io
n 
S
tu
dy
 II
, 1
98
2 
23
8,
05
8 
/3
40
, F
;  
30
1,
16
4 
/9
09
, M
 
10
 
de
at
h 
ce
rti
fic
at
es
 
Q
 
co
ffe
e 
(c
up
s/
d)
 
6+
 v
s.
 0
 
     F:
 4
+ 
vs
. 0
, 
st
ra
tif
ie
d 
by
 
po
st
m
en
op
au
sa
l  
ho
rm
on
e 
us
e 
 
ne
ve
r v
s.
 e
ve
r 
F:
 0
.9
0 
(0
.5
5–
1.
48
) 
 M
: 0
.6
3 
(0
.4
6–
0.
86
) 
 ne
ve
r: 
0.
47
 (0
.2
7–
0.
80
) 
 ev
er
: 
1.
31
 (0
.7
5–
2.
30
) 
0.
57
 
  0.
01
1 
  0.
11
 
   0.
93
 
ag
e,
 s
m
ok
in
g,
 
al
co
ho
l  
 
 
 
 
 
 
 
 
 
 
 
Fi
nl
an
d/
 (
H
u 
et
 a
l. 
20
07
a)
 
M
O
N
IC
A
, 1
98
2,
 
19
87
, 1
99
2,
 
19
97
 
15
,0
42
 /9
8,
 
F;
 1
4,
29
3 
/1
02
, M
 
21
 o
r l
es
s,
 
de
pe
nd
in
g 
on
 b
as
el
in
e 
ye
ar
 (m
ea
n 
12
.9
) 
re
gi
st
ry
 o
n 
re
im
bu
rs
em
en
t f
or
 
P
D
 d
ru
gs
, 
di
ag
no
se
d 
by
 
ne
ur
ol
og
is
t 
Q
 
co
ffe
e 
(c
up
s/
d)
 
5+
 v
s.
 0
 
0.
40
 (0
.2
3–
0.
71
) 
0.
00
5 
ag
e,
   
ed
uc
at
io
n,
 
st
ud
y 
ye
ar
,  
ph
ys
ic
al
 a
ct
iv
ity
, 
sm
ok
in
g,
 a
lc
oh
ol
, 
te
a,
  B
M
I, 
sy
st
ol
ic
 
bl
oo
d 
pr
es
su
re
, 
ch
ol
es
te
ro
l, 
hi
st
or
y 
of
 
di
ab
et
es
 
 
 
 
 
 
 
 
 
 
 
 
S
in
ga
po
re
/ 
(T
an
 e
t a
l. 
20
08
) 
S
in
ga
po
re
 
C
hi
ne
se
 H
ea
lth
 
S
tu
dy
, 1
99
3–
19
98
 
63
,2
57
 
/1
57
, F
 a
nd
 
M
 
m
ea
n 
7 
se
lf-
re
po
rt 
or
 
ho
sp
ita
l d
is
ch
ar
ge
 
da
ta
ba
se
 o
r P
D
 
re
gi
st
ry
, 
as
ce
rta
in
ed
 b
y 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
in
te
rv
ie
w
 w
ith
 
st
ru
ct
ur
ed
 Q
 
ca
ffe
in
e 
(m
g/
d)
 
  co
ffe
e 
(c
up
s/
d)
 
hi
gh
es
t v
s.
 lo
w
es
t 
qu
ar
til
e 
 2+
 v
s.
 0
 
0.
64
 (0
.4
0–
1.
03
) 
 0.
78
 (0
.5
2–
1.
17
) 
0.
01
6 
  0.
24
 
ag
e,
 s
ex
,  
 
ed
uc
at
io
n,
 y
ea
r 
of
 in
te
rv
ie
w
, 
di
al
ec
t, 
sm
ok
in
g 
        
 
 
 
 
 
 
 
 
 
 
  
 
40 
2 Review of the literature 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; R
R
, r
el
at
iv
e 
ris
k;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; N
R
, n
ot
 re
po
rte
d;
 F
FQ
, f
oo
d 
fre
qu
en
cy
 q
ue
st
io
nn
ai
re
; B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 O
R
, o
dd
s 
ra
tio
; N
IH
-A
A
R
P
, N
at
io
na
l I
ns
tit
ut
es
 o
f H
ea
lth
-A
m
er
ic
an
 A
ss
oc
ia
tio
n 
of
 R
et
ire
d 
P
er
so
ns
.  
a  
R
e-
an
al
ys
es
 o
f p
re
vi
ou
sl
y 
re
po
rte
d 
da
ta
 h
ig
hl
ig
ht
ed
 w
ith
 g
re
y 
b 
To
ta
l p
op
ul
at
io
n/
P
D
 c
as
es
  
  Ta
bl
e 
10
. (
co
nt
in
ue
d)
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
b  
, 
ge
nd
er
 
Fo
llo
w
-u
p 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(P
al
ac
io
s 
et
 
al
. 2
01
2b
) 
C
an
ce
r 
P
re
ve
nt
io
n 
S
tu
dy
 II
 
N
ut
rit
io
n 
C
oh
or
t, 
19
99
 
63
,5
90
 
/1
20
, F
; 
48
,5
32
 
/1
97
, M
 
2,
 4
, 6
, o
r 8
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 re
vi
ew
in
g 
m
ed
ic
al
 re
co
rd
s 
Q
 
ca
ffe
in
e 
(m
g/
d)
 
    co
ffe
e 
    de
ca
ffe
in
at
ed
 
co
ffe
e 
hi
gh
es
t v
s.
 lo
w
es
t 
qu
in
til
e 
   >2
 c
up
s/
d 
vs
. 
ne
ve
r 
   >2
 c
up
s/
d 
vs
. 
ne
ve
r 
F:
 0
.6
1 
(0
.3
4–
1.
09
) 
M
: 0
.4
3 
(0
.2
6–
0.
71
) 
 F:
 0
.6
9 
(0
.4
2–
1.
15
) 
M
: 0
.5
4 
(0
.3
7–
0.
80
) 
 F:
 0
.8
0 
(0
.4
0–
1.
59
) 
M
: 0
.8
1 
(0
.5
1–
1.
27
) 
0.
05
 
 0.
00
2 
  0.
09
 
 0.
00
04
 
  0.
58
 
 0.
68
 
ag
e,
 s
m
ok
in
g,
 
al
co
ho
l  
 
 
 
 
 
 
 
 
 
 
 
G
re
ec
e/
 
(K
yr
oz
is
 e
t a
l. 
20
12
) 
E
P
IC
-G
re
ec
e,
 
19
93
–1
99
9 
25
,4
07
 /8
8,
 
F 
an
d 
M
  
 
m
ea
n 
8.
45
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 w
ith
 
se
lf-
re
po
rte
d 
te
le
ph
on
e 
in
te
rv
ie
w
 
FF
Q
, 
in
te
rv
ie
w
ed
 
ca
ffe
in
at
ed
 
co
ffe
e 
(m
l/d
) 
10
0 
m
l  
in
cr
em
en
t 
0.
92
 (0
.7
2–
1.
18
) 
0.
52
3 
ag
e,
 s
ex
, 
sm
ok
in
g 
 
Lo
ng
itu
di
na
l 
 
 
 
 
 
 
O
R
 (9
5%
 
C
I) 
 
 
U
S
A
/ (
Li
u 
et
 
al
. 2
01
2)
 
N
IH
-A
A
R
P
 D
ie
t 
an
d 
H
ea
lth
 
S
tu
dy
, 1
99
5–
19
96
 
30
3,
88
0 
/1
 
10
0,
 F
 a
nd
 
M
 
fo
llo
w
-u
p 
su
rv
ey
 
20
04
–2
00
6,
 
P
D
 
di
ag
no
se
d 
af
te
r y
ea
r 
20
00
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ne
ur
ol
og
is
t o
r 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
D
ie
t H
is
to
ry
 
Q
ue
st
io
nn
ai
re
 
ca
ffe
in
e 
(m
g/
d)
 
 
hi
gh
es
t v
s.
 lo
w
es
t 
qu
in
til
e 
 
0.
78
 (0
.6
4–
0.
95
) 
0.
00
4 
ag
e,
 s
ex
, r
ac
e,
 
ph
ys
ic
al
 a
ct
iv
ity
 
  
 
41 
2 Review of the literature 
Ta
bl
e 
11
. C
of
fe
e 
co
ns
um
pt
io
n 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: N
es
te
d 
ca
se
-c
on
tro
l s
tu
di
es
. 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 
na
m
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 
as
ce
rta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
A
dj
us
te
d 
re
su
lt 
O
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
M
at
ch
in
g 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(P
ag
an
in
i-
H
ill
 2
00
1)
 
Le
is
ur
e 
W
or
ld
 
C
oh
or
t 
S
tu
dy
, 
19
81
–1
98
5 
2,
32
0 
/3
95
, F
 
an
d 
M
 
18
 
ho
sp
ita
l 
di
sc
ha
rg
e 
da
ta
ba
se
 o
r 
de
at
h 
ce
rti
fic
at
es
, 
or
 s
el
f-r
ep
or
t 
Q
 
co
ffe
e 
in
ta
ke
 
(c
up
s/
d)
 
2+
 v
s.
 0
 
0.
71
 
(0
.5
2–
0.
95
) 
0.
00
3b
 
se
x,
 b
irt
hd
at
e,
 
vi
ta
l s
ta
tu
s;
 if
 
de
ad
, d
ea
th
 
da
te
 
 
sm
ok
in
g,
  
al
co
ho
l, 
vi
ta
m
in
 
C
 a
nd
 A
 in
ta
ke
, 
bl
oo
d 
pr
es
su
re
 
m
ed
ic
at
io
n,
 
pa
rit
y 
 
 
 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(W
ird
ef
el
dt
 
et
 a
l. 
20
05
) 
S
w
ed
is
h 
Tw
in
 
R
eg
is
try
, 
19
67
 o
r 
19
73
 
2,
38
0 
/4
76
, 
un
re
la
te
d 
F 
an
d 
M
  
  41
5 
sa
m
e-
se
x 
tw
in
s 
N
R
 
in
pa
tie
nt
 
di
sc
ha
rg
e 
re
gi
st
er
 o
r d
ea
th
 
ce
rti
fic
at
es
 
Q
 
co
ffe
e 
in
ta
ke
 
(c
up
s/
d)
 
5+
 v
s.
 0
 
1.
03
 
(0
.5
3–
2.
00
) 
  1.
27
 
(0
.4
9–
3.
29
) 
0.
78
 
    0.
80
 
bi
rth
 y
ea
r, 
se
x,
 
ye
ar
 a
ns
w
er
ed
 
th
e 
Q
. C
as
es
 
ha
d 
tw
o 
se
ts
 o
f 
co
nt
ro
ls
: 
un
re
la
te
d,
 tw
in
  
ed
uc
at
io
n,
 
sm
ok
in
g,
 a
lc
oh
ol
 
 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; O
R
, o
dd
s 
ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; N
R
, n
ot
 re
po
rte
d.
   
a  
C
on
tro
ls
/P
D
 c
as
es
  
b 
U
na
dj
us
te
d 
 
  
 
42 
2 Review of the literature 
Ta
bl
e 
12
. O
be
si
ty
 a
nd
 P
ar
ki
ns
on
’s
 d
is
ea
se
: C
oh
or
t s
tu
di
es
. 
C
ou
nt
ry
/re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ (
A
bb
ot
t e
t a
l. 
20
02
) 
H
on
ol
ul
u-
A
si
a 
A
gi
ng
 S
tu
dy
 
(o
rig
in
al
ly
  
H
on
ol
ul
u 
H
ea
rt 
S
tu
dy
), 
19
65
 
7,
99
0 
/1
37
, 
M
 
30
 
ho
sp
ita
l r
ec
or
ds
, 
de
at
h 
ce
rti
fic
at
es
 o
r 
re
co
rd
s 
of
 lo
ca
l 
ne
ur
ol
og
is
ts
 
N
R
 (u
nc
le
ar
 
w
he
th
er
 
m
ea
su
re
d 
or
 
se
lf-
re
po
rte
d)
 
 sk
in
fo
ld
 
th
ic
kn
es
s 
m
ea
su
re
m
en
t 
w
ith
 L
an
ge
 
ca
lip
er
s 
 
ba
se
lin
e 
B
M
I 
(k
g/
m
2 )
 
   tri
ce
p 
sk
in
fo
ld
 
th
ic
kn
es
s 
(m
m
) 
  su
bs
ca
pu
la
r 
sk
in
fo
ld
 
th
ic
kn
es
s 
(m
m
) 
hi
gh
es
t v
s.
 
lo
w
es
t 
qu
ar
til
e 
  hi
gh
es
t v
s.
 
lo
w
es
t 
qu
ar
til
e 
 hi
gh
es
t v
s.
 
lo
w
es
t 
qu
ar
til
e 
N
R
 (j
us
t 
st
at
ed
: N
S
) 
   2.
8 
(1
.4
–
5.
6)
 
   N
R
 (j
us
t 
st
at
ed
: N
S
) 
<0
.0
01
 
ag
e,
 p
hy
si
ca
l 
ac
tiv
ity
, s
m
ok
in
g,
 
co
ffe
e,
 c
al
or
ic
 a
nd
 
fa
t i
nt
ak
e,
 B
M
I, 
su
bs
ca
pu
la
r 
sk
in
fo
ld
 th
ic
kn
es
s 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
C
he
n 
et
 a
l. 
20
04
) 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
97
6;
 
H
ea
lth
 
P
ro
fe
ss
io
na
ls
 
Fo
llo
w
-u
p 
S
tu
dy
, 
19
86
 
11
7,
06
2 
/2
02
, F
; 
47
,7
00
/2
49
, 
M
 
22
 
  14
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
, s
el
f-r
ep
or
te
d 
w
ei
gh
t a
nd
 
he
ig
ht
 (h
ig
h 
va
lid
ity
 re
po
rte
d)
 
ba
se
lin
e 
B
M
I 
(k
g/
m
2 )
 
 ea
rly
 a
du
lt 
B
M
I 
(k
g/
m
2 )
 
 w
ei
gh
t c
ha
ng
e 
(k
g)
 
 w
ai
st
-to
-h
ip
 
ra
tio
 
≥3
0 
vs
. <
23
 
  ≥2
7 
vs
. <
20
 
  ≥2
0.
2 
vs
. 
<2
.2
 
 hi
gh
es
t v
s.
 
lo
w
es
t 
qu
in
til
e 
0.
8 
(0
.6
–
1.
2)
b  
 1.
0 
(0
.6
–
1.
5)
b  
 1.
0 
(0
.5
–
2.
2)
b  
 ne
ve
r 
sm
ok
er
s:
 
2.
0 
(1
.1
–
3.
6)
b  
0.
3 
  0.
2 
  0.
6 
  <0
.0
5 
ag
e,
 c
af
fe
in
e,
 
al
co
ho
l  
 
 
 
 
 
 
 
 
 
 
 
Fi
nl
an
d/
 (
H
u 
et
 a
l. 
20
06
) 
N
R
 
23
,4
39
/2
54
, 
F;
  
22
 ,6
7/
27
2,
 
M
 
m
ea
n 
18
.8
 
re
gi
st
ry
 o
n 
re
im
bu
rs
em
en
t f
or
 
P
D
 d
ru
gs
, 
di
ag
no
se
d 
by
 
ne
ur
ol
og
is
t 
m
ea
su
re
d 
he
ig
ht
 
(w
ith
ou
t s
ho
es
) 
an
d 
w
ei
gh
t (
w
ith
 
lig
ht
 c
lo
th
in
g)
 
ba
se
lin
e 
B
M
I 
(k
g/
m
2 )
 
≥3
0 
vs
. <
23
 
2.
03
 (1
.4
4–
2.
85
) 
N
R
 
ag
e,
 s
ex
,  
ed
uc
at
io
n,
 
ba
se
lin
e 
ye
ar
, 
ph
ys
ic
al
 a
ct
iv
ity
, 
sm
ok
in
g,
 a
lc
oh
ol
, 
co
ffe
e,
 te
a,
 s
ys
to
lic
 
bl
oo
d 
pr
es
su
re
, 
ch
ol
es
te
ro
l 
    
 
 
 
 
 
 
 
 
 
 
  
 
43 
2 Review of the literature 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; R
R
, r
el
at
iv
e 
ris
k;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; N
R
, n
ot
 re
po
rte
d;
 N
S
, n
on
-s
ig
ni
fic
an
t; 
B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 C
V
D
, c
ar
di
ov
as
cu
la
r d
is
ea
se
.  
a  
To
ta
l p
op
ul
at
io
n/
P
D
 c
as
es
  
b  
R
es
ul
ts
 a
re
 p
oo
le
d 
R
R
s 
fro
m
 th
e 
tw
o 
co
ho
rts
 
Ta
bl
e 
12
. (
co
nt
in
ue
d)
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
U
S
A
/ (
Lo
gr
os
ci
no
 
et
 a
l. 
20
07
) 
 
H
ar
va
rd
 A
lu
m
ni
 
H
ea
lth
 S
tu
dy
, 
19
88
 
10
,8
12
/1
06
, 
M
 
10
 
se
lf-
re
po
rt 
or
 d
ea
th
 
ce
rti
fic
at
es
 
Q
, s
el
f-r
ep
or
te
d 
w
ei
gh
t a
nd
 
he
ig
ht
  
ba
se
lin
e 
B
M
I 
(k
g/
m
2 )
 
  B
M
I (
kg
/m
2 )
 
at
 c
ol
le
ge
 e
nt
ry
 
≥2
5 
vs
. 
22
.5
 to
 
<2
5.
0 
 ≥2
5 
vs
. 
22
.5
 to
 
<2
5.
0 
0.
86
 (0
.5
3–
1.
41
) 
  0.
49
 (0
.1
7–
1.
39
) 
N
R
 
ag
e,
 p
hy
si
ca
l 
ac
tiv
ity
, s
m
ok
in
g,
  
co
ffe
e,
 te
a,
 h
is
to
ry
 
of
 C
V
D
 o
r c
an
ce
r 
in
 1
98
8 
 
 
 
 
 
 
 
 
 
 
 
S
in
ga
po
re
/ (
Ta
n 
et
 
al
. 2
00
8)
 
S
in
ga
po
re
 
C
hi
ne
se
 H
ea
lth
 
S
tu
dy
, 1
99
3–
19
98
 
63
,2
57
/1
57
, 
F 
an
d 
M
 
m
ea
n 
7 
se
lf-
re
po
rt 
or
 
ho
sp
ita
l d
is
ch
ar
ge
 
da
ta
ba
se
 o
r P
D
 
re
gi
st
ry
, a
sc
er
ta
in
ed
 
by
 re
vi
ew
in
g 
m
ed
ic
al
 re
co
rd
s 
N
R
 
ba
se
lin
e 
B
M
I 
(k
g/
m
2 )
 
N
R
 
N
R
 (j
us
t 
st
at
ed
: N
S
 
N
R
 
N
R
 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
P
al
ac
io
s 
et
 
al
. 2
01
1)
 
C
an
ce
r 
P
re
ve
nt
io
n 
S
tu
dy
 
II 
N
ut
rit
io
n 
C
oh
or
t, 
19
92
 
14
7,
09
6/
 
65
6,
 F
 a
nd
 
M
 
13
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 
re
vi
ew
in
g 
m
ed
ic
al
 
re
co
rd
s 
Q
, s
el
f-r
ep
or
te
d 
w
ei
gh
t a
nd
 
he
ig
ht
 
ba
se
lin
e 
B
M
I 
(k
g/
m
2 )
 
 w
ei
gh
t c
ha
ng
e 
(k
g)
 
  w
ai
st
 
ci
rc
um
fe
re
nc
e 
(c
m
) 
≥3
0 
vs
. <
23
 
  20
.2
5 
vs
. 
2.
25
 lo
ss
 o
r 
ga
in
 
 10
2.
4 
vs
. 
87
.6
 
1.
00
 (0
.7
5–
1.
34
) 
 0.
56
 (0
.3
9–
0.
82
) 
  1.
35
 (0
.9
5–
1.
93
) 
0.
79
 
  0.
08
 
   0.
08
 
ag
e,
 e
du
ca
tio
n,
 
ph
ys
ic
al
 a
ct
iv
ity
, 
sm
ok
in
g,
 a
lc
oh
ol
, 
ca
ffe
in
e,
 c
al
or
ie
s,
 
da
iry
 in
ta
ke
, 
pe
st
ic
id
e 
ex
po
su
re
 
 
 
 
 
 
 
 
 
 
 
 
G
re
ec
e/
 (
K
yr
oz
is
  
et
 a
l. 
20
13
) 
E
P
IC
-G
re
ec
e,
 
19
93
–1
99
9 
25
,4
07
/8
8,
 F
 
an
d 
M
  
 
m
ea
n 
8.
45
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 w
ith
 
se
lf-
re
po
rte
d 
te
le
ph
on
e 
in
te
rv
ie
w
 
in
te
rv
ie
w
 
ba
se
lin
e 
B
M
I 
(k
g/
m
2 )
 
 
10
 k
g/
m
2  
 
in
cr
em
en
t 
0.
86
 (0
.5
3–
1.
39
)  
0.
53
 
ag
e,
 s
ex
,  
m
ar
ita
l 
st
at
us
,  
ed
uc
at
io
n,
   
fa
rm
in
g,
 p
hy
si
ca
l 
ac
tiv
ity
, s
m
ok
in
g,
  
co
ffe
e,
 e
ne
rg
y 
in
ta
ke
 
  
 
44 
2 Review of the literature 
Ta
bl
e 
13
. O
be
si
ty
 a
nd
 P
ar
ki
ns
on
’s
 d
is
ea
se
: N
es
te
d 
ca
se
-c
on
tro
l s
tu
di
es
. 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; O
R
, o
dd
s 
ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 N
R
, n
ot
 re
po
rte
d;
 N
S
, n
on
-
si
gn
ifi
ca
nt
.  
a  
C
on
tro
ls
/P
D
 c
as
es
  
b 
U
na
dj
us
te
d.
 S
ta
te
d 
in
 th
e 
te
xt
: a
ss
oc
ia
tio
n 
pe
rs
is
te
d 
af
te
r c
on
tro
lli
ng
 fo
r s
m
ok
in
g,
 g
as
tri
c 
ul
ce
r, 
an
d 
m
ea
t c
on
su
m
pt
io
n 
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 a
sc
er
ta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
A
dj
us
te
d 
re
su
lt 
O
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
M
at
ch
in
g 
A
dj
us
tm
en
ts
 
U
S
A
/ 
(P
ag
an
in
i-
H
ill
 2
00
1)
 
Le
is
ur
e 
W
or
ld
 
C
oh
or
t S
tu
dy
, 
19
81
–1
98
5 
2,
32
0/
39
5,
 F
 
an
d 
M
 
18
 
ho
sp
ita
l 
di
sc
ha
rg
e 
da
ta
ba
se
, d
ea
th
 
ce
rti
fic
at
es
, o
r 
se
lf-
re
po
rt 
Q
 
B
M
I (
kg
/m
2 )
 
 
N
R
 
N
R
 (j
us
t 
st
at
ed
: N
S
) 
N
R
 
se
x,
 b
irt
h 
da
te
, v
ita
l 
st
at
us
; i
f 
de
ad
, d
ea
th
 
da
te
 
 
N
R
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
hi
na
/ (
M
a 
et
 a
l. 
20
06
) 
N
ut
rit
io
na
l 
In
te
rv
en
tio
n 
Tr
ia
l, 
19
86
 
34
0/
85
, F
 a
nd
 
M
 
14
 
sc
re
en
in
g:
 
sy
m
pt
om
 
qu
es
tio
nn
ai
re
 a
nd
  
ne
ur
ol
og
ic
al
 
ex
am
in
at
io
n 
by
 
ne
ur
ol
og
is
t 
in
te
rv
ie
w
 
B
M
I (
kg
/m
2 )
 
 
≥2
3 
vs
. 
<2
0 
0.
43
 (0
.2
0–
0.
93
)b
 
N
R
 
se
x,
 a
ge
, 
re
si
de
nt
ia
l 
co
m
m
un
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(V
ik
da
hl
 e
t 
al
. 2
01
4)
 
N
or
th
er
n 
S
w
ed
en
 
H
ea
lth
 a
nd
 
D
is
ea
se
 
S
tu
dy
, 1
98
6–
20
09
 
33
6/
84
, 
F 
an
d 
M
 
2–
8 
cl
in
ic
al
 
ex
am
in
at
io
n 
by
 a
 
ne
ur
ol
og
is
t, 
co
nf
irm
ed
 b
y 
an
ot
he
r s
pe
ci
al
is
t 
N
R
 
(m
ea
su
re
d 
at
 th
e 
tim
e 
of
 th
e 
he
al
th
-c
ar
e 
vi
si
t) 
w
ai
st
:h
ei
gh
t 
ra
tio
 
N
R
 
0.
91
 (0
.7
7–
1.
07
)  
0.
25
3 
se
x,
 a
ge
, 
ye
ar
 o
f 
he
al
th
 
su
rv
ey
, 
su
bc
oh
or
t, 
ge
og
ra
ph
ic
 
ar
ea
 
ag
e,
 p
hy
si
ca
l 
ac
tiv
ity
, 
sm
ok
in
g,
 B
M
I 
  
 
45 
2 Review of the literature 
Ta
bl
e 
14
. M
et
ab
ol
ic
 fa
ct
or
s 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: C
oh
or
t s
tu
di
es
. 
C
ou
nt
ry
/re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 
as
ce
rta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
B
lo
od
 p
re
ss
ur
e 
 
 
 
 
 
 
 
 
U
S
A
/ (
G
ra
nd
in
et
ti 
et
 a
l. 
19
94
) 
H
on
ol
ul
u-
A
si
a 
A
gi
ng
 S
tu
dy
 
(o
rig
in
al
ly
  
H
on
ol
ul
u 
H
ea
rt 
S
tu
dy
), 
19
65
 
8,
00
6/
58
, 
M
 
26
 
ho
sp
ita
l r
ec
or
ds
, 
de
at
h 
ce
rti
fic
at
es
 
or
 re
co
rd
s 
of
 
lo
ca
l n
eu
ro
lo
gi
st
s 
m
ea
su
re
d 
sy
st
ol
ic
 a
nd
 
di
as
to
lic
 B
P
 
hy
pe
rte
ns
io
n 
N
R
 
(in
te
rp
re
te
d 
as
 y
es
 v
s.
 
no
) 
1.
25
 (0
.6
8–
2.
28
) 
 
N
R
 
ag
e 
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
S
im
on
 e
t 
al
. 2
00
7)
 
N
ur
se
s’
 H
ea
lth
 
S
tu
dy
, 1
97
6;
 
H
ea
lth
 
P
ro
fe
ss
io
na
ls
 
Fo
llo
w
-u
p 
S
tu
dy
, 1
98
6 
12
1,
04
6 
/2
64
, F
; 
50
,8
33
 
/2
66
, M
 
24
 
  14
 
se
lf-
re
po
rt,
 
as
ce
rta
in
ed
 b
y 
tre
at
in
g 
ph
ys
ic
ia
n 
or
 re
vi
ew
in
g 
m
ed
ic
al
 re
co
rd
s 
Q
, s
el
f-r
ep
or
te
d 
hi
st
or
y 
of
 p
hy
si
ci
an
 d
ia
gn
os
ed
 
hy
pe
rte
ns
io
n,
 o
r 
re
po
rte
d 
us
e 
of
 
an
tih
yp
er
te
ns
iv
e 
m
ed
ic
at
io
n 
hi
st
or
y 
of
 
hy
pe
rte
ns
io
n 
ye
s 
vs
. n
o 
0.
96
 (0
.8
0–
1.
15
)b
 
N
R
 
ag
e,
 s
m
ok
in
gc
 
 
 
 
 
 
 
 
 
 
 
 
Fi
nl
an
d/
 (
Q
iu
 e
t a
l. 
20
11
) 
N
at
io
na
l 
FI
N
R
IS
K
 S
tu
dy
, 
19
72
–2
00
2 
30
,8
15
 
/3
71
, F
; 
28
,7
25
 
/4
23
, M
 
m
ea
n 
18
.8
 
re
gi
st
ry
 o
n 
re
im
bu
rs
em
en
t 
fo
r P
D
 d
ru
gs
, 
di
ag
no
se
d 
by
 
ne
ur
ol
og
is
t 
m
ea
su
re
d 
af
te
r 5
-m
in
 
re
st
, s
ea
te
d 
ar
te
ria
l B
P
, 
m
er
cu
ry
 
sp
hy
gm
om
an
om
et
er
, 
an
d 
re
po
rte
d 
us
e 
of
 
an
tih
yp
er
te
ns
iv
e 
m
ed
ic
at
io
n 
no
rm
al
 <
13
0/
80
 
m
m
H
g,
 
hy
pe
rte
ns
io
n 
≥1
40
/9
0 
m
m
H
g 
or
 
us
e 
of
 
an
tih
yp
er
te
ns
iv
es
 
hy
pe
rte
ns
io
n 
vs
. n
or
m
al
 
F:
 1
.6
2 
(1
.0
9–
2.
42
) 
 M
: 0
.9
0 
(0
.6
3–
1.
28
) 
N
R
 
ag
e,
 b
as
el
in
e 
ye
ar
, 
ed
uc
at
io
n,
  
ph
ys
ic
al
 
in
ac
tiv
ity
, 
sm
ok
in
g,
 
al
co
ho
l, 
co
ffe
e,
 
te
a,
  B
M
I, 
di
ab
et
es
 
m
el
lit
us
,  
to
ta
l 
ch
ol
es
te
ro
l 
 
 
 
 
 
 
 
 
 
 
 
S
in
ga
po
re
/ (
Ta
n 
et
 a
l. 
20
08
) 
S
in
ga
po
re
 
C
hi
ne
se
 H
ea
lth
 
S
tu
dy
, 1
99
3–
19
98
 
63
,2
57
 
/1
57
, F
 
an
d 
M
 
m
ea
n 
7 
se
lf-
re
po
rt 
or
 
ho
sp
ita
l 
di
sc
ha
rg
e 
da
ta
ba
se
 o
r P
D
 
re
gi
st
ry
, 
as
ce
rta
in
ed
 b
y 
re
vi
ew
in
g 
m
ed
ic
al
 re
co
rd
s 
Q
, s
el
f-r
ep
or
te
d 
m
ed
ic
al
 
hi
st
or
y 
hy
pe
rte
ns
io
n 
N
R
 
(in
te
rp
re
te
d 
as
 y
es
 v
s.
 
no
) 
N
R
 (j
us
t 
st
at
ed
: N
S
) 
N
R
 
N
R
 
      
 
 
 
 
 
 
 
 
 
 
  
 
46 
2 Review of the literature 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; R
R
, r
el
at
iv
e 
ris
k;
 C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; B
P
, b
lo
od
 p
re
ss
ur
e;
 N
R
, n
ot
 re
po
rte
d;
 N
S
, n
on
-s
ig
ni
fic
an
t; 
B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 H
D
L,
 h
ig
h-
de
ns
ity
 li
po
pr
ot
ei
n.
  
a  
To
ta
l p
op
ul
at
io
n/
P
D
 c
as
es
  
b  
R
es
ul
ts
 a
re
 p
oo
le
d 
R
R
s 
fro
m
 th
e 
tw
o 
co
ho
rts
 
c  R
es
ul
ts
 w
er
e 
si
m
ila
r w
he
n 
fu
rth
er
 a
dj
us
te
d 
fo
r c
af
fe
in
e 
an
d 
al
co
ho
l i
nt
ak
e,
 B
M
I, 
hi
st
or
y 
of
 h
ig
h 
ch
ol
es
te
ro
l o
r d
ia
be
te
s 
d  
R
es
ul
ts
 w
er
e 
si
m
ila
r w
he
n 
fu
rth
er
 a
dj
us
te
d 
fo
r s
m
ok
in
g,
 c
of
fe
e,
 d
ie
ta
ry
 v
ita
m
in
 E
, B
M
I, 
ap
ol
ip
op
ro
te
in
 E
 g
en
ot
yp
e,
 b
as
el
in
e 
lip
id
-lo
w
er
in
g 
dr
ug
 u
se
Ta
bl
e 
14
. (
co
nt
in
ue
d)
 
 
 
 
 
 
 
 
 
 
C
ou
nt
ry
/re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 
as
ce
rta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
 
A
dj
us
te
d 
re
su
lt 
R
R
 (9
5%
 C
I) 
P
 fo
r 
tre
nd
 
A
dj
us
tm
en
ts
 
H
D
L 
ch
ol
es
te
ro
l 
 
 
 
 
 
 
 
 
N
et
he
rla
nd
s/
 (
de
 
La
u 
et
 a
l. 
20
06
b)
 
R
ot
te
rd
am
 
S
tu
dy
, 1
99
0–
19
93
 
6,
46
5 
/8
7,
 
F 
an
d 
M
 
m
ea
n 
9.
4 
P
D
 d
ia
gn
os
ed
 b
y 
ne
ur
ol
og
is
t a
t t
he
 
fo
llo
w
-u
p 
ex
am
in
at
io
n 
no
n-
fa
st
in
g 
bl
oo
d 
sa
m
pl
es
, s
er
um
 H
D
L 
de
te
rm
in
ed
 b
y 
au
to
m
at
ed
 e
nz
ym
at
ic
 
pr
oc
ed
ur
e 
se
ru
m
 H
D
L 
(m
m
ol
/l)
 
hi
gh
es
t v
s.
 
lo
w
es
t 
qu
ar
til
e 
 
ov
er
al
l: 
1.
81
 (0
.9
6–
3.
42
) 
 M
: 1
.3
8 
(0
.5
6–
3.
43
) 
 F:
 2
.6
9 
(1
.1
1–
6.
49
) 
N
R
 
ag
e,
 s
ex
d  
 
 
 
 
 
 
 
 
 
 
 
U
S
A
/ (
H
ua
ng
 e
t 
al
. 2
00
8)
 
H
on
ol
ul
u-
A
si
a 
A
gi
ng
 S
tu
dy
 
(o
rig
in
al
ly
  
H
on
ol
ul
u 
H
ea
rt 
S
tu
dy
), 
19
65
 
(b
lo
od
 
sp
ec
im
en
s 
19
91
–1
99
3)
 
3,
23
3/
41
, 
M
 
20
 
ho
sp
ita
l r
ec
or
ds
, 
de
at
h 
ce
rti
fic
at
es
 
or
 re
co
rd
s 
of
 
lo
ca
l 
ne
ur
ol
og
is
ts
; 
af
te
r 1
99
1,
 
ne
ur
ol
og
ic
 
ex
am
in
at
io
n 
N
R
 (f
as
tin
g 
bl
oo
d 
sp
ec
im
en
s 
ob
ta
in
ed
, 
lip
id
 d
et
er
m
in
at
io
n 
m
et
ho
d 
no
t r
ep
or
te
d)
 
H
D
L 
ch
ol
es
te
ro
l 
le
ve
l 
N
R
 
N
R
 (j
us
t 
st
at
ed
: N
S
) 
N
R
 
N
R
 
Tr
ig
ly
ce
ri
de
s 
 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G
lu
co
se
 
 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
 
 
 
  
 
47 
2 Review of the literature 
Ta
bl
e 
15
. M
et
ab
ol
ic
 fa
ct
or
s 
an
d 
P
ar
ki
ns
on
’s
 d
is
ea
se
: N
es
te
d 
ca
se
-c
on
tro
l s
tu
di
es
. 
A
bb
re
vi
at
io
ns
: P
D
, P
ar
ki
ns
on
’s
 d
is
ea
se
; O
R
, o
dd
s 
ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; F
, f
em
al
e;
 M
, m
al
e;
 Q
, q
ue
st
io
nn
ai
re
; B
P
, b
lo
od
 p
re
ss
ur
e;
 N
R
, n
ot
 re
po
rte
d;
 N
S
, n
on
-s
ig
ni
fic
an
t; 
B
M
I, 
bo
dy
 m
as
s 
in
de
x.
  
a  
C
on
tro
ls
/P
D
 c
as
es
  
C
ou
nt
ry
/ 
re
fe
re
nc
e 
S
tu
dy
 n
am
e,
 
ba
se
lin
e 
ye
ar
 
P
op
ul
at
io
n 
N
/n
a  
, 
ge
nd
er
 
Fo
llo
w
-
up
 
ye
ar
s 
P
D
 
as
ce
rta
in
m
en
t 
M
ea
su
rin
g 
m
et
ho
d 
of
 
ex
po
su
re
 
E
xp
os
ur
e 
(u
ni
t) 
E
xp
os
ur
e 
ca
te
go
rie
s 
co
m
pa
re
d 
A
dj
us
te
d 
re
su
lt 
O
R
 (9
5%
 
C
I) 
P
 fo
r 
tre
nd
 
M
at
ch
in
g 
A
dj
us
tm
en
ts
 
B
lo
od
 p
re
ss
ur
e 
 
 
 
 
 
 
 
 
 
U
S
A
/ 
(P
ag
an
in
i-
H
ill
 2
00
1)
 
Le
is
ur
e 
W
or
ld
 C
oh
or
t 
S
tu
dy
, 1
98
1–
19
85
 
2,
32
0/
39
5,
 F
 
an
d 
M
 
18
 
ho
sp
ita
l 
di
sc
ha
rg
e 
da
ta
ba
se
, d
ea
th
 
ce
rti
fic
at
es
, o
r 
se
lf-
re
po
rt 
Q
, s
el
f- 
re
po
rte
d 
hy
pe
rte
ns
io
n 
  cu
rr
en
t B
P
 
m
ed
ic
at
io
n 
us
e 
ye
s 
vs
. n
o 
  ye
s 
vs
. n
o 
0.
71
 (0
.5
6–
 
0.
89
)b
  
 0.
62
 (0
.4
8–
0.
80
) 
N
R
 
se
x,
 b
irt
h 
da
te
, v
ita
l 
st
at
us
; i
f 
de
ad
, d
ea
th
 
da
te
 
 
sm
ok
in
g,
   
al
co
ho
l, 
co
ffe
e,
 
vi
ta
m
in
 C
 a
nd
 
A
 in
ta
ke
, 
pa
rit
y 
 
 
 
 
 
 
 
 
 
 
 
 
C
hi
na
/ (
M
a 
et
 a
l. 
20
06
) 
N
ut
rit
io
na
l 
In
te
rv
en
tio
n 
Tr
ia
l, 
19
86
 
34
0/
85
, F
 a
nd
 
M
 
14
 
sc
re
en
in
g:
 
sy
m
pt
om
 
qu
es
tio
nn
ai
re
 
an
d 
 n
eu
ro
lo
gi
ca
l 
ex
am
in
at
io
n 
by
 
ne
ur
ol
og
is
t 
in
te
rv
ie
w
, 
se
lf-
re
po
rte
d 
hy
pe
rte
ns
io
n 
N
R
 
(p
re
su
m
ab
ly
 
ye
s 
vs
. n
o)
 
N
R
 (j
us
t 
st
at
ed
: N
S
) 
N
R
 
se
x,
 a
ge
, 
re
si
de
nt
ia
l 
co
m
m
un
e 
N
R
 
 
 
 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(V
ik
da
hl
 e
t 
al
. 2
01
4)
 
N
or
th
er
n 
S
w
ed
en
 
H
ea
lth
 a
nd
 
D
is
ea
se
 
S
tu
dy
, 1
98
6–
20
09
 
33
6/
84
, 
F 
an
d 
M
 
2–
8 
cl
in
ic
al
 
ex
am
in
at
io
n 
by
 a
 
ne
ur
ol
og
is
t, 
co
nf
irm
ed
 b
y 
an
ot
he
r 
sp
ec
ia
lis
t 
N
R
 
(m
ea
su
re
d 
at
 ti
m
e 
of
 
he
al
th
-c
ar
e 
vi
si
t) 
sy
st
ol
ic
 B
P
 
(m
m
H
g)
 
N
R
 
0.
98
 (0
.9
6–
0.
99
)  
0.
04
 
se
x,
 a
ge
, 
ye
ar
 o
f 
he
al
th
 
su
rv
ey
, 
su
bc
oh
or
t, 
ge
og
ra
ph
ic
 
ar
ea
 
ag
e,
 p
hy
si
ca
l 
ac
tiv
ity
, 
sm
ok
in
g,
 B
M
I 
H
D
L 
ch
ol
es
te
ro
l 
 
 
 
 
 
 
 
 
 
- 
 
 
 
 
 
 
 
 
 
 
 
Tr
ig
ly
ce
ri
de
s 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(V
ik
da
hl
 e
t 
al
. 2
01
4)
 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 a
bo
ve
 
N
R
 
(a
ss
es
se
d 
at
 ti
m
e 
of
 
he
al
th
-c
ar
e 
vi
si
t) 
se
ru
m
 
tri
gl
yc
er
id
es
 
(m
m
ol
/l)
 
N
R
 
0.
64
 (0
.4
1–
1.
01
)  
0.
05
3 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 
ab
ov
e 
G
lu
co
se
 
 
 
 
 
 
 
 
 
 
S
w
ed
en
/ 
(V
ik
da
hl
 e
t 
al
. 2
01
4)
 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 a
bo
ve
 
sa
m
e 
as
 
ab
ov
e 
fa
st
in
g 
bl
oo
d 
gl
uc
os
e 
N
R
 
N
R
 (j
us
t 
st
at
ed
 n
o 
di
ffe
re
nc
e)
 
N
R
 
sa
m
e 
as
 
ab
ov
e 
sa
m
e 
as
 
ab
ov
e 
2 Review of the literature 
48 
 
2.2.6 Summary of literature review 
It seems that the epidemiologic evidence for most of the factors examined is inconclusive, as was also 
concluded by both de Lau and Breteler (2006a) and Wirdefeldt et al. (2011). Thus far, older age and 
smoking habits are the only risk or protective factors for PD that have consistently been found across 
studies (see de Lau and Breteler 2006a). For coffee consumption, the results have been rather consistent 
for reporting an inverse association, but further evidence is needed; for example, acquisition of supportive 
evidence from clinical and animal studies is ongoing.  
For physical activity and alcohol consumption, the number of studies is growing, but the results have been 
inconclusive, finding no association or a weak inverse association. Furthermore, there are a few factors 
with some consistency in findings across studies (e.g. milk consumption, vitamin E and polyunsaturated fat 
intake, and serum uric acid concentration), but the number of studies are too limited. For other factors, 
the results have been contradictory and the number of studies is low. 
Methodological differences (especially in PD ascertainment) and incomparable reporting complicates 
summarizing the results. An agreed minimum set of adjustments, for example age, sex, and smoking, 
would be helpful for comparisons across studies. Furthermore, potential effect-modifying factors should 
be studied systematically. More prospective studies are needed to further examine the epidemiology of 
PD. Future studies should also acknowledge the preclinical phase of PD in analyses.  
 
  
3 Aims of the study 
49 
 
3 Aims of the study 
The general objective of this study was to determine whether diet, other lifestyle factors, and metabolic 
health predicted the incidence of Parkinson’s disease in population-based cohorts with a prospective 
study design.  
The specific study aims were to examine:  
- The association between food consumption, overall quality of diet, and the risk of PD (Study I);  
- The association between lifestyle factors (leisure-time physical activity, smoking, alcohol consumption, 
and coffee consumption) and the risk of PD (Studies II and III); 
- The association between metabolic health, especially body mass index, and the risk of PD (Studies II and 
IV). 
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4 Population and methods 
4.1 Study populations 
The Social Insurance Institution conducted the Finnish Mobile Clinic Health Examination Survey (FMC) 
between 1966–1972. The health examinations were carried out by mobile field clinics. The Social 
Insurance Institution continued to study the health of the Finnish population with the Finnish Mobile 
Clinic Follow-up Survey (FMCF), conducted in 1973–1976, and the Mini-Finland Health Survey, 1978–1980. 
These studies are well described on the webpages of the Finnish Mobile Clinic Surveys 
(https://www.thl.fi/fi/tutkimus-ja-asiantuntijatyo/vaestotutkimukset/autoklinikka-tutkimukset).  
Study I is based on the FMC. A total of 62,440 men and women aged 15 or over were invited to take part 
in the study, and 82.5% participated (Aromaa 1981). The baseline examinations were carried out in 31 
rural, industrial, or semi-urban populations (Figure 2). The sample was not representative of the Finnish 
population, but followed the age distribution of the general population. As part of the main study, a 
dietary history interview was performed for 10,054 selected subjects (Järvinen 1996; Seppänen et al. 
1973). Of these, participants aged 40–79 years were included in the Study I (n=4,738).  
Studies II and III are based on the FMCF (Reunanen et al. 1983), which was conducted in subpopulations of 
the baseline FMC study populations in 12 municipalities around Finland (Figure 3). Every third subject of 
those invited to the FMC, aged 20 years or older, was also invited to participate in the FMCF. Thus, 24,833 
subjects were invited, and a total of 19,518 subjects were re-examined (78.6% response rate). Studies II 
and III included only those participants between ages 50–79 (n=7,246).  
Study IV is based on the Mini-Finland Health Survey carried out in 40 areas of Finland (Figure 4) (Aromaa 
et al. 1989; Lehtonen and Kuusela 1986). The sample was a stratified two-stage cluster sample 
representative of the Finnish population of adults aged 30 years and over (n=8,000). A total of 7,217 
subjects (90%) participated in the health examination. Of these, participants between ages 30–79 were 
included in the present study (n=7,041).  
In all studies, subjects identified as PD cases at baseline were excluded. Additionally, subjects who 
reported the use of antipsychotic medication due to psychotic disorders (see chapter 4.3.2 for details) 
were excluded. Thus, the final study populations included: 
- 4,524 subjects in Study I 
- 6,715 subjects in Study II 
- 6,710 subjects in Study III, as subjects with missing information on coffee consumption were further 
excluded 
- 4,828 subjects in Study IV 
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Figure 2. The areas of baseline examinations in the Finnish Mobile Clinic Health Examination Survey in 1966–1972.  
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Figure 3. The areas of baseline examinations in the Finnish Mobile Clinic Follow-up Survey in 1973–1976. 
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Figure 4. The areas of baseline examinations in the Mini-Finland Health Survey in 1978–1980.  
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4.1.1 Ethical questions  
The three surveys used in this study precede the current legislation on ethics in medical research. In all 
three studies, the participants were fully informed about the study. They participated voluntarily and the 
use of the information for medical research was explained to them. Agreeing to participate in the baseline 
health examination was taken to indicate informed consent. The follow-up study using record linkage was 
approved by the Institutional Review Board of the National Institute for Health and Welfare on June 8, 
2011. The Social Insurance Institution of Finland approved the linkage to their registers (Kela 9/500/2011). 
All researchers in this study were obligated to professional confidentiality and no identifiable information 
is given to third parties.  
4.2 Measurement methods 
4.2.1 Measures of primary exposure variables 
Food consumption and diet quality (Study I), the FMC Survey 
At the baseline examinations of the FMC, the total habitual food consumption of the participants during 
the previous year was assessed using a dietary history interview (Koskinen 1975; Seppänen et al. 1973; 
Järvinen 1996). Trained interviewers used a questionnaire which included over 100 food items and mixed 
dishes common in the diet of Finns at the time. The frequency of food items was reported per day, week, 
month, or year, according to the choice of the respondent. Food models were used to help in recalling 
portion sizes. Furthermore, the methods of food preparation were inquired about (for example, the 
interview form included separate rows for smoked fish and fried fish). Several of the questions were open-
ended and intended to be specified by the respondent. 
Individual consumption of food items and mixed dishes was converted into grams/day. Then the 
ingredients of mixed food dishes were broken down into their component foods using a recipe file. This 
file, including the recipes of mixed dishes, was based on contemporary Finnish cookbooks and data 
collected in food consumption studies. Next, the intakes of separate food items appearing in the original 
interviews and those derived from mixed food dishes were combined and calculated per day. Finally, the 
intakes of nutrients from all food items were computed using a food composition file. Originally, the food 
composition database was compiled utilizing the contemporary Finnish food composition tables 
(Turpeinen and Roine 1967). During the late eighties, the food composition data were updated and new 
values were calculated based on the nutrient composition book published by the Finnish Social Insurance 
Institution (Rastas et al. 1989). The methods for the dietary study have also been described in detail on 
the webpage for the Finnish Mobile Clinic Surveys (https://www.thl.fi/fi/tutkimus-ja-
asiantuntijatyo/vaestotutkimukset/autoklinikka-tutkimukset/autoklinikan-moniseulontatutkimus/ 
aineisto/kenttamittausaineisto/kyselyt-ja-haastattelut).  
In Study I, the whole diet was represented with consumption of 24 food groups and items (g/d): total 
grains, rye, wheat, whole grains, total vegetables, legumes and nuts, potato, roots, total fruits and berries, 
fresh fruits, berries, margarines, oils and mayonnaise, butter, total milk and milk products, milk, cheese, 
fermented milk products, total meat and meat products, red meat, processed meat and sausages, poultry, 
ratio of white meat to red meat, fish, eggs, sugar and sugar rich condiments. The Appendix Table 2 
presents the details of the food groups and items. Intake was divided into tertiles for analyses due to the 
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absence of a predefined hypothesis for cut-off points, and to avoid the assumption of a linear association 
between exposure and PD. 
For Study I, a dietary index was created based on the definition of the Alternate Healthy Eating Index 
(AHEI), an index developed to measure adherence to the Dietary Guidelines for Americans (McCullough et 
al. 2002). A few modifications were made to adjust the AHEI index to the Finnish population in our study. 
We aimed for a similar definition whenever possible, but in comparison with AHEI, information on 
multivitamin use and alcohol consumption could not be included since these variables did not exist in the 
FMC data. Thus, the current dietary index, modified AHEI (mAHEI), included the following seven 
components: vegetables (not potato), fresh fruits (not berries), nuts and legumes, the ratio of white (fish 
and poultry) to red meat, whole grains (products containing > 25% whole grain), the ratio of 
polyunsaturated to saturated fat, and trans fats (Study I). The intakes of components were then divided 
into quintiles to assign scores. The first six components received scores in an ascending order, so that one 
point was assigned for intakes in the lowest quintile and five points for intakes in the highest quintile. The 
trans fats component received scores in descending order, with the lowest quintile gaining a value of five 
points and the highest quintile a value of one point. The total score, thus, ranged from 7 (worst) to 35 
(best). A higher score suggested a higher adherence to a healthy diet. The reasoning for constructing the 
mAHEI is further discussed in chapter 6.4.2. 
Lifestyle factors (Studies II and III), the FMCF Survey 
As part of the FMCF, all subjects completed a mailed, self-administered, health questionnaire (Reunanen 
et al. 1983). The questionnaire is available on the webpage for the Finnish Mobile Clinic Surveys 
(https://www.thl.fi/documents/10531/1925652/AU01_Peruskyselylomake.PDF/4b31c7c2-a1c6-44e6-
a666-ea46c6aa9087). The questionnaire, which was checked by a trained study nurse at the baseline 
examinations, provided information on leisure-time physical activity, smoking, and alcohol and coffee 
consumption. 
Participants were asked to classify their leisure-time physical activity during a typical week into one of four 
categories: 1) none; 2) light physical activity for at least four hours per week (e.g. walking, cycling); 3) 
heavy physical activity for at least three hours per week (e.g. jogging, skiing, vigorous gardening); or 4) 
regular heavy physical activity several times a week. The last two alternatives were combined, classifying 
physical activity into three categories (none, light, heavy).  
Furthermore, based on detailed questions about smoking habits, the participants were classified as: never 
smoker, past smoker, or current smokers (the latter category combining the following: uses cigar or pipe 
but not cigarettes, smokes less than 15 cigarettes per day, smokes 15 to 24 cigarettes per day, or smokes 
at least 25 cigarettes per day). Past smokers were classified as those who reported ever smoking for at 
least a one year time period, but who currently do not smoke. 
Alcohol consumption was assessed through ten questions regarding the amount, frequency, and type of 
alcohol consumed. A participant’s total alcohol intake was calculated as the sum of the contribution from 
beer, wine, and liquor and was expressed in grams of ethanol per day. The alcohol content by weight was 
considered to be 3.6% for beer, 8.9% for wine, and 35.0% for liquor. The cut-off points for categorization 
of alcohol consumption could not be set against recommended values of risk-level intake because alcohol 
consumption in this population was very low (median, 0 g/d). Thus, non-users were categorized as one 
group, and a consumption of approximately 3 alcohol portions per week was chosen to divide alcohol 
users in moderate (<5 g/d) and heavy consumption (≥5 g/d).  
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The health questionnaire enquired about coffee consumption with an open-ended question as the 
average number of cups per day.  
The information on BMI was obtained from the baseline health examinations of the FMCF by measuring 
height (without shoes) and weight (in light indoor clothing). The measurement of weight was rounded to 
the nearest full kilogram, and the weight of clothing was taken into account by subtracting 2 kg from the 
measurements during winter time examinations and 1 kg during summer time. BMI was calculated as 
weight in kilograms divided by the square of the height in meters (kg/m2).  
Metabolic health (Study IV), The Mini-Finland Health Survey 
The Mini-Finland Health Survey included a baseline health examination (Aromaa et al. 1989) where casual 
blood pressure was measured twice with a 1.5 minute interval by the auscultatory method. For the 
current study, the mean of the two blood pressure measurements was used in analyses.  Furthermore, 
overnight fasting blood samples were taken and stored at -20 ◦C (96.7% of the participants had at least an 
11 hour fast, mean duration of fast was 16.8 h, SD 3.5). Serum triglyceride, serum HDL cholesterol, and 
fasting plasma glucose concentrations were determined a few weeks after the samples were taken. Serum 
triglyceride concentration was determined using the fully enzymatic method (Boehringer, Mannheim, 
Germany) (Wahlefeld 1974). In the HDL cholesterol analysis, LDL and VLDL was first precipitated with Mg-
dextrane sulphate (Kostner 1976), then HDL cholesterol was determined from the supernatant by a 
modification of the direct Liebermann-Burchard method without a so-called serum-blank subtraction (Carr 
and Drekter 1956). Fasting plasma glucose was determined using a glucose oxidase method (Boehringer, 
Mannheim, Germany) (Werner et al. 1970).  
At the baseline examinations, weight (in light indoor clothing, without shoes) was measured by a 
frequently calibrated lever balance. Height was measured without shoes and with the back against a wall. 
BMI was calculated as weight in kilograms divided by the square of the height in meters (kg/m2).  
The definition of metabolic syndrome and the cut-off values for categories of the components of it were 
based on the harmonized definition of metabolic syndrome (Alberti et al. 2009). BMI was used as a proxy 
measure in the definition of metabolic syndrome by replacing the waist circumference category ‘normal’ 
with a BMI of <25 kg/m2 and the category ‘large’ with a BMI of ≥25 kg/m2, since the present data did not 
include information on waist circumference. For this reason, we used the Health 2000 data (Aromaa et al. 
2002), a representative sample of Finnish adults, to examine the validity of BMI for the cut-off point 25 
kg/m2 by using waist circumference with a cut-off value of ≥94 for men and ≥80 for women as the 
reference. We found that BMI had a reasonable sensitivity (82.5%) and specificity (85.3%), and, 
accordingly, used BMI as a proxy measure. Furthermore, the use of this proxy measure was supported by 
a recent cohort study, where the relative risk of diabetes for individuals with metabolic syndrome defined 
according to both the original definition and the proxy definition did not notably differ (RR 6.70, 95% CI 
3.61–12.4 for original definition, and RR 6.78, 95% CI 3.72–12.4 for proxy definition) (Laaksonen et al. 
2010). 
The criterion for the metabolic syndrome was the presence of any three or more of the following 
five components: BMI ≥25 kg/m2, elevated mean blood pressure (SBP ≥130 mmHg or DBP ≥85 mmHg or 
antihypertensive drug treatment), high serum triglycerides (≥1.7 mmol/L), low serum HDL cholesterol 
(<1.3 mmol/L in women and <1.0 mmol/L in men), and high fasting plasma glucose (≥5.6 mmol/L). The 
general criterion and cut-off values follow those presented by Alberti et al. (2009), but the modified 
criterion used here (with the BMI proxy measure) followed the work of Laaksonen et al. (2010).  
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4.2.2 Measures of covariates 
The comprehensive health examinations made at the baselines of the FMC, FMCF, and Mini-Finland 
Health Survey provided an ample amount of information on potential confounding factors. Despite all the 
available data from these surveys, only those factors used in current studies (I–IV) are mentioned here. 
However, it should be noted that the questionnaires used in the FMC and FMCF were not exactly similar. 
Thus, both classifications of the variables and the covariates used in the models differ between the 
studies.   
The factors used as covariates in individual studies, and their categorizations, are listed in the original 
articles in detail (Studies I–IV). Below, the assessment of these factors is described in general. 
Sociodemographic and lifestyle factors 
In both the FMC (Aromaa 1981) and the FMCF (Reunanen et al. 1983), trained study nurses reviewed, in-
person, the mailed, self-administered health questionnaire participants were asked to complete prior to 
the baseline examination. Sociodemographic factors obtained from the health questionnaire included e.g. 
age, sex, education, marital status, geographical area, community density, and occupation. Additionally, 
previous and current illnesses (e.g. diabetes and cardiovascular diseases), use of medication (e.g. use of 
antipsychotics) and other health-related information (e.g. parity) were inquired about. In the FMC, 
lifestyle factors collected in the health questionnaire included smoking and leisure-time physical activity. 
The FMC did not include questions on alcohol or coffee consumption. The FMCF, however, provided 
information on leisure-time physical activity, smoking, and alcohol and coffee consumption, as described 
above.   
In the Mini-Finland Health Survey, the background information was gathered both from a health interview 
and a self-administered questionnaire. They provided information on, for example, age, sex, education, 
smoking, alcohol consumption, leisure-time physical activity, coffee consumption, previous diseases (e.g. 
diabetes and cardiovascular diseases), and antihypertensive medication at baseline. 
Biological factors 
In the FMC, baseline examinations included measurements of casual blood pressure using the 
auscultatory method (Aromaa 1981), and collection of venous blood samples. Serum total cholesterol 
concentrations were determined via an autoanalyzer modification (Auto-Analyzer Methodology N-24a 
and N-77; Technicon, Tarrytown, NY, USA) of the Liebermann–Burchard reaction (Huang et al. 1961). 
Additionally, height (without shoes) and weight (in light indoor clothing) were measured and BMI (kg/m2) 
was calculated.  
In the FMCF, blood pressure was measured in the seated position after a 5-min rest, using a 
semiautomatic device (Elag BPM-A) (Aromaa 1981). Serum samples were taken and the cholesterol 
concentrations determined by an autoanalyzer modification of the Liebermann-Burchard reaction (Huang 
et al. 1961). 
Baseline examinations of the Mini-Finland Health Survey included blood pressure measurements and 
blood sample collection and analyses as described above (chapter 4.2.1). Also, in 2002, serum 25-
hydroxyvitamin D concentration was determined using radioimmunoassay (DiaSorin, Stillwater, 
Minnesota, USA), with an inter-assay coefficient of variation (CV) of 7.8%. In the absence of a predefined 
hypothesis, a median value was used to dichotomize the variable on serum vitamin D concentration. 
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4.2.3 Reliability of the measures 
Table 16 describes the repeatability of the exposure measures used in the present study. Previous studies 
from the FMC, FMCF, and Mini-Finland Health Survey have examined both long-term and short-term 
repeatability. Variables that were not examined previously were studied as part of the current thesis 
work.  
The intraclass correlation coefficients (ICC) for the short-term repeatability were above 0.6 for the mAHEI 
index as well as for most of the dietary factors included in this study (Table 16). This can be considered as 
acceptable agreement between the repeated measurements, and as concluded by Järvinen et al. (1993), 
the dietary patterns of examinees were sufficiently stable to be compatible with the needs of 
epidemiological follow-up studies.  
Measurement on berries and eggs, however, showed lower ICCs (r= 0.36 and 0.47, respectively), which 
may still be considered as fair agreement.  The consumption of berries and eggs was rather low, so these 
results may reflect the finding that foods eaten less often are not recalled as reliably as those eaten 
regularly (Nomura et al. 1976). 
In previous studies on food intake measured by repeated food frequency questionnaires at the interval of 
3–12 months, average correlation coefficients have ranged from 0.5 to 0.7 (Willett and Lenart 1998). 
As could be expected, the long-term agreement between the repeated measurements declined for the 
mAHEI index and all the dietary factors (Table 16). This is probably due to the effect of real changes in diet 
over time, in addition to the errors in recalling the participant’s habitual diet. In the long-term, most of the 
ICCs here varied between 0.2 and 0.5. The berry consumption and polyunsaturated:saturated ratio, 
however, had poorer agreement (r= 0.10 and 0.12, respectively). Previous studies on food intake 
measured repeatedly with more than a one-year interval have showed average correlation coefficients 
between 0.3 and 0.5 (Willett and Lenart 1998). 
For physical activity, information on short-term repeatability was available. The agreement between the 
two measurements had only fair agreement (r=0.38), which may be a concern. As with diet, measuring 
physical activity with questionnaires is challenging. Instead, smoking, alcohol consumption, and coffee 
consumption had relatively good stability with ICCs ranging mostly between 0.7 and 0.8 (Table 16).  
The short-term repeatability was not available for height and weight in the Mini-Finland Health Survey 
and was thus reviewed from the FMC. Measurements on both height and weight had excellent short-term 
repeatability, with ICCs above 0.9 (Table 16). Accordingly, BMI had excellent repeatability too (r=0.96) 
when measured with one-year intervals in the Mini-Finland Health Survey. 
The components of metabolic syndrome were measured reliably too, as the short-term ICCs varied 
between 0.7 and 0.8 (Table 16). The ICCs declined slightly when measurements were repeated at one-year 
intervals, but were all still above 0.7.  
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Table 16. Repeatability of the primary exposure variables used in the present study. 
Variable Short-term repeatability  Long-term repeatability  
 N Measurea Reference N Measurea Reference 
 FMCF  FMC vs. FMCF  
 (interval between measurements 4–8 months) (interval between measurements 4–7 years) 
Diet       
Cereals 93 0.62 b 1,844 0.39 b 
Vegetables 93 0.63 b 1,844 0.47 b 
Fruits  93 0.64 b 1,844 0.41 b 
Berries 93 0.36 b 1,844 0.10 b 
Milk products 93 0.68 b 1,844 0.54 b 
Meat products 93 0.72 b 1,844 0.47 b 
Fish 93 0.72 b 1,844 0.39 b 
Eggs 93 0.47 b 1,844 0.28 b 
Sugar and sweets 93 0.69 b 1,844 0.33 b 
P:S ratio 93 0.75 b 1,844 0.12 b 
mAHEI index 93 0.61 c 1,844 0.49 c 
Lifestyle factors       
Physical activity 282 0.38 c NA   
Smoking NA   17,631 0.82 c 
Alcohol consumption 286 0.75 c NA   
Coffee consumption 286 0.77 d NA   
Biological measures      
 FMC     
 (interval between measurements few months)    
Height  366 0.995 e    
Weight 366 0.98 e    
 Mini-Finland Health Survey  Mini-Finland Health Survey  
 (interval between measurements 3 months) (interval between measurements 1 year) 
Body mass index NA NA  417 0.96 f 
Systolic blood pressure 1,314 0.77 f 373 0.75 f 
Diastolic blood 
pressure 
1,314 0.72 f 373 0.75 f 
Serum HDL cholesterol 1,315          0.78 f 42  0.76 f 
Fasting plasma glucose 1,313 0.74 f 373 0.70 f 
Serum triglycerides 1,316       0.83 f 373 0.73 f 
Abbreviations: FMC, Finnish Mobile Clinic Health Examination Survey; FMCF, Finnish Mobile Clinic Follow-up Survey; 
y, year; P/S, polyunsaturated/saturated; mAHEI, modified Alternate Healthy Eating Index; F, female; M, male; NA, not 
available; HDL, high-density lipoprotein. 
a Intraclass correlation coefficient: r for continuous and Kappa for categorized variables (i.e. physical activity and 
smoking)  
b (Järvinen et al. 1993) 
c Katri Sääksjärvi, unpublished (analyzed for this thesis) 
d (Sääksjärvi et al. 2010) 
e (Heliövaara and Aromaa 1980) 
f Paul Knekt, unpublished (personal communication 2015) 
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In addition, the suitability of the health questionnaire in measuring coffee consumption was assessed in a 
subpopulation of participants from the FMCF by determining the agreement between the health 
questionnaire and a 1-year dietary history interview (n=4,341). The ICC was 0.86 for the agreement 
between the health questionnaire and the dietary history interview (Sääksjärvi et al. 2010). 
The relative validity of the dietary history interview used here has not been evaluated against other 
dietary methods. Previously, average correlation coefficients ranging from 0.3 to 0.8 are typically seen in 
validation studies of food frequency methods (Willett and Lenart 1998).  
4.3 Case ascertainment  
4.3.1 Identification and prevalence of PD cases 
PD cases were ascertained through the nationwide Drug Reimbursement Register of the Social Insurance 
Institution (SII) which stores data on patients receiving medication reimbursement using a unique 
personal identity number given to all Finnish residents. In this study, PD was defined as the World Health 
Organization’s International Classification of Diseases (ICD-10) code G20, which means only primary, 
idiopathic Parkinson’s disease, and thus secondary or other forms of parkinsonism were not included. 
The information on PD cases was retrieved from the SII’s register using the reimbursement right code 110. 
To obtain this allowance for free drug treatment, PD patients must apply for it and attach a certificate 
from a treating neurologist describing the clinical diagnostic criteria, including symptom history and 
findings from clinical examinations (stating the presence of characteristic motor manifestations such as 
resting tremor, bradykinesia and/or muscle rigidity, along with other findings). The allowance is granted 
after inspection of the claim by another neurologist at the SII. The medication allowance is not granted for 
patients with, for example, essential tremor, intention tremor, or parkinsonism caused by neuroleptics. 
The prevalence of PD in the Finnish population 
The prevalence of PD cases, based on the information retrieved from the Drug Reimbursement Register of 
the SII, is presented in Figures 5–8, covering those years included for follow-up in the present study. A 
direct age-adjustment was applied for calculation of the prevalence rates using the age distribution of the 
population in the year 1990. The prevalence of PD was calculated by including all patients receiving 
medication reimbursement for PD and then excluding those who also received medication reimbursement 
for psychotic disorders (reimbursement right code 112).  
The decision to exclude those PD cases who also received medication reimbursement for psychotic 
disorders was made in order to remove cases potentially suffering from drug-induced secondary 
parkinsonism. Drugs that block the action of dopamine (dopamine antagonists), such as neuroleptic drugs 
used to treat schizophrenia and other psychotic disorders, are likely to cause parkinsonism (see Lopez-
Sendon et al. 2013). Parkinsonism can occur from the use of any of the various classes of neuroleptics, but 
the highest risk is for first-generation antipsychotics (i.e. typical antipsychotics: haloperidol, 
prochlorperazine, thioxantenes, amisulpride, flupentixol, fluphenazine, levomepromazine, pimozide, 
promazine, sulpiride, thioridazine, zuclopenthixol)(see Lopez-Sendon et al. 2013).  
The prevalence of PD was considerably lower after excluding the antipsychotic medication users (Figure 
5). The difference in the prevalence between antipsychotic medication users and non-users was greatest 
during the time period between the end of the 1970’s and 1995. It could be speculated that the reduced 
difference after 1995 is because the use of classical neuroleptics has been replaced by second- or third-
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generation antipsychotics (see Rimon and Leinonen 2002), which have a lower risk of inducing secondary 
parkinsonism (see Lopez-Sendon et al. 2013).  
In this study, any further reference to the PD cases during the follow-up refers to a patient group from 
which cases with the medication reimbursement right for psychotic disorders have been excluded. 
The prevalence of PD increased during the 1970’s (Figure 6), though presumably this is not solely due to 
actual rise in prevalence of the disease, but also due to changes in the practices of clinical diagnosis of PD, 
leading to improved diagnostic accuracy of the disease. However, improvements in the medical treatment 
of PD, especially the introduction of L-dopa, have also had an effect on the prevalence rates, by altering 
the clinical course and increasing the life-expectancy of these patients (see further discussion in chapter 
6.4.3). Furthermore, the prevalence was higher in men than in women (Figures 7 and 8). 
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4.3.2 Baseline exclusion criteria of prevalent PD for the cohort design 
Follow-up information for the PD cases is based on the register information, as defined above (chapter 
4.3.1). However, the baseline exclusion of prevalent PD cases was made by using both register 
information and survey data. Exclusion criteria at the baseline of the study cohorts are described in Table 
17. 
These exclusions were made to ensure the removal of all potential prevalent PD cases, since the non-
motor symptoms of PD could, in some cases, include depression, mood disorders, and other psychiatric 
symptoms, as well as sleep disorders and cognitive impairment (see Kalia and Lang 2015a). Furthermore, 
we wanted to exclude drug-induced secondary parkinsonism potentially resulting from use of neuroleptic 
drugs. Thus, subjects with the reimbursement right codes 112 and 113 were also excluded. 
Table 17. Baseline exclusion criteria for our study cohorts. 
Finnish Mobile Clinic Health 
Examination Survey 
Finnish Mobile Clinic Follow-up 
Survey 
Mini-Finland Health Survey 
i) subjects who had PD based on 
reimbursement right code110 within 
the SII’s register, in addition to 
reimbursement right codes 112 
(difficult psychosis and other difficult 
mental illnesses) and/or 113 
(behavioral problems of the mentally 
retarded) 
 
ii) subjects who reported the use of 
parkinsonian medication or 
antipsychotic medication (according 
to Remedia Fennica 1975)  
 
iii) subjects who, at baseline 
questionnaire, reported suffering from 
mental illnesses or nervous disease 
at the time of baseline or before 
i) same for all surveys 
 
ii) further extended to those reporting 
antidepressive/psycho-stimulating 
medication (according to Remedia 
Fennica 1975)  
 
iii) subjects who, at baseline 
questionnaire, reported being 
submitted to institutional care due to 
psychotic disorders at the time of 
baseline or before  
i) same for all surveys 
 
ii) same as in the Finnish Mobile 
Clinic Follow-up Survey 
 
iii) same as in the Finnish Mobile 
Clinic Follow-up Survey 
 
 
4.3.3 Evaluation of diagnostic accuracy 
A sample of the certificates (n=126) for PD drug reimbursement were re-evaluated retrospectively against 
selected hospital records by our study neurologist, Jukka Lyytinen. The evaluation was made according to 
the National Institute of Neurological Disorders and Stroke’s diagnostic criteria for PD (see Gelb et al. 
1999). 
Patient files were reviewed, paying special attention to evidence on factors that might contribute to the 
manifestations of parkinsonism (e.g. head trauma, infections of the central nervous system, 
cerebrovascular insults, psychiatric co-morbidity, or signs of other neurodegenerative diseases). Three 
categories were used to describe the clinical evidence supporting or refuting the presence of idiopathic 
PD. Probable meant that there was major evidence in support of idiopathic PD. Possible meant that there 
was some evidence in support of idiopathic PD, but the documentation, for example, was inadequate in 
describing the diagnostic criteria. Unlikely meant that there was enough evidence to refute idiopathic PD, 
for example the presence of one or more features that were considered as exclusion criteria.  
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Results of the re-evaluation of PD case records yielded 73% of patients classified as probable idiopathic 
PD, 7% as possible idiopathic PD, and 20% as unlikely to have idiopathic PD. Those classified as unlikely to 
have idiopathic PD had, for example, used dopamine antagonists in a time frame compatible with drug-
induced parkinsonism, or had clinical “red flags” of atypical parkinsonism, such as pyramidal tract (motor 
paresis, hyperreflexia, positive Babinski sign), cerebellar (ataxia, nystagmus) or early prominent bulbar 
(dysphagia, gaze paresis) signs, or marked cognitive/postural/gait impairment at the time of diagnosis.  
In conclusion, 80% of the originally identified PD cases in the register met the criteria [Jukka Lyytinen, 
personal communication, 2015, and Weisskopf et al. (2010)], which is consistent with other estimates of 
the percentage of people clinically diagnosed with PD in the general population that meet strict PD criteria 
(Schrag et al. 2002). Neuropathologic data to confirm the diagnosis as definite was not available in any of 
the cases.   
4.3.4 Number of PD cases and length of follow-up in the sub-studies 
An individual’s follow-up time was defined as the number of days from the baseline examination to the 
date of PD occurrence, death, or withdrawal (i.e. end of follow-up), whichever came first. Table 18 shows 
the length of the follow-up periods and number of subjects identified as PD cases during this period for 
Studies I–IV. 
Table 18. The length of follow-up and number of subjects in Studies I–IV. 
Study Baseline, year End of follow-up, 
date 
Maximal (and mean) 
follow-up time, years 
No. at risk  No. of PD cases 
I 1966–1972 31.12.2007 42 (19.4) 4,524 85 
II 1973–1976 31.12.1994 22 (15.3) 6,715 101 
III 1973–1976 31.12.1994 22 (15.3) 6,710 101 
IV 1978–1980 31.12.2007 30 (22.6) 6,641 89 
 
4.4 Statistical methods 
Cox’s proportional hazards model (Cox 1972) was used to estimate the strength of association between 
exposure variables (independent variable) (Table 19) and PD incidence (dependent variable), and the 
results were presented as relative risks with 95% confidence intervals. The significance of the associations 
was tested using the likelihood ratio test. Test for trend was performed by including continuous variables 
in the models. 
Table 19. Classification of the exposure variables in Studies I–IV. 
 Exposure variables  
Study I Tertiles of the consumption of individual food groups (g/d); Quartiles of the mAHEI scores 
Study II BMI (kg/m2) = <23, 23–24.9, 25–27.4, 27.5–29.9, ≥30; Leisure-time physical activity = none, light, 
heavy; Smoking status = never, past, current; Alcohol consumption as ethanol (g/d) = 0, <5, ≥5  
Study III Coffee consumption (cups/d) = 0, 1–3, 4–9, ≥10 
Study IV BMI (kg/m2) = <25, ≥25; Blood pressure = normal, elevated (SBP ≥130 mmHg or DBP ≥85 mmHg or 
antihypertensive drug treatment); Serum triglycerides (mmol/L) = <1.7, ≥1.7; Serum HDL cholesterol 
(mmol/L) = low (<1.3 mmol/L in women and <1.0 mmol/L in men), high (≥1.3 mmol/L in women and ≥1.0 
mmol/L in men); Fasting plasma glucose (mmol/L) = <5.6, ≥5.6 
 
The association between potential confounding factors and exposure variables, and confounding factors 
and PD, were studied using the general linear model. Statistical significance was tested with the F-test.  
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Confounding factors were selected from the literature, or identified by studying the background variables 
one by one; P-value <0.5 was the inclusion criteria for potential confounders. Potential confounding 
factors were adjusted for in the different multivariate models as described in the original articles (Studies 
I–IV) and in Table 20 on analyses strategy. 
Potential effect-modifying factors were entered in the model as multiplicative interaction terms. In Study 
I, there were differences between men and women in the associations between diet and PD. The P for 
interaction was 0.08 when examining the association between mAHEI and PD. Thus, most of the analyses 
were stratified by sex in Study I.  
Some of the potential effect-modifying factors included in the analyses were selected from the literature 
(e.g., sex, smoking, and BMI); some of them were exploratory in nature and were included without a 
predefined hypothesis (e.g., education, physical activity, and blood pressure). However, the number of PD 
cases proved to be too small for most of the interaction analyses, so we were able to report only a small 
part of these results.  
In all studies, additional analyses excluding the first few years of follow-up were performed to examine 
the effect of the preclinical disease phase. Studies I and III included analyses with exclusion of the first 5 
years of follow-up, which is commonly used as the exclusion time period when studying chronic diseases 
in prospective settings. However, we later decided to use a longer exclusion period, as PD could already 
begin decades before the onset of motor symptoms and diagnosis. Thus, in Studies II and IV, the effect of 
the preclinical disease phase was studied in more detail with analyses excluding the first 10 or 15 years of 
follow-up. For the purposes of this thesis, analyses excluding the first 10 or 15 years of the follow-up were 
also performed for Studies I and III, to complement those results. Furthermore, part of the published 
results was re-analyzed to present similar adjustments across the different studies (e.g.  Studies II and III). 
In addition, the short-term and long-term repeatability of the mAHEI was examined utilizing the intraclass 
correlation coefficient (Winer 1971), with mAHEI being measured as a continuous variable. Furthermore, 
the short-term repeatability of physical activity was examined with Kappa coefficients (Fleiss 1973), as 
physical activity was a categorized variable. 
All analyses were carried out using SAS software, version 9 (SAS Institute Inc., Cary, NC, USA). 
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4.5 Description of the baseline characteristics of the data 
Table 21 briefly describes selected age- and sex-adjusted baseline characteristics of the FMC, FMCF and 
the Mini-Finland Health Survey. Factors that were comparable between the surveys were chosen.  
The associations between baseline characteristics and PD incidence, and between baseline characteristics 
and exposure factors, were studied to identify potential confounding factors and are described in detail in 
the original articles (Studies I–IV).  
In the FMC (Study I), 13.5% of PD cases were smokers, while 31.5% of subjects who were free from PD 
smoked (P<0.001). PD was not notably associated with any other background variable in the FMC. In the 
FMCF (Studies II and III), subjects who developed PD during the follow-up were older, were more often 
non-smokers, and consumed less coffee than those without PD (P<0.05). In the Mini-Finland Health 
Survey (Study IV), those who subsequently developed PD were older, more often non-smokers, had lower 
serum vitamin D, serum triglyceride, and fasting plasma glucose concentrations, and were less likely to 
have metabolic syndrome than subjects who were free of the disease (P<0.04).  
Furthermore, several background variables were associated with the diet quality scores in the FMC (Study 
I). Subjects who were in the highest quartile of the mAHEI were typically younger and married, and they 
had a higher BMI and serum total cholesterol level than subjects in the lowest quartile (P<0.05). They 
were also less likely to live in rural areas and to smoke, and more likely to take part in leisure-time physical 
activities then subjects in the lowest quartile of the mAHEI (P<0.05). 
In the FMCF (Studies II and III), BMI was associated with most of the background variables (P<0.01), but 
not with coffee or alcohol consumption. Leisure-time physical activity, in turn, was associated with all of 
the other background variables (P<0.01), except alcohol consumption. Men smoked and took part in 
heavy leisure-time physical activities more than women (P<0.001). Furthermore, smoking was associated 
with all of the background variables examined (P<0.002), except community density. Alcohol consumption 
was also associated with all of the background variables (P<0.01), but not with BMI. Subjects who did not 
drink alcohol were older and more often women (P<0.001). Coffee consumption was associated with all of 
the background variables (P<0.04), except BMI. 
In the Mini-Finland Health Survey (Study IV), the mean values and percentages for individual 
characteristics varied by categories of metabolic syndrome and its components. Subjects who had 
metabolic syndrome were more likely to be older, men, less educated, to practice less leisure-time 
physical activity, and to have a lower concentration of serum vitamin D. Furthermore, subjects who had a 
serum total cholesterol concentration above 5.0 mmol/L were more likely to be older, drink more coffee, 
and have a higher serum vitamin D concentration. 
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5 Results  
5.1 Food consumption, quality of diet, and the risk of PD (Study I) 
Most of the individual food groups or items examined had no statistically significant association with the 
risk of PD in model 3, in men or women (Figures 9 and 10). However, in men, the risk of PD was 
statistically significantly increased when the intake of fruits and berries was compared between the 
highest and lowest tertiles (RR 3.67, 95% CI 1.30–10.36, P for trend 0.60, model 3). The increased PD risk 
was also observed when the intake of fresh fruits was compared between the highest and lowest tertiles 
(RR 2.41, 95% CI 1.01–5.77, P for trend 0.48, model 3). However, after exclusion of the first 10 years of 
follow-up, these associations were no longer statistically significant (the corresponding RR being 2.71, 95% 
CI 0.93–8.00, P for trend 0.83 for the consumption of fruits and berries, and 1.63, 95% CI 0.64–4.10, P for 
trend 0.61 for fresh fruits) (Sääksjärvi et al. unpublished results). 
Women in the highest tertile for the consumption of milk had a statistically significantly higher risk of PD 
compared with women in the lowest tertile (RR 3.31, 95% CI 1.10–9.93, P for trend 0.09, model 3). 
Furthermore, there was a statistically significant inverse trend for berries (highest v. lowest tertile, RR 
0.54, 95% CI 0.23–1.27, P for trend 0.02, model 3) among women. In addition, a statistically significant 
inverse association was observed between the consumption of processed meat and sausages and the 
incidence of PD in women, with the RR of developing the disease between the highest and lowest tertiles 
being 0.39 (95% CI 0.16–0.95, P for trend.0.008, model 3). The exclusion of the first 10 years of follow-up 
did not notably change the results for the consumption of milk (RR 3.41, 95% CI 1.13–10.29, P for trend 
0.06), or berries (corresponding RR being 0.58, 95% CI 0.25–1.39, P for trend 0.04), or processed meat and 
sausages (RR 0.45, 95% CI 0.18–1.10, P for trend 0.01) (Sääksjärvi et al. unpublished results).  
Diet quality, defined by the mAHEI, did not predict PD incidence (Table 22). The RR between the highest 
and lowest quartiles of the mAHEI was 1.83 (95% CI 0.65–5.18, P for trend 0.11) in men and 0.97 (95% CI 
0.38–2.48, P for trend 0.91) in model 3. 
Excluding the first 5 years of follow-up did not notably alter the results concerning the individual food 
groups or the diet quality index (data not shown). For the mAHEI, further analyses excluding the first 10 
years of follow-up did not substantially change the results either, the corresponding RRs being 1.10 for 
men (95% CI 0.42–2.88, P for trend 0.16) and 1.00 for women (95% CI 0.38–2.63, P for trend 0.92) 
(Sääksjärvi et al. unpublished results). The exclusion of the first 10 years of follow-up decreased the 
number of PD cases from 40 to 38 in women, and from 45 to 38 in men. 
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Table 22. Multivariate-adjusted relative risks and their 95% confidence intervals of Parkinson’s disease by quartiles of 
the modified Alternate Healthy Eating Index, the Finnish Mobile Clinic Health Examination Survey, 1966–1972. 
  Diet quality index, quartilesa  
 Q1 Q2 Q3 Q4 P for trend 
Men      
Age-adjusted model     0.18 
    n/N 8/689 12/592 15/583 10/524  
    RR  1.00 1.68 2.06 1.46  
    95% CI - 0.69–4.12 0.87–4.87 0.58–3.71  
model 2b     0.13 
    n/N 8/684 12/584 15/576 10/519  
    RR  1.00 1.85 2.53 1.73  
    95% CI - 0.71–4.79 0.98–6.52 0.61–4.88  
model 3c     0.11 
    n/N 8/684 12/584 15/576 10/519  
    RR  1.00 2.00 2.52 1.83  
    95% CI - 0.77–5.22 0.97–6.55 0.65–5.18  
Women      
Age-adjusted model     0.95 
    n/N 10/572 14/565 6/522 10/477  
    RR  1.00 1.36 0.58 1.03  
    95% CI - 0.60–3.08 0.21–1.61 0.42–2.48  
model 2b      
    n/N 10/569 14/559 6/519 10/474 0.85 
    RR  1.00 1.32 0.57 1.01  
    95% CI - 0.57–3.09 0.20–1.63 0.40–2.54  
model 3c     0.91 
    n/N 10/563 14/553 6/516 10/471  
    RR  1.00 1.27 0.54 0.97  
    95% CI - 0.54–2.99 0.19–1.55 0.38–2.48  
Abbreviations: n, Parkinson’s disease cases; N, total population; RR, relative risk; CI, confidence interval 
a cut-off points of quartiles are, for men, 7–18, 19–21, 22–24, 25–34; and for women, 8–18, 19–21, 22–24, 25–34 
b adjusted for age, sex, marital status, community density, geographical area, smoking, BMI, leisure-time physical 
activity, energy 
c adjusted for all of the factors in model 2 plus hypertension, serum cholesterol, diabetes mellitus (in addition, in 
women: parity) 
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5.2 Lifestyle factors and the risk of PD (Studies II and III) 
Higher leisure-time physical activity was statistically significantly associated with a lower risk of PD (RR 
0.27, 95% CI 0.08–0.90, for subjects having heavy physical activity compared to those who had none, P for 
heterogeneity 0.04) in model 2 (Table 23). However, the association between leisure-time physical activity 
and PD risk attenuated when analyses excluding the first 10 or 15 years of follow-up were performed.  
The interaction analyses revealed an inverse association between physical activity and PD risk that was 
stronger in a few subgroups. A statistically significant inverse association with PD risk was seen in women 
(RR 0.49, 95% CI 0.28–0.85) (P for interaction 0.06), in subjects with a BMI ≥27.5 (RR 0.55, 95% CI 0.31–
0.99) (P for interaction 0.008), and in subjects drinking <3 cups of coffee per day (RR 0.42, 95% CI 0.20–
0.88) (P for interaction 0.12), when comparing those who engaged in any leisure-time physical activity to 
those who engaged in none. Possible effect modification of smoking could not be examined due to the 
small number of subjects. 
We found a statistically significant inverse association between smoking and PD (Table 23). The RR for 
current smokers compared to those who had never smoked was 0.23 (95% CI 0.08–0.67, P for 
heterogeneity 0.001) in model 2. The risk of PD was not reduced, however, for past smokers when 
compared to those who had never smoked. Furthermore, the statistically significant inverse association 
between smoking and PD risk persisted when the first 10 years of follow-up were excluded from the 
analyses. After the first 15 years of follow-up were excluded, however, while the point estimate did not 
change, the association was no longer statistically significant (RR 0.19, 95% CI 0.02–1.60, current smokers 
v. never smokers, P for heterogeneity 0.09). Interaction analyses could not be performed due to the small 
number of PD cases. 
Furthermore, we found that subjects who consumed <5g of alcohol per day had a higher risk of PD 
compared to non-drinkers (RR 1.81, 95% CI 1.12–2.93, P for trend 0.30, P for heterogeneity 0.02) in model 
2 (Table 23). This elevated risk of PD persisted after the exclusion of the first 10 (RR 1.94, 95% CI 1.09–
3.47, P for heterogeneity 0.07) and 15 years of follow-up (RR 2.66, 95% CI 1.07–6.62, P for heterogeneity 
0.11), although no trend appeared (P for trend 0.37 after the exclusion of 10 years and 0.89 after 15 
years).  
However, analyses restricted to alcohol consumers revealed that subjects who consumed ≥5g of alcohol 
per day had a lower risk of PD compared to those who consumed <5g of alcohol per day, the RR being 
0.52 (95% CI 0.26–1.06, P for trend 0.11), although the association was not statistically significant (model 
2). This suggestive inverse association was slightly attenuated after excluding the first 10 years of follow-
up (P for trend 0.11) and disappeared after excluding the first 15 years (P for trend 0.53).  
Regarding the association between alcohol consumption and PD risk, no interactions were observed. 
However, the effect modification by sex could not be examined due to the small number of PD cases. 
Finally, subjects who consumed at least 10 cups of coffee per day had a lower PD risk compared to non-
drinkers (RR 0.24, 95% CI 0.06–0.92, P for trend 0.11) in model 2. Further interaction analyses revealed 
that the statistically significant inverse association was present among overweight subjects (that is, BMI 
≥25 kg/m2) (P for interaction 0.04), and among subjects who had serum cholesterol levels under the 
median (<7.24 mmol/l) (P for interaction 0.03)(see Study III, Table 4). Furthermore, although the 
interaction was not statistically significant for any other variable examined as an effect-modifying factor, 
the inverse association was present for those who were younger (aged 50–69 years), had lower education, 
had no leisure-time physical activity, and had no hypertension. 
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The inverse association between coffee consumption and PD risk attenuated after exclusion of the first 10 
and 15 years of follow-up (P for trend 0.21 and 0.30, respectively) (Sääksjärvi et al. unpublished results). 
However, when subjects drinking at least four cups of coffee per day were compared to subjects drinking 
0–3 cups per day, the statistically significant inverse association persisted (RR 0.59, 95% CI 0.35–0.99, P for 
heterogeneity 0.06) even after excluding the first 10 years of follow-up, but not after exclusion of 15 years 
(RR 0.68, 95% CI 0.29–1.56, P for heterogeneity 0.37) (Sääksjärvi et al. unpublished results). 
In the FMCF, regarding the analyses on leisure-time physical activity, smoking, alcohol consumption, and 
coffee consumption, the number of PD cases was 66 after excluding the first 10 years of follow-up, and 28 
after 15 years. 
 
Table 23. Multivariate-adjusted relative risks and their 95% confidence intervals of Parkinson’s disease by leisure-time 
physical activity, smoking, alcohol and coffee consumption, the Finnish Mobile Clinic Follow-up Survey, 1973–1976. 
  Complete modela, b  First 10 years of follow-up 
excludedb 
 n/N RR 95% CI Pc n/N RR 95% CI Pc 
Leisure-time physical 
activity 
   004    0.06 
none 32/1,854 1.00 -  23/1,366 1.00 -  
light 62/4,190 073 047–113  41/3,280 0.65 0.38–1.10  
heavy, ≥ 3 h/week 3/472 027 008–090  2/401 0.25 0.06–1.09  
         
Smoking status    0001    0.004 
never 66/3,820 1.00 -  45/3,130 1.00 -  
past smoker 27/1,291 117 066–209  19/963 1.42 0.70–2.88  
current smoker 4/1,405 023 008–067  2/954 0.20 0.04–0.88  
         
Alcohol consumption 
(g/d)d 
   002    0.07 
0 50/3,515 1.00 -  33/2,757 1.00 -  
<5 35/1,747 181 112–293  24/1,373 1.94 1.09–3.47  
≥5 12/1,254 091 044–189  9/917 1.12 0.47–2.69  
         
Coffee consumption 
(cups/d) 
   0.11e    0.21e 
0 8/320 1.00 -  4/243 1.00 -  
1–3 21/983 0.86 0.38–1.96  17/728 1.33 0.44–4.00  
4–9 65/4,557 0.60 0.28–1.26  42/3,555 0.76 0.27–2.14  
≥10 3/656 0.24 0.06–0.92  3/521 0.48 0.11–2.19  
Abbreviations: n, Parkinson’s disease cases; N, total population; RR, relative risk; CI, confidence intervals; h, hour; g, 
gram; d, day.  
a Total follow-up 
b Adjusted for age, sex, education, community density, occupation, leisure-time physical activity, smoking, alcohol 
consumption, coffee consumption, and body mass index 
c P for heterogeneity, unless otherwise indicated 
d Alcohol consumption as ethanol g/d 
e P for trend 
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5.3 Obesity, metabolic health, and the risk of PD (Studies II and IV) 
Body mass index was studied in both the FMCF (Study II) and the Mini-Finland Health Survey (Study IV). In 
both studies, no statistically significant association was found between BMI and PD risk in the crude or 
multivariate models (Table 24). However, a positive association between BMI and PD risk appeared in the 
FMCF after excluding the first 15 years of follow-up (P for trend 0.02 in model 2).  
In the Mini-Finland Health Survey, after excluding the first 10 years of follow-up, it seemed that subjects 
with a BMI over 25 had an increased PD risk compared to those with normal weight (RR 1.75, 95% CI 1.00–
3.07). After further applying a shorter, 17-years, follow-up time, a dose-response relationship was 
revealed (P for trend 0.06 in model 3).  
In Study II, no effect modification by age, sex, smoking, alcohol consumption, or coffee consumption could 
be found before exclusion of the first 15 years of follow-up. Additionally, after the exclusion, the number 
of PD cases was too small for interaction analyses. 
The results for other variables on metabolic health are shown in Table 24, and were studied only in the 
Mini-Finland Health Survey, where data was available.  
The relative risk of PD in subjects with metabolic syndrome compared to those without was 0.50 (95% CI 
0.30–0.83) in model 2 (Table 24). Exclusion of the first 10 years of follow-up did not change this result 
(Table 24) (unpublished result Sääksjärvi et al.). Furthermore, applying a shorter follow-up time did not 
change the result either (data not shown). However, further analyses revealed that the association 
between metabolic syndrome and PD incidence was not statistically significant if serum triglycerides were 
removed from the definition of metabolic syndrome and included as an adjusting factor in the model 
(data not shown).  
When examining the individual components of metabolic syndrome, a statistically significantly reduced 
risk of PD was observed when subjects with elevated serum triglyceride concentration were compared to 
those with normal concentration (RR 0.52, 95% CI 0.30–0.89, P for trend 0.02, model 2) (Table 24). A 
statistically significant inverse association between serum triglyceride concentration and PD incidence 
remained after further adjusting for other components of metabolic syndrome (P for trend 0.02), and 
strengthened after excluding the first 10 years of follow-up (P for trend 0.01) (Table 24). Applying the 
shorter follow-up time did not change the results (data not shown).  
A statistically significantly reduced risk of PD was also seen when subjects with elevated fasting plasma 
glucose concentration were compared to those with normal concentration (RR 0.56, 95% CI 0.32–0.98, P 
for trend 0.05, model 2) (Table 24). The association weakened slightly after further adjusting for other 
components of metabolic syndrome (P for trend 0.08). Furthermore, after excluding the first 10 years of 
follow-up, the trend was no longer statistically significant (P for trend 0.19 in model 3), however, elevated 
glucose concentration still predicted a reduced PD risk (RR 0.47, 95% CI 0.23–0.97). Finally, applying a 
shorter follow-up time did not change the results (data not shown). 
The risk of PD was not statistically significantly associated with blood pressure, serum HDL cholesterol, or 
serum total cholesterol concentration in the crude or multivariate models. Neither further adjustments 
nor exclusion of the first 10 years of follow-up changed the results. Furthermore, applying the shorter 
follow-up time did not change the results (data not shown).  
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Table 24. Multivariate-adjusted relative risks and their 95% confidence intervals of Parkinson’s disease between 
categories of metabolic factors.  
Variable n/N RR 95% CI P for 
trend 
n/N RR 95% CI P for 
trend 
Finnish Mobile Clinic 
Follow-up Survey, 
1973–1976 
Total follow-upa  First 15 years of follow-up excludeda 
BMI (kg/m2)    0.33    0.02 
   <25 29/2,329 1.00 -  6/1,419 1.00 -  
   ≥25 68/4,187 1.10 0.71–1.72  22/2,679 1.77 0.71–4.42  
      
Mini-Finland Health 
Survey, 1978–1980 
Total follow-upb  First 10 years of follow-up excludedc 
BMI (kg/m2)    0.98    0.22 
   <25 29/2,980 1.00 -  19/2,623 1.00 -  
   ≥25 57/3,508 1.18 0.75–1.87  44/3,010 1.75 1.00–3.07  
Blood pressured    -    - 
   Normal 11/1,382 1.00 -  11/1,324 1.00 -  
   Elevated 75/5,108 1.07 0.55–2.07  52/4,309 0.92 0.46–1.82  
Serum triglycerides 
(mmol/L) 
   0.02    0.01 
   <1.7 69/4,670 1.00 -  53/4,188 1.00 -  
   ≥1.7 17/1,821 0.52 0.30–0.89  10/1,445 0.43 0.21–0.86  
Serum HDL cholesterol 
(mmol/L)e 
   0.97    0.10 
   High    83/6,085 1.00 -  62/5,331 1.00 -  
   Low 3/403 0.56 0.17–1.79  1/302 0.39 0.05–2.90  
Fasting plasma glucose 
(mmol/L) 
   0.05    0.19 
   <5.6  70/4,863 1.00 -  54/4,373 1.00 -  
   >5.6 16/1,628 0.56 0.32–0.98  9/1,260 0.47 0.23–0.97  
Metabolic syndromef    -    - 
   Negative 66/4,497 1.00 -  52/4,054 1.00 - b 
   Positive 20/1,994 0.50 0.30–0.83  11/1,583 0.37 0.19–0.73 b 
Serum total cholesterol 
(mmol/L) 
   0.50    0.67 
   <5 4/373 1.00 -  4/334 1.00 -  
   >5 82/6,118 0.85 0.31–2.33  59/5,299 0.68 0.24–1.92  
Abbreviations: n, Parkinson’s disease cases; N, total population; RR, relative risk; CI, confidence intervals; BMI, body 
mass index; HDL, high density lipoprotein 
a Adjusted for age, sex, education, community density, occupation, leisure-time physical activity, smoking, alcohol 
consumption, and coffee consumption 
b Adjusted for age, sex, education, smoking, alcohol consumption, leisure-time physical activity, serum vitamin D, and 
coffee consumption (model indicated with gray color in the table) 
c Adjustments as in b plus additional adjustments for BMI, blood pressure, serum triglycerides, serum HDL cholesterol, 
and fasting plasma glucose, unless otherwise indicated 
d Elevated: systolic blood pressure (SBP) ≥130 mmHg or diastolic blood pressure (DBP) ≥85 mmHg or antihypertensive 
drug treatment. Normal: Not elevated 
e High: ≥1.3 mmol/L in women and ≥1.0 mmol/L in men. Low: <1.3 mmol/L in women and <1.0 mmol/L in men 
f Defined as presence of any 3 or more of the following 5 risk factors: BMI ≥25 kg/m2, SBP ≥130 mmHg or DBP ≥85 
mmHg or antihypertensive drug treatment, serum triglycerides ≥1.7 mmol/L, serum HDL cholesterol <1.3 mmol/L in 
women and <1.0 mmol/L in men, and fasting plasma glucose ≥5.6 mmol/L 
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6 Discussion 
6.1 Food consumption, overall quality of diet, and the risk of PD (Study I) 
In general, most of the individual food groups or items examined did not predict the incidence of PD in the 
current study. A few food items, however, were found to be associated with the risk of disease.  
Milk and dairy products 
In this study, a positive association between milk consumption and PD incidence was found in women.  
Women who consumed more than 3.5 cups (6.1 dl) of milk per day, compared to those who consumed 
less than 2 cups (3.7 dl), had 3.3 times higher risk of PD. Four other cohort studies have also found a 
positive association between milk consumption and PD risk  (Kyrozis et al. 2013; Chen et al. 2007; Park et 
al. 2005; Chen et al. 2002). However, one of the studies found a positive association in men only, not 
women (Chen et al. 2002), whereas another study included only men (Park et al. 2005). Nevertheless, two 
of the studies, from the United States and Greece (Kyrozis et al. 2013; Chen et al. 2007), found a higher PD 
risk among milk consumers in both men and women. The lack of association among men in this study 
could be attributed to the different intake levels of milk for men and women. Although men consumed 
more milk than women, they had a rather narrow range of intake (Appendix table 2). Thus, it could be that 
the differences between the intakes were not large enough to observe any association in men. 
It is not clear whether nutrients or other constituents in milk would mediate this positive association 
between PD risk and milk consumption. However, a large cohort study of men and women from the 
United States concluded that it is unlikely to be due to calcium, vitamin D, or fat, as they did not have a 
positive association with PD risk when derived from sources other than dairy products (Chen et al. 2007). 
Regarding milk fat, this suggestion is supported in the present study, as high intake of reduced-fat dairy 
was also associated with increased PD risk (RR 2.69, 95% CI 1.08–6.66, comparing upper median class 
against lower median class). One possible explanation is that milk protein intake decreases the circulating 
levels of uric acid (Garrel et al. 1991), thus contributing to higher PD risk, as uric acid has been inversely 
associated with PD risk (Weisskopf et al. 2007; de Lau et al. 2005b; Davis et al. 1996). Another possibility is 
that dairy products are contaminated with neurotoxins due to their exposure to pesticides during farming, 
which may increase the risk of PD (see Priyadarshi et al. 2000).  
It remains unclear why only milk consumption had a positive association with PD in this study but not 
consumption of other dairy products. However, our finding is in line with two previous cohort studies 
observing the positive association only for milk consumption and not for other types of dairy products 
(Kyrozis et al. 2013; Chen et al. 2007). 
Meat, meat products, poultry, and fish 
An inverse association between the intake of processed meat and sausages and PD incidence was 
observed for women but not for men in this study. Women who consumed more than 35 g/d of processed 
meat and sausages had a 41% lower risk of PD than women consuming less than 13 g/d. However, no 
associations were observed for consumption of total meat, red meat, poultry, or fish in either men or 
women.   
The number of previous cohort studies on diet and PD risk is sparse, and their results have been 
inconsistent regarding the association between PD risk and the consumption of different meats, or the 
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intake of protein or iron, as described in the review by Ishihara and Brayne (2005). Only three cohort 
studies have examined the association between meat consumption and PD risk. In line with our findings, a 
nested case-control study from China found an inverse association between total meat consumption and 
PD risk. This study, however, was conducted in a region known for persistent dietary nutritional 
deficiencies. As no adjustments for caloric intake were applied, the result may reflect more the general 
nutritional status than meat consumption alone.   
A large cohort study conducted in the United States found no associations for the consumption of total 
meat, red meat, poultry, or fish, in either men or women (Chen et al. 2002). Similarly, the EPIC-Greece 
cohort study did not find an association between PD risk and the consumption of meat and meat 
products, or fish (Kyrozis et al. 2013), but they reported results for men and women together.  
The biological mechanism behind the inverse association between meat consumption and PD risk remains 
unclear. However, meat is a source of niacin, a vitamin reported to be inversely associated with PD and 
hypothesized to act via mechanisms related to nicotinamide metabolism (Hellenbrand et al. 1996). 
Another hypothesis regards the inverse association between uric acid and PD risk, as meat products are a 
rich source of animal proteins, which, in turn, contributes to higher uric acid levels (see Chaudhary et al. 
2013). However, despite these hypotheses, it is unconvincing that only the consumption of processed 
meat and sausages would protect from PD and not red meat. Thus, the possibility of a chance finding must 
be considered. 
Fruits, berries, and vegetables 
Somewhat contrasting results between women and men were found for the consumption of fruit and 
berries. An inverse association between the consumption of berries and the risk of PD was found in 
women, but not in men. On the other hand, a high consumption of fruits and berries, and fresh fruits, was 
associated with an increased PD risk in men, a finding not seen in women. Furthermore, the consumption 
of vegetables was not associated with the risk of developing the disease in either women or men.  
The present results do not support the prevailing hypothesis that the consumption of fruits and 
vegetables containing antioxidative substances would protect against the presumed oxidative stress in the 
pathogenesis of PD. The evidence from previous epidemiological studies is also inconclusive, showing 
mainly no association between the consumption of fruits and vegetables, or intakes of antioxidant 
vitamins, and PD risk (see Gaenslen et al. 2008; see Ishihara and Brayne 2005). One alternative 
explanation is that the use of pesticides in farming may increase the risk of PD, thus masking the potential 
benefit of consuming fruits and vegetables. Furthermore, a reason why berries but not fruits were 
inversely associated with PD incidence (in women) could be that the use of pesticides does not have an 
effect on berries gathered from nature, a typical source of berries in Finland. However, the pesticide 
hypothesis is also rather questionable, as a nested case–control study based on this same data (FMC) did 
not find strong evidence for an increased risk of PD due to pesticide exposure (Weisskopf et al. 2010). 
Furthermore, the intake levels of fruits and berries were rather low in this study (Appendix table 2). It is 
possible that the inverse association between berry consumption and PD risk observed here could 
disappear at higher intake levels, reflecting the optimal intake level of this food item. However, there are 
no previous prospective studies examining the consumption of berries and PD risk to compare with.  
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Multiple comparisons 
It should be noted that our study on individual food groups and items and the risk of PD included multiple 
comparisons, which increase the likelihood of a chance finding. The study included 52 significance tests; 
thus, after applying the Bonferroni correction at a significance level of 5%, we should consider each 
individual hypothesis to be statistically significant if the P-value is <0.001. After this correction, none of 
the food items studied was statistically significantly associated with PD risk. However, it could be argued 
that the positive association between the consumption of milk and PD risk is not just a chance finding, as 
similar results have been found in several previous cohort studies (Kyrozis et al. 2013; Chen et al. 2007; 
Park et al. 2005; Chen et al. 2002), although no plausible biological mechanism exists. Regarding the other 
findings on individual food items (i.e. processed meat and sausages, fruits and berries, berries, and fresh 
fruits), the possibility of a chance finding due to multiple comparisons is a concern and must be 
considered as a limitation to this study. 
The diet quality index 
The mAHEI, an index measuring adherence to a recommended diet, did not predict PD incidence in the 
present study. This is in contrast with the only other previous cohort study on diet quality and PD risk, 
which reported a reduction in PD risk with increasing diet quality as defined by the AHEI among the 
participants of the Nurses' Health Study and the Health Professionals Follow-up Study (Gao et al. 2007). 
However, in the present study, the lack of association between mAHEI and PD risk is in agreement with 
the fact that PD was also not associated with the components that make up the mAHEI, or with most of 
the food items examined here. The lack of association in our study could be due to a smaller study size, or 
due to different intake levels of food items. Additionally, the AHEI might be better suited to the diet 
common in the United States rather than Finland.  
On the other hand, it is possible that the finding by Gao et al. (2007) could be explained by some unknown 
confounding factor associated with adhering to dietary guidelines that was not present in our study. This 
question emerges, as previous observations from the same cohort Gao used did not find association 
between PD risk and consumption of white meat (fish and poultry), fruits, or vegetables (Chen et al. 2002), 
which are key components of the AHEI. However, previous results from that cohort showed a possible 
adverse effect of saturated fat for men (Chen et al. 2003), and a beneficial effect of beer consumption for 
both genders (Hernan et al. 2003). Saturated fat and alcohol consumption were also components of the 
AHEI, and these findings agree with the observation by Gao et al. (2007) regarding the inverse association 
of the AHEI with PD risk. 
Nevertheless, it seems that the mAHEI we used is a good tool for assessing diet quality, since it was 
inversely associated with the incidence of coronary heart disease in the present study population 
(Sääksjärvi et al. 2015). Furthermore, the dietary data collected in the FMC appears to be of good quality, 
as studies based on this dietary data have given consistent findings on the associations with several 
chronic diseases, such as coronary heart disease (Knekt et al. 1996), type 2 diabetes (Montonen et al. 
2005), and stroke (Mizrahi et al. 2009). Furthermore, the reproducibility of the dietary history method 
used has been examined, and was found to be acceptable (Järvinen et al. 1993). 
Effect modification 
In the present study, an effect modification of sex was observed. For example, for increasing diet quality 
scores men had point estimates above unity, whereas women had point estimates mostly below unity; the 
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P-value for the interaction term being 0.08. Similarly, the results for individual food groups and items 
showed point estimates in the opposite direction for men and women for several variables (see Figures 9 
and 10).  
One explanation is that a biological mechanism contributes to sex differences. For example, reproductive 
hormones have been associated with the risk of PD, as there are suggestions of a neuroprotection from 
estrogen, resulting in a higher susceptibility in men (see Bourque et al. 2009).  
Furthermore, women consumed considerably less alcohol than men, which may explain the gender 
difference if alcohol is an important confounding factor. For example, both low consumption of alcohol 
and high consumption of milk contributes to low plasma urate levels (see Schlesinger and Schlesinger 
2008; Choi and Curhan 2004), which in turn predicts an elevated risk of PD (see Wirdefeldt et al. 2011). 
Thus, among men, alcohol consumption could mask the potential positive association between milk 
consumption and PD risk. Unfortunately, information on alcohol consumption was not available in this 
study using the FMC data. However, in the FMCF, alcohol intake was inquired after, and analyses in that 
population showed that most women do not consume alcohol (median intake 0 g/d), whereas men do 
(median intake 36 g/d). Thus, alcohol consumption could explain the gender difference, at least for milk 
consumption. 
6.2 Lifestyle factors and the risk of PD (Studies II and III) 
Leisure-time physical activity 
In this study, subjects with heavy leisure-time physical activity had a lower risk of PD than those with no 
activity. This finding is in line with a meta-analysis pooling results from five other prospective studies, 
which reported an inverse association between physical activity and PD risk (Yang et al. 2015; Thacker et 
al. 2008). However, two of the studies included in the meta-analysis found the inverse association in men, 
not women (Yang et al. 2015; Chen et al. 2005), whereas one found it in women, not men (Thacker et al. 
2008). Furthermore, one found it in both genders (Xu Q et al. 2010), while one, which  included only men, 
found no association (Logroscino et al. 2006). Our study only found the association in women, not men. 
We found that the exclusion of potential underlying PD (i.e. excluding of first 10 years of follow-up time) 
attenuated the association to non-significant. Thus, the inverse association could be attributed to a 
decline in leisure-time physical activities among undiagnosed PD patients who are already suffering from 
preclinical symptoms. Therefore, the effect -modification by sex and BMI on the association between 
leisure-time physical activity and PD risk found in this study could be interpreted as indicating that women 
and overweight subjects were more likely to reduce their leisure-time physical activities during the 
preclinical disease phase. However, it should be noted that the reason for non-significant findings in 
analyses excluding the first 10 years of follow-up could be due to the small number of subjects engaging in 
heavy leisure-time physical activity (n=2). After all, the point estimate did not notably change after the 
exclusion, only the confidence intervals got wider.  
Finally, it should be noted that the short-term repeatability of the questionnaire on leisure-time physical 
activity was rather low. Furthermore, the overall physical activity of the participants could not be 
examined due to the lack of information on occupational physical activity. This is a limitation, as it could 
be speculated that those individuals engaged in heavy occupational physical activity might exercise less 
during their leisure-time.  
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The possible molecular mechanisms underlying the inverse association between physical activity and PD 
risk are poorly known. However, as discussed by Thacker et al. (2008), there are suggestions that exercise 
can induce an increase in neurotrophic factors (Cohen et al. 2003) or in plasma urate concentration 
(Anderson and Harris 2003; Green and Fraser 1988). Although uric acid levels have been inversely 
associated with PD risk in several prospective cohort studies (see Wirdefeldt et al. 2011), the mechanism 
is unknown, but possibly relates to the antioxidant capacity of uric acid. Neurotrophic factors, instead, 
may confer neuroprotection. An animal model found that forced exercise before injuring the 
dopaminergic neurons of rats resulted in an increase of glial cell-line derived neurotrophic factor protein, 
and attenuated the symptoms caused by the injury (Cohen et al. 2003). Also, an animal model of PD 
showed that physical activity resulted in the attenuation of dopamine depletion in the striatum of rats 
training on a treadmill, when compared to control animals (Poulton and Muir 2005), which, 
hypothetically, could attenuate symptoms and slow neurodegeneration. 
Smoking 
In the current study, an inverse association between smoking and the risk of PD was found, which is in line 
with the relatively consistent findings of previous studies (see Ritz et al. 2007; see Hernan et al. 2002). 
There are suggestions that this association is due to reduced sensation-seeking traits of PD patients (Evans 
et al. 2006). However, the results from this study indicated that the association persisted even after 
excluding the cases occurring during the first 10 years of follow-up. This challenges the hypothesis that 
reverse causation, for example a premorbid parkinsonian personality, would account for it.  
In contrast to some previous studies (Chen et al. 2010; see Hernan et al. 2002), past smokers did not have 
a lower risk of PD than those who had never smoked in this study. This lack of association, however, is in 
line with a recent finding that especially long-term smoking is associated with this reduction of PD risk 
(Chen et al. 2010). On the other hand, the lack of association between past smokers and PD could be 
interpreted as supporting the suggestion that smoking cessation could be an early preclinical condition 
occurring in PD (Ritz et al. 2014). 
Unfortunately, the association of duration or amount of smoking could not be examined in the present 
study, as the number of smoking PD cases was too small. For the same reason, potential effect 
modification could not be examined in different subgroups. However, a meta-analysis did not find effect 
modification by sex or education (see Ritz et al. 2007). In this study population, only a minority of smokers 
were women.  
There are plausible, but still debated, hypotheses of biological mechanisms for the potential preventative 
effects of smoking against PD occurrence, including the neuroprotective effects of nicotine, as reviewed 
by Quik et al. (2008). Nicotine may act by stimulating nicotinic acetylcholine receptors, which activates 
various intracellular transduction pathways, including calcium signaling. As a response, adaptations in 
immune responsiveness and trophic factors may occur, mediating the neuroprotection against neuronal 
injury (see Quik et al. 2012). 
This prospective study appears to lend some support to such hypotheses of a causal association. On the 
other hand, if smoking is neuroprotective, we would expect it to interact with genetic risk factors of PD, 
but a recent study documented no interactions between genes and smoking in PD (Chung et al. 2013).  
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Alcohol consumption  
The present study demonstrated that subjects with light to moderate alcohol consumption (alcohol intake 
>0 but <5 g/d) had an elevated risk of PD, compared to non-drinkers, and that this association apparently 
was not due to preclinical PD. Heavy consumption of alcohol was not associated with PD risk. 
In contrast, most previous studies have showed a significant or non-significant inverse association 
between alcohol consumption and PD risk, as concluded by two separate reviews (see Bettiol et al. 2015; 
see Wirdefeldt et al. 2011). We are not aware of any hypothesis for the association found in the present 
study other than possible confounding related to abstaining from alcohol. Accordingly, when the analyses 
were restricted to alcohol consumers, a suggestive inverse association between alcohol consumption and 
PD risk was then revealed.  
Residual confounding, possibly due to smoking or coffee consumption, may be an explanation for the 
inverse association. The good quality of the data in this study, however, does not lend support for this 
suggestion, as smoking behavior and coffee consumption were reliably measured (Sääksjärvi et al. 2010; 
Heliövaara et al. 1993).  
The exclusion of potential underlying PD did not change the result, at least not in the time span of 10 
years. Thus, our study provided evidence against the hypothesis that the reduced sensation-seeking traits 
of preclinical PD patients would account for the inverse association between addiction-related habits and 
PD risk (Evans et al. 2006). The attenuation of association to non-significant in the analyses excluding the 
first 15 years of follow-up could be a result of the small number of subjects.  
Unfortunately, subgroup analyses of potential effect-modifying factors could not be examined in this 
study due to the small number of PD cases. However, it should be noted that most of the alcohol 
consumers were men in this study population. Only one quarter of women in the study population 
consumed alcohol, which is consistent with women living in rural areas at the time of baseline (the 1960s 
and 70s). However, it cannot be ruled out that an underreporting of alcohol consumption may have 
affected results. In general, the underreporting of alcohol consumption varies by different demographic or 
consumption-based subgroups of the population, and might be more marked for young men and middle-
aged women (Livingston and Callinan 2015).  
The possible biological mechanism for the inverse association remains to be clarified. There are 
suggestions for a contrary hypothesis on positive association between alcohol consumption and PD risk, as 
alcohol may contribute to oxidative stress through production of alkaloids (see Collins 2002). 
Coffee consumption 
An inverse association between coffee consumption and the risk of PD was found in the present study. 
This finding is in line with results obtained from previous cohort studies (Ascherio et al. 2004; Ascherio et 
al. 2003; Ascherio et al. 2001; Ross et al. 2000).  
The inverse association between coffee consumption and PD risk attenuated after exclusion of the 
potential preclinical disease phase. However, the risk of PD was still reduced by 41% when subjects 
drinking at least four cups of coffee per day were compared to subjects drinking 0–3 cups per day, after 
excluding the first 10 years of follow-up. This result argues against the suggestion that a premorbid 
parkinsonian personality would account for the inverse association by resulting in reduced coffee 
consumption in future PD cases. To our knowledge, this is a first study to examine the effect of excluding 
such a long time to account for a preclinical disease phase. Previous studies have not made any exclusions 
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(Kyrozis et al. 2013; Liu et al. 2012; Ascherio et al. 2004; Ascherio et al. 2003; Ascherio et al. 2001; Ross et 
al. 2000), or have excluded only the first 2 (Palacios et al. 2012b) or 5 (Hu et al. 2007a) years of follow-up.  
In contrast to some previous studies (Ascherio et al. 2004; Ascherio et al. 2001), we did not find any 
difference in the results between men and women. However, the sex difference found in previous studies 
could be explained by an interaction with estrogen, as further analyses of those studies showed that the 
inverse association between coffee and PD risk was present only among women who did not use 
postmenopausal hormones (Ascherio et al. 2004; Ascherio et al. 2003). At the study baseline, during the 
1970s, the number of postmenopausal hormone users was very small (1.9%) and, accordingly, exclusion of 
the postmenopausal hormone users from the data did not alter the results (data not shown).  
Furthermore, the inverse association between coffee consumption and PD was present among subjects 
who were younger (aged 50–69 years), did no leisure-time physical activity, were overweight, and had a 
serum cholesterol concentration below the median (<7.24 mmol/l). The median value for serum 
cholesterol concentration at baseline would be considered high compared to current guidelines, however, 
those levels reflect the serum cholesterol concentration of the normal Finnish population in the 1970s 
(Reunanen et al. 1983). 
The explanation for the effect modification of these factors remains unclear, but the incidence of PD does 
increase with age (see Wirdefeldt et al. 2011). Thus, it could be argued that the inverse association 
between coffee drinking and PD risk was present in the younger age group because younger subjects are 
not yet affected by the disease progression and may still benefit from drinking coffee. Furthermore, 
increased physical activity has been associated with lower PD risk (see Wirdefeldt et al. 2011). Obesity 
might also be involved in the etiology of PD (Chen et al. 2004; Abbott et al. 2002), as found in Studies II 
and IV, although no interaction between BMI and coffee consumption has been found previously 
(Ascherio et al. 2004). Finally, another Finnish cohort study found that high total cholesterol is associated 
with an increased risk of PD (Hu et al. 2008), although the present study (Study IV) did not.  
Findings in the present study support the suggested hypotheses of physiological mechanisms for the 
beneficial effects of coffee consumption against PD. One of the hypotheses rests on the fact that coffee 
contains a considerable number of potential antioxidants (Yen et al. 2005) and is capable of increasing 
plasma antioxidant capacity in humans (Natella et al. 2002). Since oxidative stress is suggested as one of 
the mechanisms underlying PD pathogenesis (see Cardoso et al. 2005), coffee could have neuroprotective 
effects because of its antioxidant properties. Another hypothesis for the physiological mechanisms of 
coffee is the role of caffeine as an adenosine A2A receptor antagonist. As suggested by a review, caffeine 
may protect dopaminergic neurons from excitotoxic components by inactivating A2A receptors (see 
Schwarzschild et al. 2002).  
6.3 Obesity, metabolic health, and the risk of PD (Studies II and IV) 
Obesity   
Our study consistently revealed a positive association between BMI and PD risk after excluding the first 15 
years of follow-up in Study II, and the first 10 years in Study IV. However, previous studies on obesity and 
the risk of PD have been inconsistent. Two prospective studies found an increased PD risk for subjects 
with a high BMI (Hu et al. 2006) or an increased triceps skinfold thickness (Abbott et al. 2002), but three 
other cohort studies found no association (Palacios et al. 2011; Logroscino et al. 2007; Chen et al. 2004). 
Furthermore, in contrast with our findings, one nested case-control study found an inverse association 
(Ma et al. 2006).  
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The inconsistent findings could be due to the preclinical disease phase in PD, as the slow progression of 
the disease can take decades (see Gaig and Tolosa 2009). Our findings on the effect of excluding the 
potential preclinical disease phase bring important new aspects into the epidemiological study of PD and 
obesity. It seems that PD patients start to lose weight several years before the clinical diagnosis (Chen et 
al. 2003b), so the weight loss is a consequence of the disease process, implying that the preclinical disease 
stage of PD can mask the real positive association between BMI and the occurrence of PD. Most of the 
previous cohort studies have excluded the first 3–5 years of follow-up (Palacios et al. 2011; Logroscino et 
al. 2007; Chen et al. 2004) to rule out the effects of underlying PD, which could explain their lack of 
association. However, it remains unclear why the other Finnish cohort study (Hu et al. 2006) found the 
positive association without any exclusion of follow-up time. 
The potential biological mechanism remains to be determined, but a clinical observation showed that 
extremely obese persons had a lower availability of dopamine D2 receptors in the striatum than non-
obese controls (Wang et al. 2001). This could predispose them to a higher PD risk. Furthermore, it has also 
been suggested that lower dopamine receptor availability may lead to compensatory increases in 
dopamine turnover, consequently increasing oxidative stress and neuronal death (Abbott et al. 2002). In 
addition, the low-grade chronic and systemic inflammation associated with obesity (see Bastard et al. 
2006) could increase the PD risk. Alternatively, the use of pesticides, among other environmental risk 
factors, has been linked to an increased PD risk (Weisskopf et al. 2010), and adipose tissue might be 
capable of storing and releasing lipid-soluble environmental neural toxicants. 
Metabolic syndrome and factors related to metabolic health 
A decreased PD risk for subjects with metabolic syndrome was observed. There are no previous 
prospective studies predicting PD incidence by the criteria of metabolic syndrome. However, one case-
control study reported a lack of association between metabolic syndrome and PD (Cereda et al. 2012). In 
contrast to our findings, a history of diabetes has been suggested as a risk factor for PD (Hu et al. 2007b), 
but the evidence from cohort studies is conflicting (see Wirdefeldt et al. 2011; see Cereda et al. 2011).  
Further analyses indicated that the inverse association between metabolic syndrome and PD incidence 
found in the present study was mainly due to the serum triglyceride concentration. There are no previous 
cohort studies on blood triglyceride or glucose concentrations and PD risk. Our finding is, however, 
consistent with results from one longitudinal nested case-control study (Vikdahl et al. 2015) and a few 
case-control studies (Cereda et al. 2012; Scigliano et al. 2006), reporting that high blood triglyceride 
concentrations were significantly less common in PD cases than controls. However, in contrast to the 
study by Vikdahl et al. (2014), our study showed that elevated serum triglyceride concentration predicted 
lower PD risk, even after adjusting for smoking. Furthermore, we also found that hyperglycemia carried a 
reduced PD risk, consistent with findings from two case-control studies (Cereda et al. 2012; Scigliano et al. 
2006).  
One explanation for our results regarding metabolic syndrome, triglycerides, and glucose could be the 
effect of preclinical disease stage of PD. There are observations that PD patients suffer from autonomic 
disturbances, compromised hypothalamic-pituitary-adrenal axis (Awerbuch and Sandyk 1994), as well as 
from reduced sympathetic activity (see Wakabayashi and Takahashi 1997). These pathological changes 
result in, among other things, decreased cortisol and catecholamine concentrations, and lead to lower 
blood triglyceride and glucose concentrations. Indeed, a study among PD patients found a reduced 
prevalence of cardiovascular disease risk factors (i.e. diabetes, hypertension, high values of serum glucose, 
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cholesterol, triglycerides, and total lipids), presumably as a result of the reduced sympathetic activity 
caused by neurodegeneration (Scigliano et al. 2006). 
If the preclinical disease is indeed the underlying reason for our results, they indicate that serum 
triglyceride concentration could more easily be affected by the reduced sympathetic activity in PD than 
other metabolic factors. The same applies to the result on glucose concentration, although the association 
was slightly attenuated after excluding the potential preclinical disease phase. Speculatively, our results 
are worth noting when planning potential tools for early detection of preclinical PD cases. If reduced 
triglyceride or glucose concentration is an early sign of mild damage to the autonomic system, the 
triglyceride or glucose findings from blood tests could be one component in the potential risk score or pre-
screening evaluation.  
Our prospective study design, however, with a long follow-up period, raises questions about whether the 
reason for the inverse association is solely the preclinical disease phase. Moreover, our finding suggests 
that low serum triglyceride concentration could be an independent predictor of PD incidence, as the 
inverse association between serum triglyceride concentration and PD incidence remained even after the 
analyses excluding the first 10 years of follow-up.  
If serum triglyceride concentration, or fasting plasma glucose concentration, are involved in the etiology 
of PD, they should have an independent effect. Our results support this suggestion, as a dose-response 
relationship was found between them and PD risk, after adjusting for potential confounding factors. This is 
further supported by the fact that adjustments for other components of the metabolic syndrome did not 
change results (i.e. the results regarding serum triglyceride were adjusted for BMI, blood pressure, serum 
HDL cholesterol, and fasting plasma glucose; regarding fasting plasma glucose, the adjustment variables 
were BMI, blood pressure, serum HDL cholesterol, and serum triglyceride).  
The inverse association between PD risk and both triglycerides and glucose could be linked to other 
dopamine-mediated behaviors with reward sensations (e.g. smoking and alcohol consumption) that 
predict a lower PD risk, as an animal study showed an association between sugar consumption and 
dopamine release (Rada et al. 2005). High consumption of carbohydrates, especially sugars, is known to 
increase fasting serum triglycerides (see Chong et al. 2007). On the other hand, this phenomenon might 
be linked to the association between uric acid and PD, as uric acid is a by-product of uncontrolled fructose 
metabolism (see Chaudhary et al. 2013). Apart from these speculations, we have no suggestions for 
potential mechanisms behind the associations between elevated triglycerides, hyperglycemia, and 
reduced PD risk. Serum triglyceride concentration, or fasting plasma glucose concentration, could also be 
a marker for some other unknown confounding factor. 
It is not clear, however, whether 10 years is long enough to exclude the effect of the preclinical disease 
phase. When and where the neuropathological process develops in PD remains uncertain, but a recent 
review suggested that the non-motor symptoms of PD could begin decades before the onset of motor 
symptoms, although the start and progression of premotor PD is highly variable (see Gaig and Tolosa 
2009). Thus, the potential effect of a preclinical disease phase on the components of metabolic syndrome 
cannot be ruled out. 
The present study found no association between blood pressure and risk of PD. This lack of association is 
in line with some previous prospective findings (Simon et al. 2007). However, the evidence is conflicting, 
as reduced (Vikdahl et al. 2015; Paganini-Hill 2001) or increased (Qiu et al. 2011) PD risks have been found 
for subjects with hypertension. One reason for this discrepancy could be the differences in exposure 
information – some studies actually measured the blood pressure of participants (Vikdahl et al. 2015; Qiu 
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et al. 2011), while others relied on information of hypertension diagnosis that was self-reported or 
gathered from medical records (Simon et al. 2007; Paganini-Hill 2001). 
Furthermore, this study found no association between serum HDL cholesterol and PD risk, which is in line 
with previous prospective studies (Huang et al. 2008; de Lau et al. 2006b). However, at the time of 
baseline examinations, the population had rather high HDL cholesterol values. Thus, the lack of 
association in this study could be due to the small number of PD cases with reduced serum HDL 
cholesterol concentrations.  In other words, the population was not heterogeneous enough to examine 
the association between HDL cholesterol concentration and PD risk (less than 15% of the subjects had HDL 
cholesterol concentrations under the cut-off point of 1.3 mmol/L, and 80% of the subjects, from the first 
decile to the ninth decile, had HDL values between 1.22 and 2.22 mmol/L). 
Serum total cholesterol concentration also did not predict the incidence of PD in this study.  Previous 
findings have been inconsistent, reporting reduced (Simon et al. 2007; de Lau et al. 2006b) or increased 
(Hu et al. 2008) PD risk for increasing total cholesterol levels. Though the reasons for this inconsistency 
are unclear, it could, in general, be due to many factors such as methodological differences or problems 
(e.g., population demographics, exposure information, difficulties in case ascertainment, residual 
confounding). 
Finally, the definition of metabolic syndrome and the cut-off values for categories of the components of 
metabolic syndrome were based on the harmonized definition of metabolic syndrome (Alberti et al. 
2009). Unfortunately, we did not have information on waist circumference in our data; thus, BMI was 
used as a proxy measure in the definition of metabolic syndrome by replacing the waist circumference 
category ‘normal’ with a BMI <25 kg/m2 and the category ‘large’ with a BMI ≥25 kg/m2. As described in 
chapter 4.2.1, there was high correlation between waist circumference and BMI in the Health 2000 data.  
However, the use of a proxy measure could cause confounding in Study IV, as one reason for elevated 
triglyceride concentration is a large waist circumference associated with a fatty liver. However, there are 
findings that BMI also independently predicts fatty liver (Kotronen et al. 2013). Furthermore, the 
association between triglycerides and PD incidence did not change, even after adjusting for BMI and other 
causes of elevated triglycerides (i.e. alcohol consumption and impaired glucose metabolism marked as 
having a high fasting plasma glucose concentration).  
6.4 Methodological considerations 
6.4.1 Strengths and limitations 
The main strengths of the present study are its prospective design, a comprehensive set of baseline 
measurements, and a long follow-up period.  
The participation rate in all three surveys was high (82.5% in the FMC, 78.6% in the FMCF, and 90.2% in 
the Mini-Finland Health Survey). Thus, the general concern that those who do not participate have 
different health attributes than those participating in the survey has little effect in this study.  
Furthermore, the Mini-Finland Health Survey was a representative sample of the Finnish population of 
adults aged 30 years and over, and thus the results from Study IV could be generalized to the whole adult 
population. However, the FMC and its follow-up survey were not completely representative of the Finnish 
population (Aromaa 1981). This, however, is not a concern due to the etiological nature of the present 
study, and the exclusion of the eldest age groups from the analysis. 
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Causality cannot be evaluated from observational studies alone. Nevertheless, the prospective study 
design is a major advantage in studies attempting to find new etiologic clues. In comparison, a cross-
sectional or case-control study design cannot evaluate whether the exposure has occurred before the 
event, which is one of the criteria for causation. However, the long preclinical disease phase of PD (see 
Gaig and Tolosa 2009) raises concerns that, despite the prospective design, it cannot be concluded with 
certainty that the exposure was measured before the outcome occurs. Thus, we attempted to address this 
concern with sensitivity analyses, i.e. excluding the first 10–15 years of follow-up time. This, however, led 
to rather small numbers of PD cases, so these results must be interpreted with caution. Nevertheless, 
these sensitivity analyses gave valuable new insights into the interpretation of the results. Overlooking 
these kinds of sensitivity analyses in previous studies could explain the inconsistent results in the 
literature regarding PD epidemiology.  
Repeatability of the exposure factors were studied (as described in chapter 4.2.3), and was found to be 
relatively high. Thus, the associations observed were unlikely weakened by inaccurate measurements. 
There were, however, a few exposure factors with rather low repeatability, such as the consumption of 
berries and leisure-time physical activity, which raises concerns. The seasonal availability of berries may 
have affected the agreement between measurements taken several months apart. Additionally, there is 
this notion that foods consumed close to the assessment of a person’s habitual past diet intake may 
influence responses, possibly creating a bias toward recently consumed food (Fowke et al. 2004). The 
seasonal variability in physical activity habits may have also affected the repeatability. However, despite 
the low repeatability, the methods have probably been able to capture the exposure with enough 
precision to have allowed for ranking individuals in the correct order. Thus, we were able to find the 
associations between these exposure factors and PD risk.  
A long follow-up time is a major advantage in an epidemiological study of a disease that has a long 
preclinical phase and progresses slowly. The long preclinical disease phase of PD has not received much 
attention in previous studies, but the present study highlights the effect of taking it into account and 
demonstrates the need for a very long follow-up time. This especially affects the associations between 
metabolic syndrome, obesity, and PD, as discussed above. The disadvantage of a long follow-up period is, 
however, that the prediction of single-exposure measurements weakens over time. For this reason, we 
did not expand the follow-up periods any further, and a shorter follow-up time was even applied in some 
analyses.  
It is possible that long-term changes in people’s behaviors, decades after the baseline health 
examinations, may have caused conservative estimates of the associations. For example, there are 
observations that coffee consumption has decreased in Finland over the last two decades (Helakorpi et al. 
2004), which could have attenuated the estimated relative risks in this study. During the follow-up of this 
study, changes in smoking and alcohol consumption also occurred. The proportion of abstainers has 
decreased, and alcohol consumption increased between the 1980s and 2004, especially among women 
(Helakorpi et al. 2004). Smoking decreased in men and increased in women during the 1980s, but has 
remained at the same level since the mid-1990s in men and late 1980s in women (Helakorpi et al. 2004). 
Discussion on long-term population changes in diet continues in the next chapter (6.4.2). Furthermore, 
sociodemographic factors, such as marital status, education, and occupation, are likely to change over a 
long follow-up period, which may have resulted in residual confounding. 
The study populations used, the FMC, the FMCF, and the Mini-Finland Health Survey, are well-
characterized cohorts with a comprehensive set of baseline measurements. The good quality of the data 
in this study (see chapter 4.2.3) and the ability to adjust for major confounding factors reduces the 
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concern of residual confounding. However, residual confounding may still remain due to factors 
influencing PD that were unknown or not available in the data. For example, the presence of an unknown 
confounding factor might be one reason for the rather wide confidence intervals in Study I regarding the 
individual food groups and items. Potential confounders include factors presented in Figure 1, and, for 
example, serum urate concentration is a factor lacking from this study. However, the FMCF does include a 
sub-population with information on serum urate concentration, though preliminary analyses showed that 
serum urate concentration was not associated with PD risk (Paul Knekt, personal communication, 2015).  
Regarding Study I, certain lifestyle factors that are commonly considered to increase the risk of CVD seem 
to be inversely associated with the risk of PD in the present study, for example, consumption of foods that 
are major sources of saturated fat (processed meat and sausages), smoking, and the consumption of 
unfiltered boiled coffee (see Erhardt 2009; see van Dam 2008; see Srinath Reddy and Katan 2004). 
Furthermore, the consumption of foods containing antioxidant vitamins (fruits and berries) was associated 
with an increased risk of PD in men, even though they were associated with a lower risk of CVD in this 
same FMC data (Knekt et al. 1994). The explanation for these rather opposing results on PD and CVD could 
be that these two diseases do not share similar pathogenic processes. Another explanation could be that 
population selection occurred due to deaths caused by CVD before an individual even had a chance to 
reach the typical age of PD onset, and this may cause bias if these diseases have shared risk factors.  
Finally, it cannot be excluded that the small number of PD cases or multiple comparisons may have caused 
chance findings. This is of particular concern in Study I, with its somewhat unexpected results. 
Furthermore, the relatively small number of PD cases did not allow for all of the planned interaction 
analyses to be performed. In addition, these were exploratory results of uncertain interpretation, and 
future studies on this topic are needed. 
6.4.2 Methodological considerations related to the dietary method 
Dietary history interview 
In the FMC, the method for measuring the total habitual food consumption of the participants was a one-
year dietary history interview. The dietary history interview is considered to be the best method for 
measuring an individual’s habitual dietary intake in the long term (see Virtanen and Pietinen 1999). 
However, the interview is subject to the participant’s own assessment, and a 12-month time period might 
be a lengthy time to recall. To minimize potential biases related to the method, food models were used to 
diminish errors in recall, open-ended questions allowed for more specific answers, and trained 
interviewers used a structured questionnaire to reduce the differences between the interviewers. 
However, the method is also reliant on the skills of the interviewer. Thus, the repeatability of the method 
was examined (Järvinen et al. 1993). 
The repeatability of the method was found to be good at short-term (measured twice, at an interval of 4–
8 months), but declined at long-term (measured twice, at an interval of 4–7 years) (Järvinen et al. 1993). 
This implies that the method was accurate, but dietary habits changed over the long term. Indeed, during 
the period from 1972 to 1992, the diet in Finland was changing; the total fat content decreased from 38% 
of energy to 34%, saturated fat from 21% to 16%, polyunsaturated fat from 3% to 5%, and the intake of 
cholesterol decreased by 16% (Pietinen et al. 1996). Furthermore, fruit and vegetable consumption 
increased two- to three-fold, and a shift from boiled to filtered coffee occurred. It cannot be excluded that 
the lack of an association is merely due to changes in dietary habits during the extremely long follow-up 
 6 Discussion 
90 
 
 
6
 D
iscu
ssio
n
 
6
 D
iscu
ssio
n
 
period. However, these changes occurred slowly over a 20-year time period, and the subjects in this study 
had already had a long exposure to their typical diet at the time of baseline examination in 1966–1972.  
Food composition values 
The present study mainly examined the diet quality and foods groups and items. Information on 
polyunsaturated, saturated, and trans fats were, however, included in the mAHEI. Originally, the food 
composition database was compiled utilizing the contemporary Finnish food composition tables 
(Turpeinen and Roine 1967), and was updated during late eighties based on the nutrient composition 
book published by the Finnish Social Insurance Institution (Rastas et al. 1989). However, it is difficult to 
assess the agreement between the analyzed values of food samples collected during the 1980s and the 
actual food composition at the baseline of this study in 1966. Nutrient composition of foods and food 
preparation techniques have changed over time. However, ranking according to intakes is commonly used 
in epidemiologic studies, and thus, the absolute intake levels are not as important as the ability of the 
method to rank subjects in the correct order. 
Furthermore, nutrient contents of the foods referred mainly to raw foodstuffs in the FMC data (Järvinen 
1996). Thus, the effect of food preparation and food storage on nutrient content has not been taken into 
account. However, as the present study mainly evaluated food use and diet quality, this is not a concern. 
Dietary index 
To replicate the finding by Gao et al. (Gao et al. 2007), we formed the AHEI index in our database using 
components as similar as possible to the original work. A few modifications were made to adjust the index 
for the present study population. We believe that the mAHEI in our study was adequately comparable, as 
both the AHEI and our mAHEI reflected the diet quality by rewarding higher scores for the high intake of 
fruits, vegetables, legumes, whole grains, nuts, fish, and poultry, and for a low intake of saturated fat and 
trans fat. However, in comparison with the AHEI, information on multivitamin use and alcohol 
consumption could not be included, since these variables were not available in the FMC data. However, 
the use of vitamin supplements was rare at the time, so including them would probably not have affected 
the result. Furthermore, alcohol consumption among women was presumably very low at the time of 
study, as was the case in the FMCF 4–7 years later. Thus, the lack of information on alcohol consumption 
probably did not affect our results for women. Instead, among men, the lack of alcohol consumption in 
the mAHEI could explain the opposing findings in our study compared to the study by Gao et al. (2007). 
In addition, the AHEI contained a variable on fiber intake from grain sources (g/d). However, in our 
modification this was replaced with intake of whole grain items (g/d, products containing >25% whole 
grain), because the variable on fiber intake included fiber from all sources in our data. Additionally, it 
should be noted that berry consumption was not included in the total fruit consumption variable, as was 
done in the original AHEI.  
Furthermore, the scoring system was different in the mAHEI than the original AHEI. We did not set 
recommended intake levels as the cut-off value for those receiving the highest scores. Instead, we divided 
the intakes into quintiles and scored them according to the AHEI scoring principles. This was done due to 
the etiologic nature of our study. We wanted to rank the subjects by their healthy eating habits, and were 
less interested in whether the intake values were above or under the recommended intake level. 
Furthermore, our scoring system was also reasonable due to the dietary method being based on food 
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frequencies, as the method does not measure absolute intake levels of foods or nutrients, it rather ranks 
subjects in the correct order by their intake levels. 
On the other hand, we should have considered how well the mAHEI reflected the diet quality of the 
Finnish population during the 1960s. Instead of replicating the study by Gao et al. (2007) in detail, maybe 
even more attention should have been given to adapting the dietary index to the Finnish diet common at 
the time. For example, the variable on trans-fat intake could have received less weight in the total score of 
the index, as intake of trans fat was very low. However, these are rather minor concerns, as it seems that 
the mAHEI is a good tool for assessing diet quality since it had a strong inverse association with CVD 
mortality in the present study population (Sääksjärvi et al. 2015).  
6.4.3 Case ascertainment  
Diagnostic accuracy is a challenge in epidemiologic studies of PD. The most reliable antemortem 
diagnostic method is expert neurologic examination (see Tanner and Goldman 1996).  
In this study, the linkage with the Drug Reimbursement Register of the SII assured that subjects with PD 
were identified from the cohort by means that included clinical neurologic examination, a certificate 
describing the clinical diagnostic criteria, and an inspection of this certificate by two independent medical 
experts at the SII.  
It is possible that the study population includes undiagnosed PD cases, although this would not be 
expected to have great importance, since false-negative cases have no considerable effect on estimated 
relative risks, as the prevalence of PD is low in the normal population [approximately 1% among subjects 
over age 65 (see Hirtz et al. 2007)]. Furthermore, due to the free medication coverage, it could be 
expected that the majority of PD patients will apply for the allowance and thus be included in the Drug 
Reimbursement Register of the SII. 
Moreover, the possibility that all patients with PD diagnoses were not true PD cases may have biased the 
estimates of the strength of association, but this risk was shown to be minor, as our study neurologist (Dr. 
Jukka Lyytinen) retrospectively compared a sample of the certificates for PD medication reimbursement 
against hospital records and found the agreement to be 80%.  
Additionally, it should be noted that the criteria for eligibility for the reimbursement right code 110 may 
have changed over time. Currently, the reimbursement right code 110 includes certain other movement 
disorders that may either resemble PD (e.g. vascular parkinsonism) and/or benefit, at least partially, from 
dopaminergic therapy. These also include atypical parkinsonian disorders, such as progressive 
supranuclear gaze palsy and multiple system atrophy (corresponding to ICD-10 codes G23 and G90.3, 
respectively), as well as the heterogeneous group of dystonic disorders (ICD-10 codes G24.1 and G24.8). It 
was not until the end of the 1990s that the information on these specific diagnostic codes as a basis for 
the reimbursement right code 110 were incorporated into the register. This is a limitation to our study, as 
we cannot differentiate these diagnoses to be able to identify solely the cases with idiopathic PD. 
However, the number of diseases other than idiopathic PD (e.g. patients with a primary dystonic disorder) 
among the subjects with the reimbursement right code 110 is presumably very small. Primary dystonia 
(focal or generalized) is an extremely heterogeneous group of disorders, that – despite some benefit from 
dopaminergic therapy – generally is clinically quite distinct from parkinsonism. Atypical parkinsonian 
disorders, such as progressive supranuclear palsy and multiple system atrophy, are much rarer than PD, 
with an estimated prevalence ranging from 1 to 6 per 100,000 (Schrag et al. 2000; Schrag et al. 1999). 
Among the Health 2000 participants, where the reimbursement right code 110 can be differentiated by 
 6 Discussion 
92 
 
 
6
 D
iscu
ssio
n
 
6
 D
iscu
ssio
n
 
the diagnosis codes (for those entered into the SII’s register after the end of the 1990s), none of the 
subjects with reimbursement right code 110 had disease codes other than idiopathic PD (Harri Rissanen, 
personal communication, 2015). Furthermore, as stated above, the evaluation of a sample of the 
certificates for the reimbursement right code 110 supported this suggestion (see chapter 4.3.3 for details). 
The crude annual PD incidence in our study populations (31.9-44.7/100,000 in Studies I-IV) was roughly 2-
2.5 times higher than the crude annual incidence in 1992 (17.2/100,000) from a study conducted in 
southwestern Finland (Kuopio et al. 1999). The difference could arise from several reasons, such as a 
different time period, geographical area, or age distribution, as well as the above mentioned imprecision 
in PD diagnosis. 
Furthermore, the method for case ascertainment includes some delay between symptom onset and the 
date of entering the Drug Reimbursement Register of the SII. This was, however, taken into account while 
excluding the first 10 or 15 years of follow-up. This exclusion was also supported by a recent review 
suggesting that the non-motor symptoms of PD could start decades before the onset of motor symptoms 
(see Gaig and Tolosa 2009). 
Finally, the practices of the clinical diagnosis of PD have changed since the beginning of the FMC in 1966. 
Based on information from the Drug Reimbursement Register, the prevalence of PD was increasing during 
the 1970s (see Figure 5), probably due to improved diagnostic accuracy, but also due to improved therapy 
with an impact on the long-term prognosis of PD. After that time period, the prevalence stayed at the 
same level during the rest of the follow-up time in this study. It cannot be excluded that this affected the 
results of the studies from the FMC (baseline in 1966–1972) and the FMCF (baseline in 1973–1976). If the 
data included unidentified PD cases, missed during the 1970s, it may have attenuated the estimates of the 
strength of association, or even resulted in a lack of association. However, due to the low prevalence of 
PD, this is unlikely. Furthermore, the changes occurred only during the first decade of the 41-year follow-
up of the FMC and during the first few years of the 22-year follow-up of the FMCF. It is more plausible that 
the association would be emphasized during the long follow-up and thus the uncertain case 
ascertainment at the beginning of the follow-up is inconsequential. Furthermore, this does not concern 
the Mini-Finland Health Survey conducted in 1978–1980, as the baseline was at the same time as the 
prevalence stabilized.  
If the diagnosis of PD was uncertain or underdiagnosed during the 1970s, it may be that the sensitivity 
analyses we performed to exclude the potential preclinical disease phase did not capture solely the effect 
of potential underlying PD. Instead, these analyses may have also served as a clearing period: after 
excluding the first 10 years of follow-up, the analyses included more reliable PD cases. This would explain 
why the positive association between BMI and PD risk was revealed after exclusion of the first 15 years in 
the FMCF, but in the Mini-Finland Health Survey exclusion of 10 years was sufficient. 
6.5 Implications for future epidemiologic research 
The findings of this study should be replicated in other populations, especially regarding the results from 
Study IV, which was among the first of prospective studies examining the associations between blood 
triglycerides, glucose, and PD risk. Similarly, the findings on diet quality and PD risk should be replicated, 
as there is only one previous prospective study in addition to Study I on this topic. More prospective 
studies on the association between nutrients and PD risk are also needed.  
Overall, the number of prospective studies on PD and different exposures is rather limited. Other 
population-based cohorts, nationally and internationally, should make efforts to expand the study of 
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chronic diseases to include PD epidemiology, as surely there are eligible cohorts that have not attempted 
to identify PD cases yet. Recently, the EPIC-cohort, which includes several countries, went through a 
screening procedure to identify PD cases (Gallo et al. 2015), and results for further analyses on PD 
epidemiology are expected soon.  
Many of the initial studies on the epidemiology of PD were too small or methodologically limited, which 
should be considered when planning new studies. However, the low prevalence of PD in the general 
population is a challenge for increasing the size of studies. Furthermore, the multifactorial etiology of PD, 
where multiple environmental factors influence genetically predisposed individuals who are aging, makes 
observational studies on PD challenging. de Lau and Breteler (2006a) suggest that better insight into the 
role of environmental factors in the pathogenesis of the disease will be gained through the pooling of 
studies to further increase statistical power. This would also allow a more comprehensive examination of 
potential effect-modifying factors. However, different case ascertainment methods across studies may 
complicate creating uniform pooling procedures. 
Temporal aspects should be studied as an effect-modifying factor on the association between different 
exposures and PD risk as well. It is possible that there is a certain time window for the potential risk or 
protective factors to influence the risk of PD. For example, it would be of importance to study whether the 
associations between exposures and PD risk appear or disappear depending on the age of the subjects at 
baseline (early adulthood vs. middle age vs. old age), or at the time of PD diagnosis (representing the early 
onset vs. late onset phenomenon of the disease).  
Furthermore, the findings of this thesis covered a set of dietary and other lifestyle factors, as well as 
metabolic factors, but the data used in this study offer many more important areas to continue 
epidemiological studies of PD, such as the associations between PD risk and medication use, or previous 
illnesses. 
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7 Summary and conclusions 
Lifestyle factors, as well as metabolic health, may predict the incidence of PD. The main conclusions of this 
study could be stated as follows: 
- Most of the individual food groups or items considered, as well as the diet quality, did not predict 
the incidence of PD. However, a high consumption of milk was associated with an increased PD 
risk in women. In addition, an inverse association was observed for the consumption of berries, as 
well as processed meat and sausages, among women. Among men, an increased risk of PD was 
observed for a high consumption of fruits and berries, and for consumption of fresh fruits. 
However, the possibility of a chance finding due to multiple comparisons is a concern. The 
exclusion of the potential preclinical disease phase did not change the results for women, but for 
men, the associations disappeared. 
- Subjects with heavy leisure-time physical activity had a 73% lower risk of PD than those with no 
activity. Our results, with the prospective study design, support the hypothesis that physical 
activity is beneficial for neuroprotection. However, reverse causation cannot be ruled out, as this 
inverse association might be attributed to a decline in leisure-time physical activities among 
undiagnosed PD patients already suffering from preclinical symptoms decades before PD onset. 
- Current smokers had a 77% lower risk of PD than those who had never smoked. The association 
persisted even after the exclusion of the first 10 years of follow-up, thus challenging the 
hypothesis of reverse causation.  
- In subjects with light to moderate alcohol consumption (alcohol <5 g/d) the risk of PD was 
elevated by 81%, compared to non-drinkers. Heavy consumption of alcohol, however, was not 
associated with PD risk.  
- Subjects who consumed at least 10 cups of coffee per day had a 76% lower PD risk, compared to 
non-drinkers. The association attenuated little after excluding the presumable preclinical disease 
phase, but subjects drinking at least four cups of coffee per day still had a 41% lower PD risk than 
those drinking three cups or less. 
- This study revealed a positive association between BMI and PD risk, after exclusion of the 
potential preclinical PD phase (i.e exclusion of the first 10 to 15 years of follow-up). 
- A reduced PD risk for subjects with metabolic syndrome was observed. It appears this association 
was mainly due to serum triglyceride and fasting plasma glucose concentrations. Elevated 
triglyceride and glucose concentrations predicted lower PD risk even after exclusion of the first 10 
years of follow-up. However, it remains unclear whether this exclusion is long enough to take into 
account the entire preclinical disease phase. Thus, the result may be interpreted as an early 
marker of the neurodegenerative process. 
- No association between serum HDL cholesterol, or serum total cholesterol concentration, or 
blood pressure and PD risk was observed. 
Our findings on the effect of excluding the potential preclinical disease phase brought important new 
aspects into the epidemiological study of PD, highlighting the importance of acknowledging the potential 
preclinical disease phase that can even be decades in PD. However, caution is needed when interpreting 
these results, as the number of PD cases was rather small after the exclusion. Furthermore, due to the 
long preclinical disease phase of PD, reverse causation cannot be excluded, despite the prospective study 
design.  
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In light of the present study and previous findings, there are very few dietary factors predicting the risk of 
PD. However, the number of studies is so small that more studies are needed before making conclusions 
about the associations between diet and PD risk.  
Regarding lifestyle factors, this study agreed with previous findings suggesting that smoking, or coffee 
drinking, has an inverse association with PD risk. Due to the hypothesis that nicotine might have 
neuroprotective properties, there is currently one ongoing phase II randomized controlled trial 
investigating the effects of transdermal nicotine patches on PD patients (see Kalia et al. 2015b). The 
results from it will indicate whether this hypothesis needs to be revisited. Similarly, caffeine has been 
hypothesized to be a neuroprotective agent, and a long-term phase III randomized controlled trial 
investigating caffeine treatment for PD has been initiated (see Kalia et al. 2015b). A pilot study among PD 
subjects found improvement in motor symptoms for caffeine users, when compared with placebo users 
(Postuma et al. 2012). 
Summarizing the present and previous findings, physical activity seems to be inversely associated with PD 
risk, whereas the role of alcohol consumption, in relation to PD risk, remains uncertain. There are several 
randomized controlled trials investigating physical activity in PD patients, and it is clear that endurance 
exercise training improves physical conditioning in PD patients (see Lamotte et al. 2015). However, it is 
not clear whether exercise actually modifies disease progression, or if it even affects the motor symptoms 
of PD. 
The epidemiologic evidence for the association between BMI and PD risk is controversial and rather 
scarce, but adulthood obesity before the first preclinical symptoms of PD could be a risk factor for the 
disease. Even less evidence is available for evaluating the association between metabolic factors and PD 
risk, and future studies on this topic are evidently needed. 
For clinical use, a risk score assessing an individual’s risk of developing PD is needed. If disease-modifying 
therapy could be developed, it would be beneficial to administer it as early during the disease course as 
possible, preferably before the development of motor symptoms. The risk score would be helpful in 
identifying subjects at risk for PD and thus potential subjects for more intensive screening (e.g. imaging 
techniques currently under development for PD diagnosis). The score would include topics that have been 
associated with future risk of PD and considered as early markers of the disease, such as olfactory deficit, 
constipation, and perhaps, as suggested by the present study, low serum triglyceride and fasting plasma 
glucose concentrations. Finally, questions on physical activity, smoking habits, coffee consumption, and 
BMI could also be included.  
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Appendix tables 
Appendix table 1. An example of the literature search strategy, spring 2015. The following terms were used for the 
search in the PubMed database for all the possible relevant studies. 
PD and physical activity     
activit* AND cohort AND parkinson* 
exercise*  prospective   
workout  longitudinal   
training  follow?up   
conditioning  incidence   
exertion  occurrence   
fitness  relative risk   
sport*  hazard*    
  rat*   
  ratio*   
  risk*   
  cox*   
PD and alcohol consumption    
alcohol* AND cohort AND parkinson* 
ethanol*  prospective   
wine*  longitudinal   
beer*  follow?up   
cider*  incidence   
strong*  occurrence   
liqueur*  relative risk   
booze*  hazard*    
spirit*  rat*   
drinking  ratio*   
consum*  risk*   
  cox*   
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Appendix table 2. The food grouping and distribution used in the analyses for Study I, presenting also the three 
additional nutrients included in the mAHEI. 
Food groups Content, unit g/day (sum of all 
items included) 
Tertiles (T1, T2, T3) 
 (or 0 g/d vs. >0 g/d) 
 
  Men (g/d) Women (g/d) 
Grains all grains 10-236, 237-342, 343-1535 20-170, 171-249, 250-1092 
Rye rye 0-96, 97-181, 182-1026 0-60, 61-120, 121-951 
Wheat wheat 0-75, 76-149, 150-854 2-63, 64-115, 116-769 
Whole grain 
(defined as products  
containing >25%  
wholegrains. 
Categorization made 
by Jukka Montonen) 
cereal products that contain 
>25% whole grain, e.g. rye flour,  
dried rye bread, hard rye bread 
(crispbread), soft rye bread, 
potato rye bread,  sweet and 
sour bread, wheat flour 
(graham),  wheat germ,  
semolina (whole wheat), 
graham rusk, graham bread,  
dark wheat bread, bread with 
mixed flour, millet, rolled oats,  
barley flour, barley (pearl),  
buckwheat, barley bread,  
unleavened barley bread  
0-152, 153-240, 241-1321 0-102, 103-166, 167-963 
Vegetables all vegetables 5-272, 273-397, 398-1354 10-220, 221-317, 318-1026 
Legumes and nuts legumes and nuts 0-3, 4-7, 8-101 0-1, 2-5, 6-250 
Potato potato 1-186, 187-289, 290-1072 0-121, 122-192, 193-896 
Roots roots 0-9, 10-30, 31-356 0-16, 17-44, 45-579 
Fruits and berries all fruits and berries, fruit juices 
(not jams or juices with added 
sugar) 
0-64, 65-146, 147-1094 0-106, 107-203, 204-1325 
Fruits, fresh orange, avocado, banana, 
grapefruit, cherry, plum, apple, 
peach, pear, lemon, watermelon, 
grapes, fruit salad  
(no canned or dried fruits) 
0-19, 20-82, 83-906 0-47, 48-135, 136-1078 
Berries cranberry, gooseberry,  
strawberry, black currant, 
blueberry, red currant, 
lingonberry, cloudberry, sea 
buckthorn berries, raspberry, 
fresh berries average (no jams) 
0-4, 5-14, 15-308 0-8, 9-18, 19-246 
Butter and lard butter, lard 0-38, 39-60, 61-272 0-25, 26-41, 42-240 
Margarines soft vegetable margarine (Flora, 
Solive) 
0-1, 2-4, 5-211 0-1, 2-4, 5-154 
Oils, mayonnaise fish oil, vegetable oil, 
mayonnaise 
0 g/d vs. >0 g/d (1-68g) 0 g/d vs. >0 g/d (1-80g) 
Milk and milk 
products 
all milk and milk products 13-764, 765-1142, 1143-3550 8-540, 541-793, 794-3283 
Milk standard milk (3.9% fat), low-fat 
milk (2.5% fat), skimmed milk, 
beestings 
0-545, 546-950, 951-3500 7-370, 371-613, 614-3247 
Fermented milk 
products 
yogurt , buttermilk, curdled milk, 
curd 
0, 1-150, 153-2000 0-23, 24-166, 167-2000 
Cheese edam cheese (40% fat), edam 
cheese (20% fat), emmental 
cheese, blue cheese, 
homemade goat cheese, 
homemade cheese, processed 
cheese, processed cheese (high 
fat) 
0-2, 3-10, 11-182 0-2, 3-10, 11-242 
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Meat and meat 
products 
all meat and meat products 0-105, 106-181, 182-1257 0-67, 68-115, 116-819 
Red meat medium fat pork, lean pork, ham 
(pork), chop with bones (pork), 
pork loin, medium fat beef, beef 
steak, veal, veal steak, veal 
brisket, lean mutton, mutton joint 
0-56, 57-101, 102-708 0-37, 38-67, 68-784 
Processed meat and 
sausages 
bacon, pork back fat, salami-
type dry sausage, horse meat, 
canned pork, canned pork and 
beef, canned beef, jelly veal, 
sausages (“Berliini”, “Tee”, 
“Lauantai”, “Gotler”, ”Suomi”, 
“Balkan”,  “cheap”, frankfurter, 
fresh pork, and sausage stuffed 
with pearl barley)  
0-27, 28-61, 62-773 0-13, 14-35, 36-379 
Poultry broiler, chicken 0 g/d vs. >0 g/d (1-250g) 0 g/d vs. >0 g/d (1-96g) 
Ratio of white:red 
meat 
(chicken + broiler + fish)/(all 
meat and meat products - 
(chicken + broiler)) 
0-0.16, 0.16-0.36, 0.36-80 0-0.16, 0.16-0.36, 0.36-39 
Fish all fish and fish products 0-19, 20-45, 46-817 0-12, 13-27, 28-415 
Eggs eggs 0-17, 18-36, 37-501 0-12, 13-30, 31-242 
Sugar and sugar-
rich condiments 
sugar, jam, marmalade, honey, 
syrup 
0-37, 38-63, 64-317 0-31, 32-55, 56-508 
    
PUFA polyunsaturated fatty acids 1.3-6.0, 6.1-8.8, 8.9-74.2 0.8-4.3, 4.4-6.4, 6.5-52.8 
SAFA saturated fatty acids 11-56, 57-77, 78-279 8-38, 39-54, 55-179 
trans fats trans fats 0.3-1.8, 1.9-2.6, 2.7-24.8 0.2-1.3, 1.4-2.0, 2.1-18.0 
 
 
